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In the UK since the early 1990s there has been a growing trend for certain hospital 
initiated specialist drugs to be prescribed by GPs within primary care. GPs have been 
encouraged to undertake this activity supported by the use of so-called “shared care 
protocols.” Despite these arrangements this has proven difficult with concerns over 
the quality and availability of shared care protocols and reported safety related 
incidents including fatalities linked to the use of certain specialist drugs.  
GPs have benefited from the complete computerisation of general practice unlike 
their hospital based colleagues who on the whole continue to work and prescribe 
within paper-based systems. These benefits have included the use of electronic 
prescribing and the introduction of computerised decision support systems (CDSS) in 
the form of reminders and drug related warnings and alerts. Scoping reviews are an 
established way of assessing the evidence base of a subject area which can then be 
summarised to reflect the broad nature of the field. For this thesis a scoping review of 
CDSS was used to evaluate how this intervention has been used within primary care 
and to identify areas where it can be further developed. Although the use of 
information technology has been suggested as a possible solution to some of the 
problems at the primary and secondary care interface, no published studies have 
evaluated the potential for a CDSS to support the prescribing of specialist drugs by 
GPs.   
In order to explore this concept further and gain additional knowledge of current 
CDSS usage, key informants were identified and interviewed. The key informants 
described the current availability and characteristics of CDSS within UK general 
practice. The concept of developing a CDSS to support GPs in the use of specialist 
drugs to include prescribing was acknowledged as beneficial and was widely 
supported. Enablers and barriers to development and implementation were identified 
including a number of potential operating models. Key enablers included data quality 
and functionality features, joint development and implementation and to make use of 
existing systems and frameworks. Key barriers included addressing the needs of end 
users, security, regulation and funding.   
Human ergonomics was used to further investigate GPs and the actual level and use 
of computers and software programs including CDSS at the point of prescribing both 
during and outside of patient consultations. The application of an analytical approach 
to these processes through a task analysis framework identified failings in existing 





Time constraints during patient consultations and the current lack of specific 
functionality within GP computer systems including CDSS adversely affected the 
ability for GPs to address issues at the primary and secondary care interface 
including the decision making process followed towards accepting clinical 
responsibility in prescribing specialist drugs.  
A potential operating model for general practice to support GPs in the prescribing 
and use of specialist drugs has been identified. However a number of questions 
remain in terms of potential development and implementation. Government policy 
continues to drive secondary care services out into primary care and with this the 
possibility of even greater levels of specialist drugs being initiated and continued to 
be prescribed by GPs. This only adds a greater need and urgency for suppliers of 
information technology to include CDSS to provide solutions to clear safety concerns 
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1.1 Thesis overview  
The following chapters will explore the field of health informatics in relation to 
computerised decision support systems (CDSS) and opportunities to assess if and 
how CDSS can improve the quality of prescribing by GPs in the UK. Chapter 1 
describes prescribing medicines by GPs in a historical context in order to provide 
insight to the evolution and establishment of regulatory frameworks and controls in 
the UK. With the national drugs bill signifying a large proportion of NHS expenditure 
various measures and interventions have been introduced from a regulatory 
perspective in order to contain costs by influencing prescribing behaviour (Britten 
2001). Some of these interventions have allowed the development and use of a 
range of tools to measure prescribing and in specific areas have been used to 
introduce markers of prescribing quality. In addition background to these 
interventions is provided from a political and financial perspective in terms of NHS 
reforms. Defining prescribing quality is explored from a range of perspectives and 
stakeholders. Aspects of quality in prescribing are identified and improvements are 
discussed in relation to the better use of computers and health informatics including 
CDSS. 
 
In Chapter 2, CDSS is further investigated in terms of primary care settings and use 
by GPs. A scoping review of the available literature in relation to CDSS was 
conducted using a range of sources of evidence. CDSS was found to be widely 
available within primary care settings with experience of use identified in a number of 
countries including the UK. Evidence from evaluations of CDSS was collated to 
include systems either being developed or in use and from the views and perceptions 
of end users. In addition the use of CDSS was identified in terms of supporting GPs 
in a range of clinical and therapeutic areas including prescribing. A key area 
identified where the use of CDSS was lacking was in supporting GPs in the use and 
prescribing of specialist drugs particularly with the use of shared care protocols.  
 
Chapter 3 describes how the concept of developing a novel CDSS to support GPs in 
the use and prescribing of specialist drugs was explored in a research study that 
involved 12 participants representing key stakeholder groups including GPs, NHS IT 
managers, the CDSS industry and secondary care clinicians. The results of the study 
identified a number of potential operating models of a CDSS including enablers and 
barriers to support implementation.  
 




Chapter 4 describes how this concept was further explored with a second research 
study involving nine GPs, who were users of three major GP clinical systems in the 
UK. This study involved an analytical examination of the way GPs actually used their 
computers and software applications both during and outside consultations. This 
analysis was used to further develop and build key operational functionalities to a 
potential CDSS that could support GPs in prescribing specialist drugs.    
 
1.2 Thesis aims and objectives 
Aim 1: To identify from a scoping review the evidence base in relation to the use of 
CDSS by GPs in the UK.  
Objectives 
 To assess the level and quality of evidence in relation to CDSS, to identify 
experience of use and areas or opportunities for CDSS to improving 
prescribing quality  
 
Aim 2: To assess the feasibility of developing a CDSS to support GPs at the point of 
prescribing in the use and management of specialist drugs. 
  
Objectives 
 To gain an understanding of current usage, system types and characteristics 
of CDSS within primary care.   
 To build a practical understanding of current NHS management systems in 
relation to information technology, general practice  and CDSS  
 To explore how current financial constrains with the NHS may impact the 
delivery of CDSS in primary care  
 To understand from commercial suppliers both historic, current and future 
strategy with regards to CDSS particularly in light of current NHS reforms  
 To explore with secondary care clinicians the shared care protocol 











Aim 3: To identify an operating model for a potential CDSS to support GPs in the use 
of specialist drugs in order to ensure high level safety and quality in prescribing. 
 
Objectives 
 To determine the actual level and use of computers and software applications 
including CDSS at the point of prescribing both during and outside of patient 
consultations by GPs 
 To identify potential weakness or failings in existing systems that could be 
identified and be used in the development of a CDSS to support the use of 
specialist drugs.  
 
1.3 UK national drug expenditure 
Medicines are used in almost all NHS services making this the largest single 
expenditure in the NHS after staff costs (Picton 2008). Nationally the NHS spends 
around £12 billion on medicines with around 30% used in the hospital sector and the 
rest in primary care with the vast majority prescribed by General Practitioners (GPs). 
Figures provided by the Health and Social Care Information Centre (HSCIC) reported 
that in 2013 over 1 billion prescriptions were dispensed in England at a cost of £8.6 
billion (HSCIC 2014). Table 1.1 summarises some of the statistics published by the 
HSCIC relating to prescriptions dispensed in the community in England during 2013.  
 
Table 1.1 Prescriptions dispensed in England during 2013 (HSCIC 2014) 
 1,030,079 prescription items were dispensed at a total cost of £8,625,076 
 The leading British National Formulary (BNF) chapter in terms of prescription 
items dispensed was the cardiovascular system (307,424) and in terms of 
net ingredient cost was the central nervous system (£1,878,279) 
 The leading BNF section in terms of prescription items dispensed was 
hypertension and heart failure (68.7 million) and in terms of net ingredient 
cost was drugs used in diabetes (£793.8 million)  
 83.9% of all prescription items were prescribed as generic medicines  
 The average net ingredient cost per head of population was £160.18 
compared to £150.16 in 2003 








1.4 Regulation of medicines in the UK 
In 1957 the drug thalidomide was launched in Germany, as an over the counter 
medicine to promote sleep. The following year it became available in the UK as a 
prescription only medicine. At a paediatric conference in November 1961 it was 
reported that there was a possibility that, if taken in pregnancy, thalidomide might 
have harmful effects on the developing embryo (Rivett 2012). With increasing reports 
of adverse effects from around the world it became clear the drug was linked with 
causing abnormal birth defects. It is estimated that 10,000 babies were born with 
phocomelia and other deformities (Rago and Santoso 2008). In the UK the 
Government soon intervened and following consultation the Committee on Safety of 
Drugs (CSD) was formed in 1963 introducing a system of checking new drugs 
through three stages of assessment: laboratory toxicity trials, clinical trials on 
humans and post-marketing surveillance. With similar powers granted in the USA to 
the Federal Drug Agency (FDA) the thalidomide disaster also induced the process of 
harmonising drug regulation across the European Union through a number of 
Directives with the aim of creating a common market for medicines resulting in 
establishment of the European Medicines Evaluation Agency (EMEA) in 1993 (Rago 
2008). The CDS was renamed the Committee on Safety of Medicines (CSM) in 1970 
and later the Commission on Human Medicines (CHM) advising the UK government 
on the safety, quality and efficacy of all medicines establishing the process of safety 
monitoring otherwise known as pharmacovigilance. The CHM is now one of eight 
expert groups that advise the Medicines and Healthcare Products Regulatory Agency 
(MHRA) which was formed in 2003. The MHRA is responsible for the regulation of all 
medicines, medical devices, equipment used in healthcare, and the investigation of 
harmful incidents.  
 
1.5 The NHS and the role of GPs.  
The 1911 National Health Insurance (NHI) Act consolidated existing contribution or 
insurance schemes placing all eligible working males on the panel of a named GP 
(Simon 2009). Under the Act, 80% of the working population of the UK were insured 
against sickness and debilitation and were able to receive a low sick payment that 
covered the cost of a doctor and prescribed medicine (Heller 2007). A capitation 
system of payment was introduced that meant income for GPs was related directly to 
the number of panel patients registered rather than the quality of medical care 
provided which eventually lead to a cap of 3000 panel patients per GP list in 1920 
(Hardy 2001).  




During the inter-war years the Labour party built up social welfare policies 
culminating in the 1942 Beveridge report, which first outlined the basis for a centrally 
funded welfare state to include a National Health Service or NHS (Laybourn 2000). 
Nye Bevan’s NHS Act went much further than the Beveridge Report by proposing the 
nationalisation of hospitals and to draw GPs into the NHS on a partly salaried basis. 
Despite opposition internally from the Cabinet, the British Medical Association (BMA) 
and in particular hospital consultants, the NHS Act was passed in 1948 thus ensuring 
the original panel system was extended to cover the entire population of the UK. GPs 
acted as gate-keepers to the NHS, referring patients where appropriate to hospitals 
or specialist treatment and prescribing medicines and drugs.  
 
1.6 Regulation of GP prescribing  
Concerns over escalating costs and prescribing patterns led to the Hinchcliffe 
Committee Inquiry which in its final report in 1959 recommended that expensive 
elegant preparations should give way to simpler preparations of the same drug, and 
doctors should be convinced of the superiority of a branded product before 
prescribing it rather than its generic equivalent (Rivet 2012). Following the Hinchliffe 
Report arrangements were made to for the eight prescription pricing offices in 
England and Wales to obtain adequate statistical information about prescribing by 
analysis of samples of prescriptions submitted by community pharmacists. In addition 
prescribing data was collated quarterly and annually at both regional and national 
level to provide a means of drawing attention to specific patterns of prescribing of 
individual drugs or drug groups. By the early 1970s the availability of both 
educational and expenditure reports were supported by regional medical officers who 
would visit GPs annually with nearly 3,000 GPs specifically visited regarding the 
pattern and cost of their prescribing (Parish 1976). In 1977 the national pricing offices 
were renamed as the Prescription Pricing Authority (PPA) and reformed as a Special 
Health Authority. In 1988 the PPA overhauled its reporting format and introduced 
prescribing analysis and cost tabulation (PACT) data. Although traditionally PACT 
was mainly used as a financial tool to help health authorities set and monitor general 
practice prescribing budgets other purposes soon emerged such as audit and 
research, improved methods of funding high cost drugs, and the development of 
practice formularies and prescribing indicators (Majeed et al 1997).  
 
The 1990 NHS and Community Care Act (Department of Health 1990) removed 
hospitals and community services from the managerial control of health authorities 
and allocated to them functions as either a “purchaser” or a “provider.”  




Providers could not rely on year on year funding, and in effect had to “compete” for 
contracts, and become more efficient and responsive to the needs of the purchaser. 
Fund holding allowed GPs to purchase health care from NHS trusts and the private 
sector, initially phased in with the first wave limited to those practices with list sizes in 
excess of 11,000. With successive waves of fund holding, allowing smaller practices 
to apply, the proportion of patients covered by fund-holding practices increased from 
7% in 1991 to 51% by 1996 (Savage and Atkinson 2001).  
 
The introduction of GP fund-holding and the internal market meant changes to both 
NHS district and regional management structures. This provided new strategic and 
operational opportunities for pharmacists to support GP fund-holders in prescribing 
management and started the concept of primary care pharmacy (Silcock et al 2003).  
Whilst fund–holding practices were allowed to overspend by up to 5% of their total 
spend (including prescribing), non-fund holding practices that overspent on 
prescribing were subject to possible sanctions ultimately resulting in the withholding 
of remuneration (Ryan and Yule 1993). By the end of the 1990s pharmaceutical 
advisers were employed by every Health Authority in England with others 
increasingly working directly for or within GP practices. The need for increasing 
levels of pharmaceutical support was in the main to control and manage an ever 
increasing national drugs bill. The primary care drugs bill in England had increased 
from £2.02 billion in 1989 to £5.2 billion by 1997 (Department of Health 2000). In 
2003 the Audit Commission highlighted the sharp contrast between general drug 
inflation at 7% compared to 25% in areas linked to National Service Frameworks 
(NSFs) and guidance from the National Institute of Clinical Excellence (NICE); with 
the most significant factor driving the increases in drugs spending being the NSF for 
coronary heart disease (National Audit Office 2003). By 2007 the annual primary care 
drugs bill in England had reached £8 billion, an increase of 60% in real terms over 
the previous decade, with a 55% rise in the number of prescription items dispensed 
(National Audit Office 2007). 
 
1.7 Defining Prescribing Quality 
In the UK the first reference to prescribing quality was suggested by Parish (1973), 
placing it in the context of a cash-limited health service as being appropriate, safe, 
effective and economic. Taylor (1977) described published studies at the time had 
focussed mainly on increasing drug expenditure whereas other perspectives 
reflecting the quality of prescribing were of a greater fundamental importance. 




In this review the author banded the published literature into three categories; either 
using a descriptive approach based upon retrospective research of records, a 
deductive approach linking prescribing to morbidity or therapeutic intent, or from a 
qualitative perspective to examine personal influences on prescribing. Taylor (1977) 
concluded that without the support of continuous prescribing review systems as a 
basis of continuing education, GPs would have faced a greater degree of prescribing 
restriction.  
 
1.7.1 Rational Prescribing 
Taylor (1978) in a second review of GP prescribing referred to a definition of rational 
prescribing based on the US Task Force on Prescription Drugs being “necessary, 
effective, safe and economic identifying both coercive and persuasive controls to 
improve GP prescribing.” Coercive controls were described as controls applied on 
manufacturers, prescribers and patients by external agencies, in essence 
Government regulation. Persuasive control was discussed in the context of 
postgraduate education, a wider use of approved publications e.g. the British 
National Formulary (BNF) and the use of detailed prescribing data. In contrast 
Bradley (1991) in a review of the published literature concluded that although the 
huge interest in escalating costs had led to initiatives that had curbed or altered 
prescribing it was the decision making process that underpinned prescribing and 
required a better understanding, particularly the decision to treat due to the lack of 
empirical evidence in this area.  
 
1.7.2 The World Health Organisation 
In 1985 the World Health Organisation (WHO) formally defined requirements of 
rational prescribing as those required to meet the appropriate clinical needs of 
patients, at an appropriate dose for an appropriate period of time and at the lowest 
cost to them and their community (Le Grand et al 1999). Hogerzeil (1995) reported 
that in order to measure rational prescribing an adequate reference standard was 
required, as knowledge of rational drug use did not always result in rational 
prescribing behaviour. In the early 1990s the WHO in collaboration with the 
International Network of Rational Drug Use (INRUD) developed and tested 12 key 









Table 1.2 Rational prescribing indicators developed by the World Health 
Organisation (Hogerzeil 1995 p2) 
Prescribing Indicators 
 Average number of drugs per encounter 
 Percentage of drugs prescribed by generic name 
 Percentage of encounters with an antibiotic prescribed 
 Percentage of encounters with an injection prescribed 
 Percentage of drugs prescribed from an essential drugs list or formulary 
Patient Care Indicators 
 Average consultation time 
 Average dispensing time 
 Percentage of drugs actually dispensed 
 Percentage of drugs adequately labelled 
 Patient knowledge of correct dosage 
Facility Indicators 
 Availability of a copy of essential drugs list or formulary 
 Availability of key drugs 
 
The World Health Organisation (WHO) continued to highlight the problems 
associated with irrational prescribing e.g. “poly-pharmacy” estimating that worldwide 
more than 50% of all medicines are prescribed, dispensed, or sold inappropriately, 
while 50% of patients failed to take them correctly and have recommended core 
interventions to combat irrational prescribing (World Health Organisation 2002). 















Table 1.3 Promoting the rational use of medicines by the World Health 
Organisation.   
 A mandated multi-disciplinary national body to coordinate medicine use policies 
 Clinical guidelines 
 Essential medicines list based on treatments of choice 
 Drugs and therapeutics committees in districts and hospitals 
 Problem-based pharmacotherapy training in undergraduate curricula 
 Continuing in-service medical education as a licensure requirement 
 Supervision, audit and feedback 
 Independent information on medicines 
 Public education about medicines 
 Avoidance of perverse financial incentives 
 Appropriate and enforced regulation 
 Sufficient government expenditure to ensure availability of medicines and staff 
 
With UK national annual prescribing costs in excess of £3 billion, Barber (1995) 
suggested an overhaul of the definition of rational prescribing by highlighting flaws in 
previous studies particularly where authors were mainly academic clinical 
pharmacologists. In addition the author added that in these cases prescribing quality 
was assessed against the biomedical model, balancing effectiveness of treatment 
against risk. Barber (1995) suggested a new definition of rational prescribing based 
on the premise that it was better to define what a good prescriber should be trying to 
achieve at the time of prescribing and subsequent management through four aims; to 
maximise effectiveness, to minimise risk; to minimise cost and to respect patient 
choice. Figure 1.1 shows how the author represented these four aims 
diagrammatically, plotting their commonest conflicts which could be used as an aid to 







































Figure 1.1 Aims of good prescribing and their commonest conflicts 
(Barber 1995 p924) 
 
In 1996 the Department of Health launched the National Prescribing Centre (NPC) to 
facilitate the promotion of high quality and cost effective prescribing through a 
programme of activities aimed at supporting all relevant health professionals and 
managers in NHS (Simister 2000). The NPC based their working definition of 
prescribing quality in conjunction with both Barber and the WHO as a balance of the 
traditional teaching of safety and efficacy with the need to be cost-effective and 
involving the patient in treatment (National Prescribing Centre 2007a).  
Maximising effectiveness 
 
Normally achieved by 
pharmacological manipulation of the 
body to improve or remove a 
condition. 
 
 An objective, numerical measure to 
assess effect e.g. lowering blood 
pressure, or a subjective measure 




Immediate costs to include drug 
expenditure and associated costs e.g. 
blood monitoring or drug 
administration.  
 
Costs to be taken from the 
perspective of the NHS as this was 
funded by public money. 
 
Respecting patient choices 
 
To ensure both ethical and practical 
reasons why a patient's choice, 
particularly informed choice were 
taken into account. 
 
 A patient would choose whether to 
have a prescription dispensed, and 
whether to when and how to take 
prescribed drugs.  
Minimising risk 
 
The probability of an untoward event 
resulting from drug treatment, which 
could include transient side effects, 
rather than an adverse drug reaction 
causing harm. 
 




1.7.3 Prescribing Indicators in the UK 
Bateman et al (1996) convened a consensus group consisting of 8 GPs and a 
resource team to develop, define criteria and set standards of prescribing 
performance using PACT data and then applied these to all 518 practices in the 
former Northern Regional Health Authority. The group developed criteria and set 
numeric standards for thirteen aspects of prescribing performance in four areas: 
generic prescribing, prescribing within specific therapeutic groups, drugs of limited 
clinical value and standards based on prescribing volume. Cantrill et al (1998) on 
behalf of the National Primary Care Research Centre (NPCRC) developed a set of 9 
prescribing indicators combining both measures of appropriate and inappropriate 
prescribing including non-PACT indicators (see Table 1.4). The authors concluded 
that despite being too labour intensive for routine use these prescribing indicators 
were useful as a research tool and that with developments with information 
technology would increase wider accessibility.  
 
Table 1.4 Reliable Indicators of Prescribing Appropriateness (Cantrill et al 
1998) 
 The indication for the drug is recorded and upheld in the BNF 
 The reason for prescribing a drug of limited value is recorded an valid 
 Compared with alternative treatments in the same therapeutic class , which 
are just as effective, the drug prescribed is either one of the cheapest or  a 
valid reason is given for using alternative 
 A generic product is used if one is available  
 If a potentially hazardous drug-drug combination is prescribed, the 
prescriber shows knowledge of the hazard 
 If the total daily dose is outside the range stated in the BNF, the prescriber 
gives a valid reason 
 If the dosing frequency is outside the range stated in the BNF, the prescriber 
gives a valid reason 
 If the duration of treatment is outside the ranges stated in the BNF, the 
prescriber gives a valid reason 









Avery (1998) reported that although over 400 prescribing indicators had been 
developed by various groups and organisations in the UK, including Health 
Authorities, many were not as robust as others in expressing the appropriateness of 
prescribing. Campbell et al (2000) used a modified two round Delphi questionnaire 
sent to all medical and pharmaceutical advisers in England (n = 305) to face validate 
31 indicators in current use. From 79 respondents (26%) only 12 of the 31 indicators 
were rated as valid for either cost or quality perspectives. This suggested limitations 
in terms of application. Avery (1998) suggested that although prescribing indicators 
required further evaluation as to what they were trying to measure, they all had 
potential for development and could be incorporated into GP clinical systems as 
computerised prompts to encourage appropriate prescribing.  
 
Limitations with PACT data, and in particular prescribing indicators, have been 
attributed to the lack of clinical information such as diagnosis and other patient 
specific denominators (Lloyd 2001). Guptha et al (2003) could only apply 9 out of 14 
hospital derived indicators to an elderly population in the community and described 
primary care based prescribing indicators as inaccurate as they were based on 
overall prescribing and lacked patient clinical data. Key requirements for the 
development of prescribing indicators for use in the NHS is the need for them to be 
based on scientific evidence supplemented by expert advice and represent clinical 
areas regarded as important by clinicians and also in line with national health policies 
(Kendall 2004).  
 
NHS reforms over recent years have seen huge increases in funding but with it a 
target driven and performance management framework across the whole NHS. 
Initiatives such as primary care benchmarking schemes or scorecards were 
introduced in order to measure GP practices against a range of performance targets 
that included prescribing indicators based on PACT data (Primary Care Contracting 
2006). In 2006 the NHS Institute for Innovation and Improvement introduced three 
“Better Care Better Value” prescribing indicators to nationally benchmark all PCTs 
against the top quartile of performing organisations. In response to financial 
challenges, the Department of Health established quality, innovation, productivity and 
prevention (QIPP) as the guiding principles to help the NHS deliver its quality and 
efficiency commitments (Department of Health 2009b).  
 
 




The QIPP medicines use and procurement criteria developed by key stakeholders, 
including the National Prescribing Centre, aimed to ensure that value for money was 
further enhanced whilst maintaining or improving quality of care by optimising the use 
of medicines. In order to support QIPP the continued use of prescribing indicators 
were central to measure and identify a range of prescribing initiatives and key 
therapeutic areas for implementation by local medicines management teams 
(National Prescribing Centre 2012). 
 
1.7.4 Evidenced Based Medicine  
Historically the formal assessment of medical interventions has principally been 
based around the evidence obtained from clinical trials. During the 1980s the concept 
of evidenced based medicine emerged, challenging this formal process and 
introducing a more practical methodology of assessment. Evidenced based medicine 
has been defined as “the conscientious, explicit, and judicious use of current best 
evidence in making decisions about the care of individual patients” (Sackett et al 
1996 p71). The basic principle of evidenced based medicine has been described as 
to treat where there is evidence of benefit and not to treat where there is evidence of 
no benefit (or harm), and that is of relevance at all levels of the NHS both 
strategically, tactically and individually (Besley 2009). The practice of evidenced 
based medicine involves integrating individual clinical expertise with the best 
available external clinical evidence from systematic research. Stephens (2005) has 
described a range of tiered hierarchy approaches to ranking evidence from the most 
reliable evidence to the least based on the design or nature of the source. The most 
reliable sources being systematic reviews including meta-analysis of randomised 
controlled trials and the least from sources such as expert opinion or case studies.   
 
In the UK delivering evidenced based recommendations on medical interventions 
including drugs at a national level is the responsibility of the National Institute of 
Health and Clinical Excellence (NICE). Launched in 1999 as a Special Health 
Authority, the Institute aimed to produce and disseminate clinical guidelines on the 
relevant evidence of clinical cost effectiveness, associated audit methodology and 
information on good practice (Stephens 2005). In addition having a national body to 
assess new technologies overcame the previous often chaotic approach that led to 
postcode prescribing. Using a six-tiered approach to review evidence, 
recommendations, standards and services were developed in consultation with 
independent committees and experts. In addition NICE commissioned independent 
academic centres to review the published evidence on the relevant technology.  




Granby (2005) has described the need for a structured approach to prescribing 
taking into account the efficacy and cost-effectiveness of treatment options, how to 
check the evidence, the benefits or harms of a treatment and, the patient’s own 
involvement in the treatment plan. In contrast inappropriate and non-evidence-based 
prescribing can be detrimental, harming patients through side effects, adverse drug 
reactions, hospital admission and in some cases fatality.  
 
1.7.5 Prescribing formularies: Historical perspectives 
In 1864 the newly created General Medical Council (GMC) was authorised to prepare 
the British Pharmacopoeia, which for the first time in the UK laid down legally 
enforced standards for the quality individual drugs used in medicines (Wade 2003). 
In 1927 the British Medical Association (BMA) and the then Retail Pharmacist 
Association (now National Pharmaceutical Association) developed the first national 
medicines formulary containing 295 monographs (Thomson 2007). With the launch of 
the NHS in 1948 both the BMA and the Pharmaceutical Society of Great Britain 
(PSGB) worked together through a Joint Formulary Committee (JFC) leading to the 
publication of the first British National Formulary (BNF) in 1949. The following years 
saw the JFC implement periodical changes to content and design as new drugs and 
formulations became available. However with concerns growing over the influence of 
the Pharmaceutical Industry on doctors, during the mid-1970s the JFC were 
instructed to produce a BNF with much greater level of detail on all medicines 
available, drug prices and also of a size that would fit in a coat pocket (Wade 2003). 
Often described as the therapeutic bible, the BNF is considered by many as essential 
for clinical practice, bringing together authoritative and independent guidance on best 
practice with clinically validated drug information, enabling healthcare professionals 
to select safe and effective medicines for individual patients (Britton 2009).  
 
1.7.6 Developing hospital and primary care formularies 
Historically formularies have their origins in secondary care and were originally 
produced to encourage hospital doctors to prescribe from the selection of drugs 
contained therein (Furness 2000). Over time hospital formularies have changed to 
accommodate advances in medical practice, newer drugs and the wider availability of 
associated prescribing information. Modern hospital drug formularies are source of 
detailed local prescribing information incorporating treatment guidelines and 
summaries of best practice (Khan 2002). Central to formulary management process 
was the role of local drugs and therapeutic committees (DTCs).  




Stephens (2005) described the evolution of DTCs in the UK since the 1970s and their 
original format of “hospital pharmacy committees” with GPs included in a minority 
capacity. Burrill (2003) reported on the response of former Health Authorities to a 
direction from the Department of Health {EL(94)72)} that required appropriate action 
was taken on hospital-led prescribing and new drugs that led to the formation of area 
prescribing committees (APCs). Stephens (2005) described a growing frustration in 
terms of inequitable access to medicines and the emergence of APCs such as the 
Midland Therapeutic Review and Advisory Committee (MTRAC) as an attempt to 
deal with these pressures. A national survey of 77 APCs in England resulted in the 
publication of a national guide to good practice including advice on the drug 
recommendation process (National Prescribing Centre 2000). “Managing Medicines 
across the Health Economy” outlined a fitness for purpose framework for APCs to 
review and restate their role, or help to identify improvements (National Prescribing 
Centre 2007b).  
 
In 1989 a review reported that although there had been increased quality in 
prescribing from the introduction of formularies in UK hospitals and general practice, 
measurable outcomes were difficult to quantify (Anon 1989). In addition the review 
described cost reduction as a secondary aim and although clear in general practice 
this was but less easy to evidence in secondary care where many factors contributed 
to the drugs bill. Duerden and Walley (1999) reported a lack of examples of 
successful joint formularies and suggested that with primary care reforms in 
commissioning the use of joint formularies would reduce problems encountered at 
the primary and secondary care interface.  In addition the authors reported that many 
local decisions around drug choices would be superseded by national decisions 
made by NICE. Furness (2000) also reported on the limitations of primary care or 
joint formulary implementation, citing difficulties such as time constraints, updating 
and monitoring a formulary list, and concordance at practice level. Smith (2005) 
reported on the outcome of a national survey conducted by Pharmacy Management 
Magazine of 220 primary care organisations. The survey reported that 64% of former 
PCTs were working with a formulary or an approved list of drugs in primary care and 
that 47% shared a formulary of with their local hospitals. In a survey of all 1099 GPs 
(43% response rate) in the South West where a joint formulary was in existence, the 
authors reported an overall positive attitude towards the process particularly towards 
the educational value and the potential for improving prescribing across the interface 
(Heal et al 2006).  




1.7.7 Financial incentives in prescribing and the GP contract 
In the UK, GPs have traditionally been offered a range of financial incentives, via a 
national contract, that has offered a mix of remuneration including fee for service, 
capitation, salary and information technology (Smith and York 2004). In addition the 
traditional GP contract encouraged public health interventions such as vaccinations 
and screening. Under GP fund-holding, practices that achieved savings from 
indicative prescribing budgets were able to reinvest this money to improve patient 
care. In a further initiative the Health Service Circular 1999 / 228 identified to newly 
formed Primary Care Groups (PCGs), which later became Primary Care Trusts 
(PCTs), a framework to ensure prescribing incentive schemes were offered to all GP 
practices. Evaluations of such incentive schemes have provided mixed outcomes. 
Ashworth et al (2002, 2003) surveyed PCG / PCT prescribing advisors over two 
consecutive years in London and South East (n = 113, 2000; n = 145, 2001) to 
investigate the use of prescribing incentive schemes. A reduction of overspending 
PCGs / PCTs on prescribing budgets in year 2 (38%) from year 1 (88%) and that 
nearly all had adopted quality prescribing indicators by year 2 within these incentive 
schemes was reported. However the authors added that many schemes could have 
been better designed to reinforce the national policy emphasis on quality 
improvement. In a national survey of all PCGs / PCTs in England, Mason et al (2005) 
requested original copies of all incentive schemes to explore whether this was a 
useful approach to encourage quality prescribing. This study identified that many 
schemes had not been finalised and that although schemes generally covered similar 
therapeutic areas, they varied considerably in length, complexity and reward 
structure. 
 
In 2004, following an evaluation of a two year primary care quality improvement 
scheme pilot project in East Kent, a new contract for general practice was announced 
(Smith and York 2004) The new contract represented a significant shift in the way 
GPs worked, and promoted principles of high quality and evidenced based care and 
consistency in care for patients across the country. A fundamental part of the new 
contract was the Quality and Outcomes Framework (QOF). The framework created a 
point based system which remunerated general practices for providing quality care to 
patients. In order to support QOF, a national IT system, the Quality Management and 
Analysis System (QMAS), was introduced that provided GP practices and PCTs 
objective evidence and feedback on QOF performance.  
 




The QOF comprised of a range of criteria referred to as indicators that were linked to 
both clinical and organisational domains to support the management of long-term 
conditions such as cardiovascular disease and diabetes (NHS Employers and the 
BMA 2009). In addition indicators were introduced in relation to systems and process 
that supported medicines management such as repeat prescribing and medications 
review.    
 
Roland et al (2005) used both qualitative interviews with 20 GPs and a quantitative 
survey of 1035 GPs to examine the impact of QOF. Results suggested that although 
patients were being seen more frequently, particularly in nurse-led clinics, overall 
there were possible unintended consequences of an incentive driven contract such 
as reduced continuity of care, care fragmentation, neglect of clinical areas excluded 
from QOF and damage to internal motivation. Bland (2005) on behalf of the BMA, 
reported on the success of QOF in improving quality of care and that the prescribing 
of QOF drugs had not been at the expense of others.  
 
A limited number of studies have evaluated the impact of QOF in relation to 
prescribing in primary care. Two studies examined attainment within small groups of 
practices (n = 18, Steele et al 2007, n = 26 Guildford et al 2007) and three have 
examined national performance data (Tsimtsiou et al 2009, Ashworth et al 2007, 
Petty and Lloyd 2008). MacBride-Stewart et al (2008) conducted a review including 
92 practices within one NHS region in Scotland. A common theme identified was the 
relationship between rising prescribing levels of QOF drugs compared to non-QOF 
drugs in relation to QOF scores and or improved clinical management. Steele (2007) 
reported that the standard of care provided for conditions not presently managed 
within the QOF had been maintained. Ashworth et al (2007) reported on the 
relationship of social deprivation to QOF outcomes in coronary heart disease and the 
use of cholesterol lowering agents. The authors described a 34.5% variation in statin 
prescribing by GPs and that the most powerful predictors for prescribing were higher 
social deprivation, higher prevalence of coronary heart disease and achievement of 
cholesterol targets for diabetics. In addition statin prescribing was reported to be 
higher in more deprived communities, even after adjustment for increased disease 









1.7.8 The Kings Fund: The quality of GP prescribing 
“Improving the quality of care in general practice” was the most extensive review of 
quality across general practice (The Kings Fund 2011). One part of the inquiry 
focussed on GP prescribing with specific reference to the patients’ perspective and to 
their ‘journey’, and the effect of prescribing on patient safety (Duerden et al 2011). 
This comprehensive study included a literature review of GP prescribing, and a 
scoping review for guidance and commentary from professional bodies and 
organisations. The authors reported that a clear definition of prescribing quality was 
elusive and that any description was guided by the wide range of stakeholder groups 
involved in the prescribing process either from an academic, clinical, managerial or 
commercial perspective. The review highlighted the need to improve knowledge 
about pharmacology and therapeutics, to enhance prescribing support systems, drug 
monitoring, prescription reviews, and communication with patients in order to achieve 
concordance. The authors reported that a clear definition of prescribing quality was 
elusive and that any description was guided by the wide range of stakeholder groups 
involved in the prescribing process either from an academic, clinical, managerial or 
commercial perspective. One of the recommendations was to develop quality 
indicators in relation to prescribing including the use of computerised decision 
support systems (CDSS). In the UK a shift from paper based to paperless medical 
records within GP practices had introduced a range of benefits such as automated 
restructuring of records, speeding, guiding, and validating data input such as through 
templates and the availability of CDSS (Purves 1996). 
 
Despite the years the original definition of prescribing quality by Parish (1973) placing 
it in the context of a cash-limited health service is a stark reality considering the 
current financial climate within the UK economy including the NHS. Over the decades 
a number of Government schemes and initiatives have been introduced in order to 
curtail an escalating drugs budget. In 2010 the Government announced in the White 
Paper “Equity and excellence: Liberating the NHS” that it would release up to £20 
billion of efficiency savings by 2014 which would be reinvested to support 
improvements in quality and outcomes (Department of Health 2010). With the NHS 
targeting continued efficiency savings one specific CDSS that offers cost effective 
prescribing choices to GPs at the point of prescribing including has been increasingly 








1.8 Computers in UK general practice  
Computers first entered UK general practice in the early 1970s, initially designed to 
collate epidemiological data by enthusiasts. Much of the pioneering use of computers 
during GP consultations took place in Exeter, particularly at the Ottery Health Centre 
which during the late 1970s, operated a computerised system that was fully 
integrated with the local hospital, allowing general practitioners and hospital staff to 
share the same information, subject to access controls (Benson 2002). Early 
experimental systems were often paid for by GPs until the “Micros for GPs” scheme, 
a Government sponsored program to encouraged national take up of computer 
systems (Benson 2002a). However progress was relatively slow due to constraints of 
money and time and to uncertainties about the most appropriate hardware and 
software to use (Jones 1986). Two computer suppliers in the late 1980s introduced 
schemes whereby practices were provided free systems in return for comprehensive 
data on morbidity and prescribing which could be sold to pharmaceutical companies 
for post marketing surveillance, market research and clinical trials (Benson 2002a). 
These schemes were soon scrapped when Government eventually introduced a 
direct reimbursement scheme in 1989. This led to a dramatic increase in uptake and 
by the 1990s over 50 commercial systems were available with 8,500 practices fully 
computerised (Millman et al 1995). Technical improvements allowed improved 
functionality such as links to pathology laboratories, internet access, and data 
management to support clinical audit. In addition computers transformed prescription 
management systems, because illegible handwriting has been widely acknowledged 
as a major cause of medical error (Bruner and Kasdan 2001).  
 
1.9 Computerised decision support systems (CDSS) 
Wyatt (1991a) has described a deductive approach to decision making by clinicians 
from symptoms to aid diagnosis by drawing on medical knowledge to form one or 
more hypothesis about their cause. Historically medical knowledge to aid decision 
making has been in a conventional format such as books, journals, discussion with 
colleagues or through educational meetings (Wyatt 1991a). The negative aspects of 
books and journals include their size and number, storage, reliability, publication bias 
and need for updating. Computers introduced a novel concept in that apart from 
being able to store medical knowledge they also allowed this knowledge to be 
manipulated as text meaningful to users, but also encoded as symbols meaningful to 
computers (Wyatt 1991b).Encoding this knowledge allowed better user interaction to 
locate data from the knowledge base and to act as both a teaching and medical 
decision aid.  




Wyatt (1991b) described computerised medical decision aids as best classified by 
their clinical role, citing early examples of their use in medicine for interpreting 
abnormal data e.g. laboratory results or patient specific data to aid clinical diagnosis.  
 
With the expansion of computer use within healthcare settings interest emerged in 
CDSS, with initial development aimed at aiding diagnosis and dose calculations. 
However this led to the development of GP and pharmacy systems to support 
prescribing via alerts to warnings on drug interactions, allergies and contraindications 
(Barber 2004). Shortliffe (1987 p61) defined CDSS as “any computer program 
designed to help health professionals make clinical decisions.” The author described 
three levels or tools for support from a generalised level to a patient specific level, as 
either:  
 
 Tools for information management: e.g. hospital information systems to 
access patient data or bibliographic retrieval systems 
 Tools for focussing attention: e.g. clinical laboratory systems that flag 
abnormal values  
 Tools for patient specific consultations: e.g. programs that provide customised 
assessments or advice based on sets of patient specific data    
 
This broad definition included any computerised system such as electronically 
available books and journals. Wyatt and Spiegelhalter (1992 p3) provided a more 
specific approach to CDSS defining it as "active knowledge systems which use two 
or more items of patient data to generate case-specific advice.” From an operational 
perspective in terms of how CDSS are used within clinical settings; Haijoff (1998) 
described a simple classification model of a CDSS being either passive or active. In 
passive systems the user would interrogate the CDSS for information that was not 
patient specific, such as an electronic formulary or a clinical guideline. In contrast 
active systems would aid the user at a patient specific level often through the 
interaction of electronic or computerised databases such as providing simple drug 
alerts, reminders or more sophisticated systems that supported diagnosis or disease 
management. A range of techniques have been utilised in the design methodology of 
CDSS ranging from simple logics such as problem specific algorithms to more 
complex mathematic modelling, and the predominant Bayesian statistics, decision 
analysis and the computer science subfield known as “artificial intelligence” (Shortliffe 
1987). 




Thornett (2001) described these techniques from an operational perspective as one 
of two levels of CDSS. A simplistic level that encouraged users to follow a logical 
approach to decision making or a “rule based system” or in contrast to more complex 
“expert system”, that could answer medical queries and provide patient tailored 
advice. 
  
1.9.1 Rule based systems  
These encourage the user to think through decisions logically and to enter data 
logically similar in fashion to large flow charts. Commonly available as electronic 
protocols these systems present information in context and in response to prompts or 
steps that guide for example drug choice or a possible diagnostic strategy (Delaney 
et al 1999). One example of such a system in the UK is the NHS Direct triage service 
that provides advice to health professionals during telephone consultations. These 
systems rely on the application of a set of rules which that are based on clinical or 
demographic characteristics or the results of previous steps. In addition the rationale 
behind the rule set may range from national guidance, expert opinion or examples of 
best practice. In addition due to their nature these systems reflect a gradual 
accumulation of data and assimilation into practice.  Another common example of a 
rule based system are reminders and alerts that are linked to screening, 
immunisations or drug therapy such as warnings and drug interactions.   
 
1.9.2 Expert based systems 
Expert–based systems operate through a series of interactions between a database 
of knowledge e.g. clinical guidelines, a decision making component and the patient 
record that present to the end-user clinician as an interface framework within the 
healthcare setting (Haijoff 1998). These systems attempt to model the thought 
process of the human mind by selecting additional rules based upon a set of 
hypotheses (Thornett 2001). Often known as probabilistic systems, patient data is 
modelled to predict possible future health interventions or outcomes. An advantage 
of this model is that knowledge is separated from inference and in addition systems 
can be readily updated exemplified in the UK with the availability of cardiovascular 










1.10 Discussion  
Protti (2005) suggested that although modern society had adapted to computerised 
technology with innovations seen in a range of industries, healthcare had continued 
to lag behind with the overwhelming majority of computers used for simple 
accounting and statistical reporting. The author added that due to the lack of 
adequate support systems, most clinicians continued to practice 'memory-based 
medicine.” Delaney et al (1999) reported that despite the UK having the most 
extensively computerised primary healthcare system it was surprising that CDSS was 
not commonplace, citing a number of factors such as the absence of national agreed 
standards. The authors concluded that although CDSS had demonstrated benefits 
such as in the management of anticoagulation further research was required in 
patient orientated outcomes and that that despite the huge potential in its use the 
concept had largely failed due to the failure to examine the needs of practitioners 
more closely. Coiera et al (2006) reviewed the literature in relation to the safety and 
quality of CDSS in both primary and secondary care from the UK and abroad. The 
author described CDSS as a potent intervention that improved the quality, safety and 
effectiveness of clinical decisions however uptake levels had remained low. It is has 
been estimated that thousands of CDSS have been made available for use by 
clinicians within healthcare settings (Morris 2002). In addition despite the huge 
investment of time and money into these CDSS little is known of the tens or 
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The previous chapter outlined how CDSS was identified as a specific area for further 
investigation for improving the quality of prescribing by GPs. In order to identify 
international literature on the use of CDSS within primary care settings a number of 
additional methodologies were considered including the use of scoping reviews. 
When evaluating evidence, Stephens (2005) described systematic reviews of well-
designed randomised controlled trials as the gold standard. Systematic reviews use a 
transparent process to define a research question, search for published studies and 
to assess their quality (Armstrong et al 2011). A crucial step in the systematic review 
process is to define the scope of the research question, and this requires an 
understanding of existing literature, including gaps, uncertainties and clarification of 
definitions related to the research question. However an increasingly popular way to 
collate important background information and assess the existing evidence base of a 
subject area is to conduct a scoping review (Armstrong et al 2011).  
 
2.2 Scoping reviews 
A key difference between scoping reviews and systematic reviews is that the scoping 
review provides an overview of existing literature usually without assessing the 
quality of included studies (Armstrong et al 2011). Scoping reviews are commonly 
described as following a mapping process that summarises a range of evidence in 
order to convey the breadth and depth of a particular field (Levac et al 2010). A 
scoping study can determine the size and nature of the evidence base for a particular 
topic area, which in turn can be used to identify gaps in the literature and make 
recommendations for future research. Anderson et al (2008) described scoping 
reviews as imprecisely defined, but were commonly non-systematic reviews of a 
subject area. A summary of the key differences between systematic reviews and 














Table 2.1 Key differences between systematic reviews and scoping reviews 
(adapted from Brien et al 2010) 
Systematic Reviews Scoping Reviews 
Focused research question with narrow 
parameters 
 
Research question(s) often broad 
 
 
Inclusion / exclusion criteria usually 
defined at outset 
 
Inclusion / exclusion criteria can be 
developed post hoc 
 
Quality filters often applied 
 
Quality not an initial priority 
 
Detailed data extraction 
 
May or may not involve data extraction 
 
Quantitative synthesis often performed 
 
 
Synthesis more qualitative, and typically 
not quantitative 
 
Formally assesses the quality of studies 
and generates a conclusion relating to 
the focused research question 
Used to identify parameters and gaps in 
a body of literature 
 
 
A number of different approaches to scoping reviews have been reported. Arskey 
and O’Malley (2005) described a step-wise approach as part of a methodological 
framework to scoping. Anderson et al (2008) described a process of mapping the 
relevant literature, policy, stakeholder consultation and conceptualisations of the 
research area, however the authors stated that this was by no way comprehensive or 
restrictive. In the UK the Service Delivery and Organisation Research Program 
(SDO) has had extensive experience of commissioning and using scoping reviews 
within the health service (Anderson et al 2008). Key lessons from the SDO included 
the need for scoping teams to be multi-disciplinary, have sufficient time to integrate 
diverse findings and the need for research commissioners to be explicit about the 
aims and intended use of scoping studies. In the UK examples of scoping reviews 
used to evaluated aspects of prescribing within primary care have included the extent 
and uptake of nurse and pharmacist supplementary prescribing (Bissell et al 2008). , 
and the quality of prescribing by GPs (Duerden et al 2011).  
 
 




In both of these studies the research teams complemented healthcare database 
searches with a range of additional methods in order to obtain further evidence and 
literature in relation to the specific subject areas including engagement with 
stakeholders. Bissell et al (2008) reported a scoping review strategy that included a 
thematic review of published and grey literature, interviews with key stakeholders 
involved in supplementary prescribing, a postal questionnaire survey of nurses 
(n=518) and pharmacists (n=411). In addition ten detailed case studies of 
supplementary prescribing practice were included supported by observations, 
interviews and prescribing data. In a scoping review of the quality of GP prescribing 
in the UK, Duerden et al (2011) obtained guidance and commentary from 
professional bodies and organisations using an initial stakeholder meeting. A further 
stakeholder event involved 27 attendees from across a range of disciplines and 
backgrounds to include GPs, academics, NHS Connecting for Health, the CDSS 
industry and patient representative groups.    
 
Arskey and O’Malley (2005) described a five stage framework underpinned by 
attributes characterised by systematic reviews as  each stage is conducted in a 
rigorous and transparent way so that the process be documented in sufficient detail 
to allow the study be replicated by others. A summary of this methodological 









Table 2.2: An overview of a methodological framework for conducting a scoping review (adapted from Arskey and O’Malley 2005) 
Framework Stage Description 
1. Identifying the 
research question 
Identifying the research question is the starting point that guides the way which search strategies are developed 
and conducted. A wide approach is suggested in order to provide breadth of coverage. 
2. Identifying relevant 
studies 
This stage involves identifying relevant studies and developing a decision plan at the outset about coverage of 
the review in terms of time span and language. for where to search, which terms to use, which sources are to be 
searched, time span, and language. Sources include electronic databases, reference lists, hand searching of key 
journals, networks, organisations and conferences. Breadth is important however practicalities of the search are 
as well such as time constraints, budgets and personnel resources as these may be potential limiting factors on 
the search strategy.   
3. Study selection Study selection involves post hoc inclusion and exclusion criteria based on the specific research question but 
also an increasing familiarity of the literature was identified and reviewed.    
4. Charting the data A data-charting form is developed and used to extract data from each study which can be a mixture of general 
information e.g. study population, intervention type and outcomes. A 'narrative review' or 'descriptive analytical' 
method is used to extract contextual or process oriented information from each study. 
5. Collating, 
summarising and 
reporting the results 
A basic numerical analysis can present the extent, nature and distribution of studies identified.in either tables or 
charts. An analytical framework or thematic construction is used to provide an overview of the breadth of the 
literature.   
 





For this study a scoping review was selected as the method of choice and was 
performed based on the methodological framework outlined by Arksey and O'Malley 
(2005). In the development of a research question, aspects of the research area 
were considered. The research team had developed a working knowledge and 
experience of IT within UK general practice and primary care. In addition in the UK, 
CDSS was widely available within GP clinical systems and community pharmacy 
computer systems. Drawing on this experience and an overview of the literature, the 
primary research question was to identify the use and evaluation of CDSS in primary 
care. The rationale behind this research question was to gain an understanding of 
the evidence base of CDSS in primary care and to identify opportunities to us this to 
improve prescribing by GPs in the UK.  
 
2.3.1 Identifying relevant studies  
A number of steps were taken firstly to obtain relevant information in the form of 
published articles and studies available from healthcare databases and then 
extending the scoping review to include a review of the grey literature. Grey literature 
was identified using further internet searches, website reviews and personal 
communication with representatives from the CDSS industry. Table 2.3 summaries 













Table 2.3 Methods used to obtain relevant studies and additional evidence 
Evidence Source Methods Inclusion / Exclusion Criteria  
1.Healthcare database 
searches from 1990 to 2010 
AMED, BNI, HMIC, MEDLINE, 
EMBASE, PsycINFO, CINAHL, 
and HEALTH BUSINESS. This 
search was repeated in March 
2011.  
Key words, “computerised decision support”, “physician order 
entry and prescribing”  
Inclusion criteria limited to the use of 
CDSS in primary care settings only. 
These included in supporting 
prescribing, clinical guidelines, 
therapeutic control, medicines 
management. Other articles of interest 
were identified including literature 
reviews of CDSS including expert 
opinion  
2. NHS Connecting for Health 
(CFH).  
 
Searches and interrogation of the CFH website.  Webpages and policy documents 
identified 
3. National Institute for Clinical 
Excellence (NICE) 
Searches and interrogation of the NICE website.  Web pages and evidence identified 
4.  Other Sources Known websites in relation to CDSS and health informatics. 
Websites visited: First Databank, Script-Switch®, INRstar®. In 
addition the websites of GP clinical system providers in the 
UK: EMIS, INPS (Vision), Micro-Test, iSOFT and SystmOne 
were reviewed.  
 
Web pages and evidence identified  
5. Personal Communication Discussions with representatives from a commercial CDSS 
supplier. One informal interview and one informal telephone 
conference call.  








2.3.1.1 Healthcare database searches  
Published studies and articles were identified from healthcare database searches 
conducted in December 2010 with a date range from 1990 to 2010 using AMED, BNI, 
HMIC, MEDLINE, EMBASE, PsycINFO, CINAHL, and HEALTH BUSINESS. The 
results of these database searches are shown in Table 2.4 
 
Table 2.4 Results of healthcare database searches 
Healthcare databases searched including search 
terms used 
Numbers of citations 
AMED, BNI, EMBASE, HMIC, MEDLINE, PsycINFO, 
CINAHL, HEALTH BUSINESS ELITE; Duplicate 
filtered:  "computerised decision support" AND 
“prescribing”).ti,ab;  
114 
AMED, BNI, EMBASE, HMIC, MEDLINE, PsycINFO, 
CINAHL, HEALTH BUSINESS ELITE; Duplicate 




Three hundred and thirty three references to articles and studies were initially 
identified from the healthcare database searches. Lists of these citations were 
printed and reviewed for duplications and against an initial set of inclusion and 




 Reports, studies and articles in relation to CDSS within primary care settings 
 Limited to use by GPs, however in UK studies were included that referred to 
use by nurses in either general practice or other primary care settings 
 Limited to the UK, USA, Australia and Europe 
 Relevant background literature in relation to health informatics and CDSS 
 
Exclusion criteria  
 Reports, studies and articles in relation to CDSS within secondary or tertiary 
care settings 
 Reports, studies and articles in relation to CDSS within pharmacies  
 Literature in relation to related to wider aspects of healthcare delivery namely 
electronic health records, electronic transfer of prescriptions and systems or 
frameworks supporting this process. 




References of selected studies were checked for any additional sources of 
information. The healthcare database searches were repeated in March 2011 and 3 
additional articles were identified.   
 
2.3.1.2 Website reviews 
Further evidence was obtained from a number of website searches to include NHS 
Connecting for Health (CFH), the National Institute of Clinical Excellence (NICE) and 
commercial providers of CDSS are summarised in Table 2.5 
 
Table 2.5 Summary of website searches of commercial providers of CDSS 
Website Summary  
NHS Connecting for 
Health (CFH): 
 Accessed March 2011 
 Documentation from either web pages or policy 
documents in relation to CDSS availability  
The National Institute 
of Clinical Excellence 
(NICE) 
 Accessed in December 2010 and March 2011 
 Documentation from either web pages or published 
evidence to support the use of CDSS from technology 
appraisals or for the use in supporting the 
implementation of clinical guidelines. 
Commercial providers 
of CDSS 
 Accessed March 2011 
 First Databank® 
 Script - Switch® 
 INR-Star® 
 
In addition the websites of the five GP clinical system 
suppliers EMIS, INPS (Vision), Micro-Test, iSOFT and 
SystmOne were reviewed.  
 
2.3.1.3 Personal communication  
In May 2011 personal communication with a CDSS representative was made by the 
lead researcher (NC) and an informal meeting was arranged. This meeting was held 
in June 2011 where background information was collated on the CDSS industry in 
the UK, and further information with regard to the availability of additional published 
evidence. In addition a telephone conference call was arranged by the researcher 
(NC) and other representatives from the same CDSS supplier which was conducted 









2.3.2 Study selection 
Studies and articles were all checked against the inclusion and exclusion criteria.  
 
2.3.3 Charting the data  
This stage of the scoping review involved charting aspects of evidence identified and 
to support this  a data charting form was created using Microsoft Excel to include the 
following information where possible:   
 
 Author (s)  
 Year of publication  
 Source i.e. publication title or website name 
 Country of origin 
 Type of intervention and or design  
 Aims of study if applicable 
 Relevant results  
 Relevant outcome measures  
 
The evidence identified was then characterised in one of four types of evaluation of 
the research area; systematic reviews of controlled trials of the use of CDSS, reports 
or evaluations of CDDS either in development or in use, evaluations of CDSS from 
the perspective of end users (qualitative or quantitative) and general literature from 
publications to include journal articles, expert opinion and from book chapters.  
 
2.4 Results 
A total of 333 citations were identified from searching the literature databases, from 
which after screening and further checking 150 were determined as relevant to this 
scoping review. Figure 2.1 shows a flow diagram of the steps followed during the 
scoping review and the results obtained.  Characterisation of data identified from the 
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Summary of outcomes  
Systematic 
Reviews  
22 systematic reviews of controlled trials including RCTs. Reviews were of 
a range of parameters including prescribing, drug dosing, drug monitoring 
and clinician performance.  
From these reviews 53 RCTs were identified of CDSS in use 
from the USA, UK and Europe based in primary care settings that 
were published from 1990. All of the RCTs were checked against 
the healthcare database searches for duplication, 31 additional 
RCTs identified.  
Evaluations or 
reports of CDSS 
in use  
Studies or reports of CDSS in use or in development including prototypes 
from the UK, Europe and abroad including the USA in primary care 
settings.  
58 articles identified on the use of CDSS in primary care either 
from descriptive reports, testing, trials of CDSS (including RCTs) 




Primary care based studies that evaluated CDSS from an end user 
perspective.  
31 studies identified of which 19 were from the UK. Methods 
used included interviews, focus groups, observational studies 
and surveys.  
Other supporting 
literature 
Articles including relevant literature reviews, articles, conference abstracts 
editorials, a university tutorial, and book chapters. 
A range of supporting literature on CDSS including historical 
aspects to decision making, defining CDSS and use in healthcare 
settings. Websites identified were interrogated and data collated 
from either web pages or available documents 
 




2.4.1 Systematic reviews 
Twenty two systematic reviews of a range of controlled trials, including randomised 
controlled trials (RCTs) in relation to CDSS were identified from the scoping review 
and these examined a broad range of parameters including prescribing, drug dosing, 
drug monitoring and clinician performance. Three reviews were updates from 
previous studies (Hunt et al 1998, Garg et al 2005, Durieux et al 2008) whereby 
additional trials were added. Evaluations of CDSS demonstrated positive outcomes 
in terms of improvements in prescribing (Yourman et al 2008), clinician performance 
(Garg et al 2005), adherence to guidelines (Jamal et al 2009) and drug dosing and 
therapeutic response (Durieux et al 2008). In contrast other systematic reviews 
highlighted a lack of high quality studies that demonstrate improved patient outcomes 
(Mollon et al 2009), a need for better implementation strategies (Bryan and Boren et 
al 2008) and an increase in the risk of adverse events or mortality (Eslami et al 
2007a).  
  
Summarised in Table 2.7 are 15 of the 22 systematic reviews that included primary 
cared based trials. Of these only two (Bryan and Boren 2008, Elsami et al 2007a) 
specifically focussed only on the use of CDSS within in primary care settings The 
other 13 reviews included data from studies from both primary and secondary care 
settings. Four of the systematic reviews included trials based in secondary care 
settings only (Walton el 1999, Walton et al 2001, Kaushal et al 2003, Eslami et al 
2007b, Main et al 2010). Of the 11 RCTs identified by Kawamato et al (2005), 2 of 
the primary care based trials were from the 1980s. All of the 7 trials identified by 
Fitzmaurice et al (1998a) in relation to anticoagulation were either pre-1990 and or 
based in secondary care. Bryan and Boren (2008) identified 17 studies including 5 
non-randomised observational studies and 12 RCTs; all based in primary care 
settings. Of the 12 RCTs, 2 were from the UK, 1 from Italy and 9 from the USA. 
Thirteen studies (76%) found either positive or variable outcomes related to CDSS 
intervention with 4 studies (24%) showed no significant effect. Although CDSS was 
found to have the potential to produce statistically significant improvement in 
outcomes, there was much variability among the types and methods of CDSS 
implementation and resulting effectiveness. The authors recommended that further 
work was needed to determine effective implementation strategies for the use of 








Eslami et al (2007a) evaluated the impact of CPOE on patients in primary care 
settings from 30 studies. Of these 3 were based in the UK. Outcome measures 
included the adherence to alerts, safety, time, organisational efficiency, satisfaction, 
usage and usability Although CPOE appeared to support the adherence to 
guidelines, the authors concluded that overall there was little evidence available that 
demonstrated CDSS improved safety measured by medical errors or adverse events. 
After checking for duplication amongst the systematic reviews 53 RCTs specifically 
undertaken in primary care from 1990 were identified. A number of studies were 
identified but not selected as they were either non-randomised trials or observational 
studies. Once checked for duplication against the healthcare database searches 31 
of the RCTs identified were then included as part of the final scoping review. 




Table 2.7 Systematic reviews of CDSS 
Authors  Aims Methods Results Outcomes 
Austin et al  (1994) To assess the clinical value of 
electronic reminders 
Meta-analysis was used to combine 
quantitative data from 10 RCTs 
selected from the Columbia 
registry. Trials were conducted in 
family or internal medicine clinics all 
based in the USA. 
Four trials concerning 
immunisations or cervical screening 
were included in the final analysis. 
Evidence for the use of reminders in 
tetanus immunisation was much 
stronger than that for cervical 
screening. 
 
Electronic reminders were an 
effective information intervention 
that could improve compliance for 




To systematically review 
controlled trials of electronic 
medication reminders or 
feedback directed to healthcare 
providers or patients  
Healthcare database searches, 
reference list reviews and searches 
of conference proceedings. A total 
of 76 studies were identified of 
which 26 were selected that made 
29 comparisons of medication 
management to a control group.  
 
RCTs were included from both 
primary and secondary care 
settings, 24 from the USA, 1 from 
Norway and 4 from the UK. 
Examples of reminders from 
primary care trials included disease 
management and clinical 
guidelines, investigations, specific 
drug related messages and drug 
switching recommendations. 
  
Heterogeneity of trials prevented 
meta-analysis. Reminders were 
found to be more effective than 
feedback in modifying clinician 
behaviour. 
 
Bryan and Boren 
(2008) 
To evaluate the use and 
effectiveness of CDSS from 
controlled trials within primary 
care settings.  
Healthcare database searches. 
Studies were selected for review if 
they involved CDSS as a single 
intervention and included 
quantifiable outcome measures. 
Seventeen studies were included in 
the review, including 12 RCTs, of 
which 2 were from the UK, 1 from 
Italy and 9 from the USA. Thirteen 
studies found either positive or 
variable outcomes related to CDSS 
intervention with 4 studies showed 
no significant effect. All were 
primary care based studies.  
CDSS was found to be a validated 
intervention that had the potential 
to produce statistically significant 
improvement in outcomes. 
Variability was found amongst the 
types and methods in the 








Table 2.7 Systematic reviews of CDSS (cont.)  
Authors  Aims Methods Results Outcomes 
Durieux et al (2008) 
 
To assess from controlled trials 
whether CDSS advice on drug 
dosage had beneficial effects on 
the process or outcome of 
healthcare. An update of a 
previous study (Walton et al 
2001) 
Healthcare database searches. 
Hand  searches  of relevant and 
reference lists from primary articles 
26 comparisons (23 articles) met 
the inclusion criteria. 7 trials were 
based in primary care settings 3 
from the UK, 1 from France, 1 from 
Canada and 1 multicentre study 
across Europe. 16 trials were 
based in secondary care settings, 
11 from the USA and 5 from across 
the world.  
 
CDSS to support drug dosing had 
some benefits that led to a more 
rapid therapeutic control. It also 
reduced the risk of toxic drug levels 
and the length of time spent in 
hospital, however it had no effect 
on adverse events.  
   
Eslami et al (2007) To evaluate the impact of CPOE 
on patients in primary care 
settings.  
Healthcare database searches.  
Studies that included CDSS that 
were not part of CPOE systems 
were excluded.  
30 studies were included for final 
analysis.  Outcome measures 
were   adherence to alerts, safety, 
time, organisational efficiency, 
satisfaction, usage and usability. 
Of the 30 studies 3 were from the 
UK. All studies were based in 
primary care 
 
Although CPOE appeared to 
support the adherence to 
guidelines, overall little evidence 
was available in improving safety 
measured by medical errors or 
adverse events.  
Garg et al (2005)  To review controlled trials 
assessing the effects of CDSS 
and to identify study 
characteristics predicting 
benefit. This study was an 
update from Hunt et al (1998).  
Healthcare database searches. 
Studies were included that 
evaluated the effect of CDSS on 
practitioner performance or patient 
outcomes. 
 
100 studies were included for final 
analysis with 55 from primary care. 
CDSS improved practitioner 
performance in 62 (64%) of the 97 
studies assessing this outcome 
including the use of diagnostic 
systems, reminder systems, 
disease management systems, 
and drug-dosing or prescribing 
systems. 
Improved practitioner performance 
was associated with CDSS that 
automatically prompted users 
compared with those requiring 
users to activate the system. 
However the effect of CDSS on 
patient outcomes was 
understudied and when studied 
was found to be inconsistent 
 
 




Table 2.7 Systematic reviews of CDSS (cont.)  
Authors  Aims Methods Results Outcomes 
Hunt et al  
(1998)  
To assess the effects of CDSS 
on clinician performance and 
patient outcomes. An update 
from a previous study 
(Johnstone et al 1994)   
Healthcare database searches. 
Reference lists and conference 
proceedings reviewed. An update of 
an earlier study, adding searches from 
1992–1998.  
68 controlled trials were characterised 
to evaluate a range of uses of CDSS 
such as drug dosing, diagnosis, and 
disease management.  
Published studies of CDSS were 
increasingly of an improved quality. 
CDSS was found to enhance clinical 
performance in drug dosing, 
preventative care and other aspects 
of medical care. The effect on patient 
outcomes was found to be 
insufficiently studied.  
 
Jamal et al 
(2009) 
To assess the impact of 
information technology on the 
quality of healthcare  
Healthcare database searches. 
Searches for relevant conference 
proceedings a review of reference lists.  
A total of 23 studies were included for 
final analysis including 8 RCTs of 
which 7 were from primary care. A 
positive improvement, in relation to 
their compliance with evidence-based 
guidelines, was seen in 14 studies.  
As with similar previous reviews 
information technology increased 
clinicians’ adherence to guidelines.  
Johnston et 
al  (1994)  
To review the evidence from 
controlled trials of the effect of 
CDSS on clinician 
performance and patient 
outcomes.  
Healthcare database searches. 
Conference proceedings and reference 
lists reviewed.  
28 controlled trials were included for 
final analysis. Studies were of the use 
of CDSS in supporting drug dosing, 
diagnosis, preventative care reminders 
and clinician performance.   
Strong evidence was identified that 
some CDSS could improve physician 
performance. Further well designed 
studies were needed to evaluate their 
effects and cost effectiveness 










Table 2.7 Systematic reviews of CDSS (cont.)  
Authors  Aims Methods Results Outcomes 
Mollon et al 
(2009) 
A systematic literature review 
of CDSS for features 
predicting the success of 
CDSS for Prescribing 
Healthcare database searches.  
Studies were screened for 28 pre-
determined system features 
41 RCTs met the inclusion criteria of 
which were from both primary and 
secondary care settings. 23 trials were 
conducted in primary care settings with 




Statistical analysis was not able to be 
done due to the small number of 
studies and lack of diversity of 
outcomes. While CDSSs have 
potential to change health care 
provider very few high quality studies 
to show patient outcome 
improvements.  
 
Moxey et al  
(2010) 
A systematic review to explore 









Most studies explored clinician’s 
opinions of a specific CDSS (n = 50). 
38 were in primary care of which 35 
from the USA. 
 
Despite advances in technology and 
CDSS sophistication, most factors 
were consistently reported over time 
and across ambulatory and 
institutional settings.  
Pearson et al  
(2009) 
A systematic review to 
evaluate if CDSS changed 
prescribing practice 
Healthcare database searches.  56 studies met the inclusion criteria of 
which 38 addressed initiating, 23 
monitoring and three stopping therapy. 
46 RCTs were from primary care 
settings of which 6 were from the UK.  
CDSS that impacted on specific 
aspects of the prescribing process 
remained relatively limited. Future 
implementation was suggested to be 
built on effective approaches 
including the use of system-initiated 
advice to address safety issues and 










Table 2.7 Systematic reviews of CDSS (cont.) 
Authors  Aims Methods Results Outcomes 
Schedlbauer 
et al (2009) 
 
A systematic review to gather 
evidence of the types of 
alerting and reminding 
mechanisms that were in use. 
  
Healthcare database searches. Trials 
included if they were RCTs, time series 
analysis and before and after studies.  
 
Twenty studies were included for final 
inclusion however due to considerable 
variation in characteristics of these 
trials pooling of data was not 
appropriate. Studies were 
characterised as describing either 
basic or advanced alerts. Only 4 of the 
studies were RCTs, 2 based in primary 
care.   
Most of the studies that evaluated the 
effects of prompts and alerts on 
prescribing behaviour showed 
positive, outcomes. This review was 
used as part of report for NHS 
Connecting for Health although none 
of the studies included were from the 
UK 
Sintchenko 
et al (2007) 
A systematic review of the 
evidence associating the use 






Healthcare database searches. 







Twenty four RCTs were selected for 
final analysis of which 14 were from 
primary care settings. 6 of the RCTs 





Published RCTs of CDSS were found 
to be more effective in secondary 
care settings. CDSS was found to 
improve prescribing practice in acute 
illness but was less effective in 
changing clinician performance or 
health outcomes in primary care 
Yourman et 
al (2008) 
Systematic review of CDSS to 
improve prescribing in the 
elderly  
Healthcare database searches   
Studies were eligible if they described 
a CDSS intervention intended to 
improve medication prescribing in 
adults aged over 60 years.  
 
 
Of those 10 studies testing CDSS 
interventions, 8 showed at least 
modest improvements in prescribing,  
Findings for the impact of CDSS 
interventions on clinical outcomes 
were mixed and were reported for only 
2 studies. Of the 7 primary care 
studies 1 from UK, 2 from Canada and 
4 from USA 
Various CDSS was found effective in 
improving prescribing but few studies 








2.4.2 CDSS and international experience in primary care 
From the results a wide range of clinical and therapeutic areas were identified where 
CDSS had either been investigated or used in both developmental and or actual use. 
Evidence of the use of CDSS from the 121 evaluations either from direct use or from 
experiences from end users within primary care settings included 49 (41%) from the 
USA, 47 (38%) from the UK, 8 (7%) were from Australia and 4 (3%) were from 
Canada. The remaining 11% of studies were from the following European countries: 
Denmark (1), France (1), Holland (4), Ireland (2), Italy (1), Norway (3) and Spain (1).  
 
In the USA electronic prescribing systems supported by CDSS are often described in 
relation to computerised physician order entry (CPOE), which integrates other 
electronic systems such as pathology, radiological investigations and medication 
orders (Groundrey-Smith 2008). However despite this experience and reported 
benefits which include a reduction in prescribing and medication related errors, these 
benefits may not be realisable in the UK due to differences in health service 
structure, clinical practice, medicine costing and reimbursement systems (Groundrey-
Smith 2006).   
 
With CPOE systems predominantly based within hospitals, primary care experience 
of CDSS in the USA has remained limited. However notable experience has been 
reported from a number of sites that introduced local prescribing systems and where 
controlled trials that have evaluated CDSS have shown positive outcomes in 
supporting prescribing in paediatrics (Christakis et al 2001, Davis et al 2007), 
antibacterial prescribing (Samore et al 2005) and disease management (Rossi and 
Every 1997, Sequist et al 2005, Lester et al 2005, Roumie et al 2006, Hicks et al 
2008). In contrast a number of other trials demonstrated poor outcomes such as 
adherence to guidelines (Tierney et al 2003) and low response rates to alerts (Judge 
et al 2006). Montori et al (2002) reported that a planned care model supported by 
CDSS in management of diabetes was associated with improved performance but 
not on metabolic outcomes. A lack of improvement or benefits in terms of patient 
outcomes was also described with CDDS supporting the management of 
cardiovascular disease (Tierney et al 2003) and chronic obstructive airways disease 
(COPD) patients (Tierney et al (2005). From a retrospective analysis of 3481 
consecutive drug alerts in primary care practices that used a common CPOE system 
for prescription writing, Weingart et al (2003) reported that GPs overrode 91% of drug 
allergy and 89% of high-severity drug interaction alerts.  




In a larger retrospective analysis of 233,537 medication safety alerts generated by 
2,872 clinicians, Isaac et al (2009) reported an override rate of 77% of allergy alerts 
and between 57% to 98% of high severity drug interaction alerts with the authors 
concluding that medication alerts were possibly inadequate in protecting patient 
safety.   
 
A number of studies including end user evaluations of CDDS within primary care in 
the USA have reported on a mixture of views and experiences. These have included 
the nature and intrusiveness of alerting systems (Krall and Sittig 2001) and their 
specific usability and usefulness (Krall and Sittig 2002). In a survey of 725 GPs and 
142 pharmacists the respondents reported mixed views regarding the effect of CPOE 
on their roles and that alerts provided were useful but still required additional work 
and improvements to increase their clinical utility (Ko et al 2007). Sittig et al (2006) 
reported from a survey of 225 GPs that although the majority of CDSS alerts were 
not explicitly followed and the participants felt they were useful and would be more 
beneficial if they had more time available to address them.  
 
Other notable reports CDSS experience within primary care from either controlled 
trials or end user evaluations from other countries included Canada (Lowensteyn et 
al 1998, Tamblyn et al 2003, Field et al 2009), Australia (Ahearn et al 2003, Bennett 
at al 2003, Swiedan et al 2009, Swiedan et al 2010, Robertson et al 2011) and some 
European countries (Poels et al 2008, Fillipi et al 2003, Martens et al 2007).  
 
End user evaluations from Australia reported a similar mixed picture in terms of views 
and experiences of CDSS. In a national survey of over 3000 GPs McInnes et al 
(2006) described positive outcomes in terms the introduction of CDSS and electronic 
prescribing systems in reducing medication errors. In contrast a number of evaluation 
have reported on drawbacks such as ignoring alerts and missing important drug 
interactions (Ahearn et al 2003), a lack of agreed national standards (Ahearn et al 
2003, Robertson et al 2011), the need for better integration of CDSS with GP clinical 
systems (Robertson et al 2011) and for CDSS developers to recognise GP practice 
concerns over costs and time constraints Robertson et al 2011). Using a modified 
Delphi process with a 12-member multidisciplinary expert panel, Sweidan et al (2010) 
identified 114 features of e-prescribing software systems including CDSS that would 
support safety and quality and could be used to develop software standards, and 
adapted if necessary for use in other settings and countries.  
 




2.4.3 CDSS and UK experience in primary care  
The scoping review identified 46 relevant articles and studies including randomised 
controlled trials that had reported on either the development, use of, or evaluation of 
CDSS in the UK and these are summarised in Table 2.8. Experience of CDSS was 
identified in areas such as chronic disease management, implementation of clinical 
guidelines, triaging, and prescribing support to include the use of drug related 
warnings, alerts and dosage or therapeutic control. Evaluations were of both 
prototype CDSS and of those in use such including 14 RCTs. In addition 11 studies 
involved GPs and nurses as end users of primary care CDSS reported on the use of 
and perceptions towards CDSS either from surveys or qualitative studies such as 
interviews and focus groups.   
 
Although the majority of evidence in relation to the use of CDSS is from GPs 
experiences, there were studies which described CDSS from a nursing perspective 
(Robinson 2004) and in the provision of nurse led primary care services such as in 
anticoagulation management (De Lusignan et al 2004). In an evaluation of four types 
of CDSS used in triaging by NHS Direct, O’Cathian et al (2003) reported on large 
differences in outcomes when nurses were presented with 119 case scenarios 
developed from actual calls made to ambulance services. In a national survey of 
nurses employed in both NHS hospitals and in primary care settings Mitchell el al 
(2009) identified 141 different CDSS in use of which 33 were used within primary 













Table 2.8 UK experience of CDSS within primary care settings 









The authors have reported that this CDSS has been increasingly being 
commissioned by PCTs and that the NHS has been targeting  efficiency 
savings this CDSS could be very important in offering cost effective drug 
choices 
Avery et al (2005) 
 
 
Two - round electronic Delphi survey, completed by a 21-member 
multidisciplinary expert panel, all from the UK 
 
There was a high level of agreement among the expert panel members 
that indicated clear themes around the need for the improvement of safety 
features in GP clinical computing systems 
Avery et al (2007) 
 
Qualitative study using semi-structured interviews with 31 
participants, representing relevant disciplines and interest groups 
There were significant opportunities for the improvement in the safety 
features of general practice computer systems 
Broderwick (1999) 
 
Review article published by National Prescribing Centre (NPC) on 
PRODIGY, a CDSS for use in GP practices 
Background to the PRODIGY project, how it was used and rolled out to 
GP practices in the UK 
Chapman (2007) 
 
Development of CDSS to aid prescribers in the management of stroke 
and diabetes 
Report describing the work of Keele University. 
 




To evaluate the implementation of a primary care, nurse-led, near 
patient anticoagulant monitoring service. Action research workshops, 
supported by questionnaires and clinical audit involving staff from 13 
GP practice 
The group shared their experiences and developed an understanding of 
when it might be appropriate to vary from the CDSS recommendations 
and how this could be audited 
 
Eccles et al 
(2000) 
 
A before and after cluster RCT (The COGENT Study). See Eccles et 
al (2002) 
Initial report of a proposed study of a CDSS  
 




A cluster RCT to study the effect of a CDSS on managing 
computerised evidence based guidelines on managing asthma and 
angina involving 60 GP practices in the North East of England 
 
The CDSS (PRODIGY) was found to have no significant effect on 
consultation rates, process of care measures (including prescribing), or 






A retrospective paired before and after study that compared 
anticoagulant management in secondary care for the year prior to the 
introduction of near-patient testing in a single GP practice, and in the 
subsequent year after it was introduced. 
The primary care results were slightly poorer than secondary care based, 
although the authors maintained these were not clinically or statistically 
important. 




Table 2.8 UK experience of CDSS within primary care settings (cont.) 
Author Type of Evidence Main outcomes  
Emery et al 
(2000) 
Cross-over experiment with balanced block design to assess a CDSS 
with 41 GPs to interpret family history of breast and ovarian cancer 
The use of this CDSS could enable GPs to be more effective gatekeepers 
to genetics services 
Fernando et al 
(2004) 
 
Laboratory testing of 4 of the main GP clinical systems against a list 
of 18 theoretically derived scenarios related to safety 
 
The safety features of the 4 systems that covered three quarters of UK 
general practices were found to have clinically important deficiencies 
 




Evaluation of a CDSS to support oral anticoagulation management by 
measuring proportions of patients adequately controlled defined as 
being within INR range 
 
CDSS enabled safe and effective transfer of anticoagulation management 
from hospital to primary care 
 
 
Fitzmaurice et al 
(1998b) 
 
Prospective evaluation of therapeutic control of all patients taking 
warfarin at one GP practice in Birmingham 
 
CDSS enabled safe and effective transfer of anticoagulation management 
from hospital to primary care 
 




RCT in 12 primary care practices in Birmingham to evaluate oral 
anticoagulant management supported by CDSS in primary care 
compared to secondary care 
 
Care using this method in primary care that supported by CDSS was at 
least as good as routine hospital follow up 
 
 
Fitzmaurice et al 
(2001) 
Retrospective follow up to include patients involved a previous study 
(Fitzmaurice et al (2000) 
Within these practices, oral anticoagulation management was safe and 
effective 
Fitzmaurice et al 
(2002) 
 
RCT of 49 patients from 6 GP practices randomised to either self-
management or routine primary care anticoagulation management  
 
First UK data to show self-management was as safe as primary care 
management. 
 
Fitzmaurice et al 
(2005) 
 
Multi-centre open RCT in the Midlands involving 2530 patients from 
49 from GP practices identified to determine effectiveness of self-
management compared to routine care 
No significant differences were found groups in terms of time spent in INR 
range or adverse effects 
 
Franke et al 
(2000) 
Questionnaire survey of 263 GPs in Nottingham 
 
GPs commonly had problems in drug dosing for certain groups of patients. 
CDSS could have helped in these situations 
 
 




Table 2.8 UK experience of CDSS within primary care settings (cont.) 
Author Type of Evidence Main outcomes  





Cohort study using a sample taken from the West Midlands portion of 
the General Practice Research Database. Of this sample 664,241 
patients were assessed for the probability of recurrent stroke and risk 
and or benefit of treatment with aspirin 
 
Use of decision analysis in practice was limited by the availability of 








Prospective controlled trial introducing PRIMED, a CDSS used in the 
management of hyperlipidaemia across 25 GP practices in 
Birmingham 
 
GPs favoured the concept but cited technical problems. Greater 
integration of CDSS software and practice based handling systems was 
required 
 
Hor et al (2010) 
 
 
Cross sectional study with a questionnaire sent to 262 GPs in the 
West of Ireland to survey current use and GP attitudes towards 
adoption of CDSS 
Despite favourable attitudes towards the adoption of CDSS many barriers 
were perceived that impeded incorporation into clinical practice 
 
Johnson et al 
(2000) 
 
Review article that described the background to Phase 3 of the 
PRODIGY project.  
Phase 3 was being tested for a formal evaluation 
 




An evaluation of PharmDIS-e+ software a CDSS for predicting serum 
digoxin levels in patients. The study included 45 patients were 
recruited from 2 GP practices 
 
PharmDIS-e+ software was able to predict serum digoxin levels with 
acceptable accuracy in most patients 
 
 




RCT conducted to examine the clinical effectiveness of providing 
GPs with the results of a self-administered computerised assessment 
of common mental disorders (PROQSY) in 681 patients that attend a 
GP practice in South London 
The Group receiving PROQSY showed a modest clinical improvement at 
6 weeks, but no difference at 6 months 
 
 
Magnus et al 
(2002) 
 
Questionnaire survey of GPs in four PCTs in the Nottingham area of 
the UK 
 
A minority of GPs admitted to frequently overriding their drug interaction 
alert systems without properly checking them. The type of computer 
system used could affect whether alerts were overridden 
 
 




Table 2.8 UK experience of CDSS within primary care settings (cont.) 
Author Type of Evidence or Design Main outcomes  




Controlled trial to evaluate of feedback of GP's data on aspirin 
prescribing aimed at increasing coded aspirin prescribing in patients 
with heart disease 
 
Feedback of prescribing practice can increase the proportion of patients 
with ischaemic heart disease receiving prescribed daily aspirin 
 
 
McCowan et al 
(2001) 
 
RCT to evaluate whether CDSS used in the management of patients 
with asthma improves clinical outcomes in 447 patients from 17 GP 
practices.  
The use of CDDS that implemented guidelines during patient 
consultations could improve clinical outcomes for patients with asthma 
 
Morris et al (2005) 
 
Questionnaire survey of GPs to assess their views on the importance 
of specified patient safety features on clinical computer systems.  
Patient safety was a key issue specifically in relation to deficiencies in 
features of clinical computer systems 





Cluster RCT to investigate the effect of a CDSS and a risk chart on 
absolute cardiovascular risk, blood pressure, and prescribing of 
cardiovascular drugs in hypertensive 614 patients based in 27 GP 
practices in Avon 
 
The CDSS did not confer any benefit in absolute risk reduction or blood 
pressure control and required further development and evaluation before 
use in clinical care could be recommended 
 
 
Mitchell et al 
(2009) 
 
National survey of selected NHS Trusts of nurses to examine nature 
and type of CDSS used including PCTs 
 
Of the 141 different CDSS in use. 33 were used within primary care 
settings in either maintaining electronic patient records, triage, 
assessment, or prescribing 
O'Cathain et al 
(2003) 
 
To examine the consistency of triage outcomes by nurses using four 
types of computerised decision support software in NHS Direct 
 
There were large differences in outcomes between nurses using different 
software systems to triage the same calls. If the variation was primarily 




To establish and evaluate an external quality assessment scheme for 
warfarin dosing for users of a CDSS by analysis 12 months of clinical 
data from 10 primary care centres 
Practices were successful in maintaining good therapeutic international 










Table 2.8 UK experience of CDSS within primary care settings (cont.) 
Author Type of Evidence or Design Main outcomes  
Pell et al (2003) 
 
 
Retrospective analysis of patients receiving oral anticoagulant therapy 
in a single general practice compared to those managed in secondary 
care 
INR control achieved in a general practice setting was superior to that in 





Interim report of Phase 1 of the PRODIGY project 
 
 
PRODIGY was likely to be suitable as the basis of a practicable system 
for long term use. A continual process of improvement and updating to 
both guideline contents and supportive software would be necessary 
Purves et al 
(1999) 
Review article describing the background to PRODIGY and a summary 
of the first 2 phases of project 




Review article of the use of PRODIGY in practice 
 
Nurses were able to use PRODIGY guidance as a resource to enhance 
both their personal and professional practice 
Rousseau et al  
(2003) 
 
Qualitative interviews with 13 participants from 5 GP practices 
(including 8 GPs) in the North East of England, part of a RCT involving 
40 clinicians 
Negative comments about CDSS significantly outweighed the positive or 
neutral comments 
 




An evaluation of achieving therapeutic INR targets in the control of 
warfarin in a community clinic supported by point of care testing 
(POCT) compared to a hospital laboratory testing in a RCT that 
involved 46 patients 
It was possible to introduce a reliable and safe community anticoagulant 
service based on POCT monitoring 
 
 
Short et al (2003) 
 
 
Qualitative interviews with 15 GPs in the West Midlands to investigate 
sub-optimal prescribing of aspirin 
 
GPs need support in assessing the risks and benefits of prescribing for 
patients with combinations of complicating risk factors which could be 
incorporated into a CDSS 
Short et al (2004) 
 
Qualitative interviews with 15 GPs in the West Midland to investigate 
barriers to the use of CDSS during consultations 
Designers of CDSS for use in primary care consultations should account 










Table 2.8 UK experience of CDSS within primary care settings (cont.) 
Author Type of Evidence or Design Main outcomes  




RCT based in 5 GP practices involving 762 patients to evaluate the 
use of a computerised psychosocial assessment that generated a 
report for the GP including patient-specific treatment 
recommendations 
Only small benefits were found to be likely from using case finding 
followed by patient-specific guidelines to improve 
clinical management of common mental disorders in primary 
care 
Toth-Pal et al 
(2008) 
 
To explore the influence of a guideline-based CDSS how GPs 
managed cases of chronic heart failure 
 
Using a guideline-based CDSS for GPs' own patient cases had an impact 
on the GPs' confidence in the diagnosis of chronic heart failure and their 
considerations about investigations and medications 
Vadher et al 
(1997) 
RCT based in a hospital but involved both in-patients and out-
patients 
CDSS was found to be safe and effective and improved the quality of 
initiation and control of warfarin treatment by trainee doctors 




Questionnaire survey of 30 GPs investigating the acceptance of a 
potential CDSS within primary care 
 
 
70% of GPs intended to use the system with a 2 minute increase in 
consultation times, whilst 77% did not intend to use the system with a 5 
minute increase in consultation time 
 




Cross-over experiment with balanced block design involving 50 GPs 
in Oxfordshire to evaluate the effect of CAPSULE, a CDSS designed 
to support prescribing  
 
CAPSULE significantly improved the quality of prescribing and improved 
compliance with guidelines. The system was easy to use and most of the 
participating GPs were likely to use it in practice 
 




Cluster RCT to evaluate a CDSS to support complimentary 
interventions in familial breast cancer in 57 GP practices compared to 
advice provided by a counsellors in regional centres 
 
The CDSS could not be recommended for widespread use without further 
evaluation and testing in real practice 
 
 
Xiao et al (2011) 
 
 
Review article of an electronic health record to support methadone 
treatment incorporating CDSS by use of a web-based data entry 
system 
A discussion of the potential of implementing a web-based data entry 
system incorporating elements of a paper prescription form whilst at the 
same time facilitating CDSS 




One of the earliest published studies to evaluate CDSS within UK general practice 
was a prospective evaluation of the management of hyperlipidaemia involving 25 GP 
practices in the Midlands (Hobbs et al 1996). Although favouring the concept, users 
criticised technical problems and recommended that greater integration of CDSS with 
practice clinical systems was required. In addition uptake was lower than expected 
and prescribing, a key outcome measure, showed no significant alteration following 
system use. In contrast positive attitudes towards computerised prescribing support 
by GPs was reported by Walton et al (1998) from an evaluation of a CDSS prototype 
CAPSULE with 42 randomly selected GPs in Oxfordshire. This evaluation, based on 
36 simulated cases constructed from real consultations, concluded that computerised 
support significantly improved the quality of prescribing, compliance with guidelines, 
was easy to operate and that most participating doctors would be likely to use it in 
practice.  
 
In 1995 the NHS Executive commissioned the Sowerby Centre for Health Informatics 
at the University of Newcastle to research the acceptability of CDSS to GPs, its 
impact on prescribing habits and to address a range of other questions pertinent to 
the future development of general practice. An interim report suggested positive 
steps in the provision of drug and patient advice leaflets (Purves and Sowerby 
1996).The research team adopted a rapid iterative methodology with NHS Executive, 
academic project team, GPs and the five leading GP computer suppliers 
collaborating to develop and improve the product known as PRODIGY (Purves et al 
1999). The first phase involved GP system suppliers recruiting 137 GP practices and 
the second phase 183 GP practices with sites located in 61 of the then 91 Health 
Authorities in England. PRODIGY was launched in 1999, available free to all GPs, 
fully funded by the NHS and provided on screen advice about referral, investigations, 
specific non-drug advice, doctor / patient shared advice screens and the provision of 
condition specific patient information leaflets (Broderick 1999). However a 
subsequent evaluation of the system, using a randomised controlled trial within 60 
GP practices in the North East of England showed there was no significant effect on 
consultation rates, patient outcomes or process of care measures including 
prescribing (Eccles et al 2002). In addition authors reported that the overall usage of 
the CDDS was low.   
 
PRODIGY was eventually withdrawn in 2006 amongst reports that it had never been 
used by more than 10% of GPs and that it should not have received NHS funding 
(Bostock 2007).  




PRODIGY was replaced with Clinical Knowledge Summaries (CKS) in a contract 
awarded to a consortium of the Sowerby Centre and EBSCO (an international 
medical publisher). In 2011 CKS became incorporated into the clinical work program 
of NICE. 
 
A number of notable CDSS systems have been developed by the University of Keele 
to support disease management such as stroke and diabetes (Chapman 2007). In 
recent years a number of other commercial CDSS have been introduced offering a 
range of services particularly with drug information and prescribing support. Script-
Switch®, a CDSS that links with GP clinical systems, in to provide at point of 
prescribing local formulary choices, advice on cost effective alternative medicines 
and messages reminding clinicians of any relevant information such as safety or 
effectiveness issues (Anon 2010a). In addition NHS primary care organisations were 
able to manage and locally author these messages and receive reports about uptake 
by individual GP practices and the resulting savings generated in prescribing. The 
Script-Switch® website reported that over 124 primary care organisations across the 
UK had commissioned the software on behalf of 5,500 GP practices (Anon 2011a).  
 
2.4.3.1 CDSS UK end user evaluations 
Evaluations of CDSS usage and perceptions of GPs provided a range of both 
positive and negative outcomes. A number of studies have provided some evidence 
that CDSS have improved outcomes for patients such as providing better drug 
dosing information in high risk groups compared to paper based resources (Franke et 
al 2000), in managing asthma (McCowan et al 2001) and in the use of aspirin in 
patients following a stroke (Short et al 2003). However some studies, although 
demonstrating either some or limited benefits, have recommended CDSS use without 
further testing or evaluation such as in cardiovascular risk management (Montgomery 
et al 2000), cancer screening (Emery et al 2000, Wilson et al 2005) and in supporting 
mental health conditions such as depression (Thomas et al 2004).  
 
In an evaluation of a CDSS supporting the availability of electronic guidelines, 
concerns reported by GPs included the timing of the guideline trigger, ease of use of 
the system, and helpfulness of the content (Rousseau et al 2003). The authors 
concluded significant barriers existed to the use of complex CDSS for chronic 
disease by GPs. These included the relevance and accuracy of messages and 
flexibility for the GP to respond to other factors influencing decision making in primary 
care.  




Short et al (2004) undertook qualitative interviews with 15 GPs in the West Midlands 
and reported on practical barriers to the use CDSS during consultations including 
limitations of practitioners’ IT skills, a lack of  understanding of the risk output of 
systems, concerns about communicating risk sufficiently well to patients and time 
constraints of using CDSS during consultation. 
 
2.4.3.2 Safety deficiencies and overriding of CDSS alerts  
The scoping review identified a number of evaluations of CDSS in the UK were 
focussed on not just end users such as GPs, but also key stakeholders such as GP 
clinical system suppliers, academics and primary care managers. These studies 
evaluated the safety of alerting systems provided by CDSS within GP clinical 
systems and the results are summarised in Table 2.9. A prominent feature of CDSS 
is the safety functionality of warnings and alerts and the ability for users to cross 
check prescriptions for known sensitivities, drug interactions and active ingredient 
duplications. In a questionnaire survey of 334 GPs in the Nottingham area 49 of the 
220 respondents (22%) admitted to frequently or very frequently overriding drug 
interaction alerts without proper checking, reasons cited as the perception that the 
alerts were frequently irrelevant (Magnus et al 2002). Fernando et al (2004) 
described concerns with safety deficiencies of the CDSS alerts provided by the main 
GP clinical system suppliers in the UK and identified that all systems could fail to 
warn a GP in a situation where a warning was expected. Key features for improving 
safety and the quality of CDSS alerts have been suggested, such as the need to 
avoid spurious alerts (Avery et al 2005), making it difficult to override critical alerts 
(Avery et al 2005) and ensuring that software developers were made aware of the 
importance of human ergonomics in the design of hazard alerts (Avery et al 2007). 
Morris et al (2005) described the importance of safety alerts available from within GP 
clinical systems and that deficiencies included a lack of awareness of specific 
functions in relation to safety and in the level of training available to support the use 












Table 2.9 Studies have evaluated the safety of alerting systems provided by CDSS within GP clinical systems 
Author Design Results Outcomes 
Magnus et 
al (2002) 
Questionnaire survey of 336 GPs based in 
four PCTs in the Nottingham area of the UK 
to assess GPs’ views on the relevance of 
information provided by alert systems. 
Response rate was 70%, analysis conducted 
on 220 replies.  
22% (49 of 220) of GPs admitted to frequently or very 
frequently overriding drug interaction alerts without 
properly checking them. Potential reasons for overriding 
alerts included the perception that the alerts were 
frequently irrelevant.  
A minority of GPs admitted to frequently 
overriding their drug interaction alert 
systems without properly checking them. 
The type of computer system used by GPs 
may have made it more or less likely to 
override alerts. 
Fernando 
et al (2004) 
Laboratory testing of 4 of the main GP clinical 
systems against a list of 18 theoretically 
derived scenarios related to safety drawn up 
by an expert panel via a 2 round Delphi 
Approach  
None of the systems produced alerts for all 18 
scenarios. In one scenario of prescriptions with similar 
drug names none of the systems warned for all 10 drug 
pairs considered 
The safety features of the 4 systems that 
covered three quarters of UK general 
practices had clinically important 
deficiencies. 
Avery et al 
(2005) 
Two - round electronic Delphi survey, 
completed by an expert panel. The main 
outcome measure was percentage 
agreement of the panel members on the 
importance of the presence of a number of 
different safety features (presented as clinical 
statements) on GP computer systems. 
90% or greater agreement on the importance of 32 
(58%) statements. These statements, indicating issues 
considered to be of considerable importance, related to: 
computerised alerts e.g. the need to avoid spurious 
alerts and making it difficult to override critical alerts  
The high level of agreement among the 
expert panel members indicated clear 
themes and priorities that needed to be 
addressed in any further improvement of 
safety features in primary care computing 
systems.  
Morris et al 
(2005) 
Questionnaire survey of 609 GPs based in six 
PCTs from the Midlands and North West 
England to assess GPs’ views on the 
importance of specified patient safety 
features on their clinical computer system; 
their knowledge of the presence of specified 
safety features; previous training and 
perceived future training needs. Response 
rate was 64%, analysis conducted on 381 
replies. 
Although patient safety features were considered to be 
an important part of their clinical computer system by 
the vast majority of GPs, many were unsure as to 
whether the system they were using actually possessed 
some of these specific features. Some of the GPs 
believed in error that their computers systems would 
warn them about potential contraindications or if an 
abnormal dose frequency had been prescribed. Only 94 
of the GPs (24%) had received formal training on the 
use of these specific patient safety features 
Patient safety was an issue high on the 
agenda of this cohort of GPs. The 
importance of raising GPs’ awareness of 
both the potential use and deficiencies of 
the safety features on their clinical computer 
systems and ensuring that appropriate 
training is available should not be 
underestimated. 




Table 2.9 Studies have evaluated the safety of alerting systems provided by CDSS within GP clinical systems (cont.) 
Author Design Results Outcomes 
Avery et al 
(2007) 
Qualitative study using semi-structured 
interviews with 31 participants, representing a 
broad range of relevant disciplines and 
interest groups e.g. clinicians, computer 
system suppliers, drug database suppliers 
and academics with interests in health 
informatics  
Participants identified deficiencies in current systems 
that pose serious threats to patient safety. To bring 
about improvements, providers need to supply clinicians 
with safe, accurate and accessible information for 
decision support.   
Priorities included improving the knowledge 
base for CDSS, paying greater attention to 
human ergonomics in system design, 
improved staff training and the introduction 
of new regulations mandating system 
suppliers to satisfy essential safety 
requirements 




2.4.3.3 CDSS and therapeutic blood monitoring  
One area where CDSS has been shown to provide clear benefits in terms of clinical 
management and improved patient outcome supported by robust evidence has been 
in therapeutic blood monitoring. In the UK, with the exception of a single study that 
reported on an evaluation of a CDSS designed to predict digoxin blood monitoring 
within 2 GP practices (Kroesse et al 2005), evaluations have centred on the 
effectiveness in the monitoring and dosing of one oral anticoagulant drug, warfarin. It 
is estimated that around one million patients in the UK receive oral anticoagulation 
medicines such as warfarin which is commonly indicated for use in the prevention of 
embolic stroke and transient ischaemic attacks in patients with atrial fibrillation 
(Matthey 2007). Once initiated subsequent doses of warfarin are adjusted dependant 
on prothombin time reported as an international normalised ratio (INR) which 
requires regular blood monitoring. Introduced in the 1980s manual algorithms to 
predict doses based on mathematical correlations were proving costly, laborious, and 
produced indifferent results when compared to those calculated using computers 
which were as reliable (Treharne - Jones et al 2005).  
 
2.4.3.3.1 Primary care anticoagulation management 
In the 1990s primary care based clinics in general practice were established to 
support the shift of clinical services from secondary care to primary care for a range 
of conditions and treatments including anticoagulation (Treharne Jones et al 2005). 
CDSS became available to support point of care testing (POCT) using commercial 
meters that measured INR using capillary samples of blood rather than sending 
venous samples of blood to a hospital clinic. Summarised in Table 2.10 are UK 
studies that established an evidence base for the effectiveness of CDSS in 
anticoagulation management in primary care. 
 
Early studies (Pell et al 1993, Fitzmaurice et al 1996, 1998b) reported on the positive 
outcomes in anticoagulation management within general practice when compared to 
hospital based clinics in terms of the level of INR control. Following a similar design 
but including a larger number of patients (377 from 12 GP practices, Fitzmaurice et al 
(2000) further demonstrated that patients attending GP practice based clinics had a 
significant improvement in the proportion of time spent within INR ratio compared to 
those attending hospital clinics. In a later retrospective analysis of patients receiving 
warfarin from this study including new patients initiated on treatment (n = 452) 
Fitzmaurice et al (2001) compared INR management in a total of 122 patients 
managed in practice based clinics against 330 in hospital based clinics.  




The authors reported no significant difference between the two groups in terms of 
percentage time in spent in INR range (69% practice based vs. 64% hospital based), 
recall or adverse effects. This resulted in the ‘Birmingham model of oral 
anticoagulation management’ comprising of near patient testing for INR 
measurement and CDSS to interpret the INR within practice nurse led primary care 
clinics.  
 
Shiach et al (2002) reported the success in achieving therapeutic INR control in a 
community setting when compared with hospital laboratory testing but also patient 
satisfaction. They concluded it was possible to introduce a reliable and safe 
community anticoagulant service acceptable to medical and nursing staff and was 
popular with the patients. The need for accuracy in measuring INR led to the 
development of an external quality assessment scheme to ensure measurement of 
INR was consistent in different environments. Oppenkowski et al (2003) reported on 
the development and implementation of the first scheme for a specific CDSS,“BAP-
PAC” in a 12 month evaluation of the management of 367 patients based in 10 GP 
practices in England. Practices were required to submit data on patients for external 
assessment at an academic centre. The results demonstrated that all practices using 
BAP–PC were maintaining good therapeutic INR control, with patients achieving 60% 
or higher time in range at and an average of 69%.  
 
A further development in anticoagulation management was patient self-management 
using POCT. Fitzmaurice et al (2002) reported on the first randomised trial to 
compare routine primary care management of oral anticoagulation with patient self–
management. Although it proved to be a more costly model the results showed 
patient self-management was as safe and effective as routine care. Following a 
larger multi-centre trial based in the Midlands, Fitzmaurice et al (2005) reported that 
with appropriate training, self-management was safe and reliable for a sizeable 
proportion of patients receiving oral anticoagulation treatment and that it may 
improve the time spent in the therapeutic range for patients with initial poor control.  
 
 




Table 2.10 UK studies of CDSS in anticoagulation management in general practice and the development of self-management    
Author Design Results Outcomes 
Pell et al 
(1993) 
Retrospective analysis involving 32 patients 
receiving oral anticoagulant therapy in a 
single general practice and 123 patients 
and a dedicated hospital anticoagulant 
clinic in Fife, Scotland.  
In 261 of the 1088 general practice appointments 
(24.0%) resulted in adjustment of the dose of warfarin 
compared with 726 of the 2828 hospital attendances 
(25.7%). In addition 51.6% of general practice 
appointments and 45.5% of hospital appointments, 
venous thrombotest INR results fell within the 
therapeutic ranges 
 
The findings of this study suggested that 
INR control achieved in a general practice 
setting was superior to that in a dedicated 
hospital anticoagulant clinic 
Fitzmaurice 
et al (1996) 
Randomised trial involving 49 patients from 
2 GP practices. Evaluation of CDSS for oral 
anticoagulation management by measuring 
proportions of patients adequately 
controlled defined as being within INR 
range.  
Significant improvements were seen in INR control from 
23% to 86% in the practice where CDSS was used. 
Mean recall times were significantly extended in the 
practice where dosing was managed by CDSS from 24 
days to 36 days.  
CDSS enabled safe and effective transfer of 
anticoagulation management from hospital 
to primary care. This model allowed 
improved patient outcomes in terms of level 
of control, frequency of review and general 
accessibility 
Fitzmaurice 
et al (1998b) 
Prospective evaluation of therapeutic and 
clinical control of patients using warfarin in 
29 patients in a practice that had introduced 
a primary care clinic supported by CDSS 
This study reported the first data from a long-standing 
clinic outside of a formal study. Twenty nine patients 
seen in 208 appointments with the mean percentage of 
patients within INR range was 72% at a cost to the 
practice of £1751 compared to £2290 if patients were 
seen at hospital.  
 
CDSS in a nurse led clinic delivered oral 
anticoagulation monitoring that could  
enable the safe transfer of the majority of 
patients from secondary to primary care 
Fitzmaurice  
et al (2000) 
Randomised trial involving 377 patients 
from 12 GP practices in Birmingham. 
Patients randomised to attend 3 control 
practices (143) to receive  hospital care or 9 
intervention practices (224) to receive either 
hospital care (102) or practice based care 
(122) 
Practice based care was in the form of a nurse led clinic 
offering POCT and with dosing managed by CDSS. The 
INR control in the intervention group was no different to 
the control group. The time spent within INR range in 
intervention group showed significant improvement 
compared to control group 
Anticoagulant management using this 
model of care was at least as good as 
routine hospital follow up and could be 
generalised to primary care health centres 
in developed healthcare systems. 




Table 2.10 UK studies of CDSS in anticoagulation management in general practice and the development of self-management (cont.) 
Author Design Results Outcomes 
Fitzmaurice 
et al (2001) 
Retrospective follow up of anticoagulation 
management in patients based in 12 GP 
practices in Birmingham. These practices 
were involved in a previous study 
(Fitzmaurice et al 2000). Outcome measures 
were INR control, adverse effects and recall 
frequency 
 
There were no significant differences between practice-
based and hospital-based populations in terms of the 
percentage time in range, (69% and 64% respectively). 
There was no difference between the two populations in 
terms of mean follow-up time (36 days in each group). 
There were no significant differences between groups 
for the number of clinical outcomes per patient. 
This study confirmed that, within these 
practices, oral anticoagulation 
management was safe and effective using 
the Birmingham model. 
Shiach et al 
(2002) 
Randomised crossover trial involving 46 
patients measuring success in achieving 
therapeutic INR targets in a community clinic 
was compared with hospital clinic laboratory  
Time in INR target range between the groups was 
similar, with 60·9% on the POCT monitor and 59·3% 
with the clinic laboratory, with no significant difference in 
mean INR. Patient questionnaires showed greater 
satisfaction with community POCT monitoring. 
Equal success of an anticoagulant service 
based on community POCT monitor whole 
blood testing compared with results from a 
long-established hospital anticoagulant 
clinic that was acceptable staff and 
popular with patients. 
Fitzmaurice 
et al (2002) 
Randomised trial involving 49 patients from 6 
GP practices assigned to either self-
management or routine primary care 
management of anticoagulation. 
To test whether self - management was safe and 
effective in terms of INR control. No significant 
differences found between the two groups in INR 
control or adverse events. The cost of self-management 
was much higher £90 vs £425 / patient per year 
 
This study was the first available evidence 
to show self-management was as safe as 
primary care management. 
Oppenkowski 
et al (2003) 
Analysis of 12 months of clinical data from 10 
primary care centres using BAP-PC within an 
oral anticoagulation clinic of 367 patients 
based in 10 GP practices.  
On average, patients spent 69% of time in the 
therapeutic range INR (range, 60-76%). In total, 33 
adverse events were reported.  
Practices were successful in maintaining 
good therapeutic INR control, with centres 
achieving 60% or higher time in range. 
Data extraction from practices was used in 
the development of an external eight point 
quality assessment scheme 
 
 




Table 2.10 UK studies of CDSS in anticoagulation management in general practice and the development of self-management (cont.)  
Fitzmaurice 
et al (2005) 
Multi-centre open randomised trial in the 
Midlands including 617 patients from 49 from 
GP practices identified to determine 
effectiveness of self-management compared 
to routine care in patients on long term 
anticoagulation.  
In 337 patients randomised to the intervention group of 
whom 242 were successfully trained for self-
management. 280 patients were randomised for routine 
care. There was no significant difference between 
groups in terms of time spent in INR range or adverse 
events. Self-managed patients with poor control before 
study showed an improvement and this was not seen in 
the other group. 
 
Following appropriate training self-
management was found to be safe and a 
reliable model of anticoagulation 
management.  




2.4.3.4 Other supporting literature   
Thirty items of additional supporting literature about CDSS and references to wider 
aspects of health informatics were collated. This information provided both historical 
and conceptual aspects to developments in the field. Data was identified in the form 
of book chapters, articles and papers written by academic experts.  
 
2.4.3.5 Website Reviews  
Two NHS websites and eight websites of commercial CDSS suppliers including GP 
clinical system suppliers were searched for evidence in relation to the availability of 
CDSS.    
 
NHS Connecting for Health  
Evidence was found in relation to CDSS however this was aimed to support the use 
of CDSS as part of a wider roll out of proposed electronic prescribing within 
secondary care in the form of guidance and policies.  Fourteen "world view reports" 
authored by Professor Dennis Protti, between February 2005 and August 2006, 
concerning IT in healthcare were reviewed.  
 
The National Institute of Clinical Excellence 
Evidence was identified from the NICE shared learning section of the website about 
CDSS developed by the University of Keele, to support the implementation of NICE 
hypertension guidelines (NICE 2009). In addition a 2005 press release (NICE 2005) 
and a 2005 progress report (Phillips and Cox 2005), were identified that described a 
proposed feasibility study to look at whether existing NICE methodologies such as 
Technology Appraisals (TAs) could be applied to an evaluation of CDSS.  
 
Commercial providers of CDSS   
The websites of known commercial organisations that provided CDSS in the UK, 
First Databank®, Script-Switch® and INR-star® .were searched. In addition the 
websites of GP clinical system providers EMIS, INPS (Vision), Micro-Test, iSOFT 
and SystmOne all confirmed the provision of CDSS to support GPs in the provision 
drug databases to include automatic drug related warnings and alerts. In addition the 
GP clinical system suppliers offered through partnership programs a range of 
external web-based applications to support a variety of functions to support the 
running general practice including the national GP contract. A summary of evidence 
of the availability of CDSS from these websites is shown in Table 2.11. 
 




Table 2.11 Summary of the availability of CDSS from commercial providers in 





Evidence identified  
First Databank  December 
2011 
The CDSS within the “Multilex Drug Data File “ provided 
by Firstdata Bank provided functionality to check when 
medication was about to be prescribed or dispensed 
against information held in an electronic patient held 
record as a real time alert. The alerts included drug 
interactions, drug food interactions, sensitivities, 
contraindications, drug doubling, therapeutic doubling 
similar names and dose range checking.  
Script-Switch
®
  May 2011 The software application was in use in 5,500 GP 
practices in the UK, commissioned by 124 NHS primary 
care organisation. In general outcomes were expressed 
in cost savings in relation to prescribing budgets. In 
terms of additional evidence this was available in the 
form of PCT case studies and one survey of 106 GP 
users conducted by a market research company on 
behalf of the company On-line demonstrations were 
viewed that showed how the application worked within 





The software application was in use in nearly 2000 
locations in the UK and abroad. A brochure was 
downloaded that described features of the CDSS, 
benefits, training and support for NHS commissioners 











All of the GP clinical system suppliers provided details 
of in-built CDSS to support prescribing as drug related 
warnings and alerts. A wide range of platform sharing 
with external software applications was available from 
each system, but all suppliers were linked to a national 
framework to support the GMS contract. Links were 









2.4.3.6 Personal Communication  
Personal communication with the lead researcher (NC) and representative of a UK 
commercial provider of CDSS took place in 2011 as one informal meeting with one 
representative and a telephone conference call with two other representatives from 
the same commercial provider. General details of CDSS usage and availability in the 
UK were discussed. Information regarding the provision of CDSS by this provider 
was already available from the company website. During these discussions no 
additional information was made available such as pending or unpublished trials or 
studies including randomised controlled trials or qualitative evaluations.   
 
2.5 Discussion  
The scoping review methodology resulted in the development of a catalogue of 
literature concerning the use CDSS in primary care. The studies and articles included 
in the final analysis came from a number of countries, with the majority from the USA 
and UK. Advances in information technology, particularly within primary care over the 
last 30 years has meant computers are widely available and are routinely used for 
nearly all healthcare activities within UK general practice. Experience of CDSS was 
identified in a wide range of clinical areas such as disease management, drug 
dosing, therapeutic control and prescribing. In addition the clinical systems used by 
GPs in the UK all provided CDSS in the form of alerts and warnings to allergies and 
drug interactions and additional functionality to allow access to a range of software 
applications.  
A specific area where positive outcomes were identified was in the development of 
CDSS to support primary care based anticoagulation management. In addition this 
has further been supported by the inclusion within the GMS contract as an enhanced 
service specification (NHS Employers 2009). This service requires GP practices to 
demonstrate adherence to a wide range of clinical and performance measures 
including an annual review to include details of any CDSS used and arrangements 
for internal and external quality assurance. In addition anticoagulant prescribing 
within the service specification is supported by guidelines devised by the British 
Society of Haematology. These guidelines have highlighted the safety and 
effectiveness of CDSS in supporting warfarin dosing and have recommended the use 
of CDSS over manual dosing (Keeling et al 2011). In addition under the enhanced 
services specification GP practices are required to subscribe to a national external 
quality assessment service (NEQAS) that provides assessments of tests of blood 
coagulation for a range of clinical indications including systems designed for point of 




care testing (POCT). Matthey (2007) has described a number of UK based models to 
support anticoagulation management supported by the availability of both 
commercial POCT meters and CDSS such as 4S Dawn®, Hirumed RAID® and 
INRstar® In terms of INRstar® the website, reported that this application was the UK 
market leader for anticoagulation management and was being used in over 2,000 
clinics in the UK and abroad (Anon 2011b). The CDSS Script-Switch® was reported 
to be installed in over 5,500 UK GP practices (Anon 2011a). However evidence from 
published trials of evaluations, or the views and experiences of GPs in using this 
CDSS were as not available. The website provided evidence of case studies from 
individual PCTs and substantial cost benefits to the NHS reported as savings against 
primary care prescribing budgets. 
 
Key themes that emerged from studies and evaluations of the CDSS evidence base 
from the UK, USA and Australia included safety deficiencies in systems (Fernando et 
al 2004, Avery et al 2005, 2007, Sweidan et al 2010), over-alerting, ignoring or and 
the overriding of alerts (Magnus et al 2002, Ahearn et al 2003, Weingart et al 2003, 
Isaac et al 2009) and the need for developers of CDSS to engage with the end users 
in the design of CDSS (Avery et al 2007, Robertson et al 2011). In addition some of 
negative outcomes of CDSS usage were also apparent across the UK and USA to 
include poor usage (Rotman et al 1996, Eccles et al 2002, Judge et al 2006), 
adherence to guidelines (Tierney et al 2003, Rousseau 2003) and patient outcomes 
(Montori et al 2002, Eccles at al 2002).  
 
These outcomes correlated with of the evaluations of the literature in relation to 
CDSS. Coiera et al (2006) reviewed the literature in relation to the safety and quality 
of CDSS in both primary and secondary care including the UK, USA and Australia. 
Although the authors reported that CDSS was a potent intervention to improve the 
quality, safety and the effectiveness of clinical decisions uptake levels remained low. 
Barber (2004) examined the experience in the UK and USA in the development of IT 
systems in both primary and secondary care. CDSS was described in relation to 
doctors’ performance, patient outcomes, managing therapeutic control of drug 
concentrations and also in helping patients in managing screening or treatment.  
The author critiqued the various CDSS models suggesting a lack of evidence that 
had demonstrated improved patient outcomes and evaluations of the field were of a 
limited quality and could not be generalised.  
 
 





There were a number of limitations to this scoping review. The main issue was the 
lack of time and available resources in terms of being able to actively engage further 
particularly with stakeholders. There was only one lead researcher (NC) and no 
additional staff or resources were available so the scope was limited to healthcare 
database searches, interrogation of known websites and informal discussions with 
informants from a specific stakeholder.  Only one commercial CDSS supplier was 
engaged with and research team were not able to engage with representatives from 
other providers particularly GP clinical system suppliers or indeed from with 
stakeholder groups such as NHS IT management or from the end users of CDSS i.e. 
GPs. Other alternative options which could have been explored included the use of 
existing networks, which could have included medicine management teams or 
primary care commissioners, based on the reported usage and availability of CDSS 
applications such as Script-Switch® and INRstar®. In addition time was not available 
to consider attending conferences in relation to commercial providers of CDSS and 
or wider aspects of NHS information technology provision either at a local level or 
with Department of Health. In addition the views and experiences of patients would 
have been particularly useful not just in their views of the use of IT but especially of 
how CDSS would benefit them during consultations or in other aspects of their 
healthcare needs.   
 
2.7 Further work 
A number of gaps in the literature in relation to CDSS use in the UK were identified 
such as an understanding of current usage, system types, available and specific 
features and characteristics. Although the use of CDSS underpinned data transfer to 
support the GMS contract no evidence was available on the actual awareness or use 
of additional software applications that were available through GP clinical system 
suppliers. The lack of independent trials or evaluations of Script-Switch® could also 
form the basis of additional research. Although the company provided reports on 
usage, including acceptance rates of messages or alerts this data was only available 
to NHS medicines management teams for localised use. The views or opinions of 
this CDSS could be sought from not only end users such as GPs but also from the 
medicine management teams that author the content of these messages.  
Although INRstar® was identified as an established CDSS provider no evaluations 
had been published on in terms of effectiveness or patient outcomes across larger 
geographical areas or indeed at a national level to include the use of other providers 
of CDSS in anticoagulation management.  




Xiao et al (2011) was the only study that explored the potential of developing and 
implementing a web based health record that incorporated elements of a paper 
prescription form whilst at the same time facilitating CDSS in assisting GPs in 
managing the use of drugs used to treat substance misuse, namely methadone. The 
authors explored the concept model approach for the use of international standards 
including SNOMED CT, and although described a lack of enthusiasm from GP 
clinical system suppliers, they reported that this model could be extended to other 
drugs. This raises the potential to consider other areas for research where CDSS 
could support GPs such as in primary care management is dependent on the 
reliance of input from either secondary care advice from clinicians or the need for the 
results of pathology or other monitoring arrangements.  
 
In 2010 the Government White Paper “Equity and Excellence, Liberating the NHS” 
outlined plans to transfer the commissioning of the £80 billion NHS primary care 
budget to newly formed GP consortia (Department of Health 2010). GP consortia 
became responsible for the management of the national drugs bill alongside planning 
if, how and where traditional hospital based activity was to be provided in primary 
care. This has been described as an opportunity to change the arrangements for 
either the administration or prescribing of specialist drugs avoiding the need for 
patients to attend hospital clinics with new services available within a GP surgery, 
community hospital or primary care based clinic (Anon 2012).One specific area 
where there has been no published evidence is the availability of CDSS to support 
GPs in managing the prescribing of either high risk drugs, drugs initiated by hospital 




This scoping review highlighted a range of issues with regards to the use of CDSS 
within primary care in the UK. Despite of the reported widespread availability of 
CDSS the available evidence in terms of quality such as in randomised controlled 
trials was limited and was mainly found in supporting anticoagulation management. 
Key aspects that emerged both in the UK and from abroad were problems associated 
with low usage, over-alerting, concerns with safety and the need for improvements 
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3.1 Specialist drugs and shared care  
Integrating primary and secondary care services was a direction introduced into the 
NHS in the early 1990s through the concept of “shared care” and the development of 
schemes intended to address many of the difficulties of the referral system especially 
in the long-term management of chronic disease (Hickman et al 1994). Such 
schemes were based around the joint participation of hospital consultants and GPs in 
the planned delivery of care and an enhanced exchange of data over and above 
normal referral and discharge letters. A wide variety of such schemes soon evolved 
across the UK encompassing a range of long term conditions such as asthma, 
diabetes and hypertension. Hickman et al (1994) characterised schemes identified 
from two surveys into six models of care including community clinics run by 
specialists and the use of patient held shared care record cards. Other models 
included the use of computer assisted shared care with data shared across 
secondary care and GP practice systems and the early piloting in Derbyshire of the 
use of electronic mail. Hampson et al (1996) reviewed the supporting literature to 
identify practice exemplars that could be adapted for local use. One important aspect 
identified was communication between primary and secondary care in addition to 
shared prescribing and disease management. The authors suggested that the most 
effective system or models of shared care had yet to be established and that 
although the available literature described practice exemplars communication 
between professionals continued to be a problem.  
 
Despite the huge financial investment in the NHS and primary care, the evidence to 
support shared care has remained limited. A systematic review of 20 studies of 
shared care interventions including 6 from the UK, reported that apart from 
prescribing there was insufficient evidence to demonstrate significant benefits of 
shared care in disease management due to methodological shortcomings and the 
lack of evidence to support the widespread introduction of shared care services 
(Smith et al 2009). The concept of shared care was not just restricted to chronic 
conditions such as asthma or diabetes, which were routinely managed by GPs in 
primary care, but also to specific drugs of a specialist nature. Specialist drugs have 
been defined as having “significant pharmacological complexity and / or rarity of use 
to make the prescribing of the medicine relatively uncommon in the community” 
(Greater Manchester Medicines Management Group 2011 p2). In addition patients 
receiving these drugs may require complex monitoring requiring specialist knowledge 
for interpretation and management.  
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Guidance from the NHS Management Executive (EL (91)127) outlined core principles 
and responsibilities associated with prescribing particularly with the transfer of 
treatment between secondary and primary care. Where this involved new or rarely 
prescribed treatments including unlicensed drugs, shared care arrangements were 
proposed in the form of a protocol outlining responsibilities for both hospital and 
primary care clinicians (Department of Health 1991). Prescribing any drug carries 
significant risk with regards to side effects and adverse reactions; however there is 
also the associated clinical and legal responsibility that will rest with the clinician who 
signs the prescription (Khambh and Barnick 2007). In general, once a patient leaves 
hospital, clinical care is transferred wholly to the GP with any appropriate support and 
advice. If the patient is receiving a specialist drug, consideration needs to be given 
that not all GPs will have the relevant experience or specialist expertise to undertake 
full clinical and legal responsibility for prescribing (Khambh and Barnick 2007). The 
aim of a shared care protocol is to provide clear specific information regarding the 
specialist drug and to set out individual clinicians’ roles and responsibilities.  
 
3.1.1 Specialist drugs: Primary care prescribing trends 
Avery (2010a) has described the increased complexity in prescribing faced by GPs 
over the last twenty years with key contributory factors including managing larger 
numbers of patients on multiple medications and having to learn about the safe and 
effective management of high-risk drugs. This has required improvements in systems 
for follow-up and monitoring of patients in general practice. In recent years there has 
been an increasing level of prescribing of specialist drugs by GPs in primary care, 
factors which contributed to this have included patient convenience, better risk 
management, a reduction in secondary care workload (e.g. out-patient appointments) 
and the transfer out of prescribing expenditure (Anon 2008). Electronic prescribing 
analysis and cost tabulation (ePACT) data provides detailed information on a range 
of cost and volume derived indices to include individual drugs or drug groups at 
prescriber, practice, or NHS organisational level. In addition a number of prescribing 
indicators are available which have been specifically developed to allow practice 
comparison and are widely used by prescribing management teams. One indicator is 
based on the prescribing profile of designated specialist drugs. Figure 3.1 represents 
quarterly prescribing rates and expenditure on all specialist drugs in primary care 
(NHS Prescription Services 2012).   
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Figure 3.1 Quarterly prescribing rates and expenditure on all specialist drugs 
in primary care between 2006 / 07 and 2010 / 11 in England. 
 
During this period, annual prescription items increased by 252,148 (18%) with annual 
expenditure decreasing by 2.1%. Total prescription items in 2010 / 11 amounted to 
just over 1.6 million at a cost of £250 million, 3.13% of the total £7.98 billion national 
primary care drugs bill.  
 
Table 3.1 lists the top 10 specialist drugs prescribed in England during 2010 / 11 by 
cost (NHS Prescription Services 2012). The highest expenditure by drug type was 
£80.4 million (32.2%) on the gonadorelin analogues buserelin, goserelin, leuprorelin, 
histrelin and triptorelin; followed by £65.7 million (26.3%) on the immunosuppressant 





















































































































































































































































































































































































































Total Items  Total Act Cost  
Chapter 3: An exploratory study using key informants to investigate the use of computerised 
decision support software (CDSS) within UK general practice 
90 
 
Table 3.1 Top 30 Specialist Drugs prescribed in primary care (GPs) by cost in 
England 2010 / 2011 
BNF Name  Total Items  Total Act Cost  
Zoladex® LA Implant 10.8mg SafeSystem  124,048 £29,104,469 
Goserelin Acetate Implant 10.8mg  105,815 £24,852,565 
Mycophenolate Mofetil Tablets 500mg 104,075 £15,122,265 
Tacrolimus Capsules 1mg 53,327 £9,863,894 
Prostap® 3 Depot Injection 11.25mg  45,688 £9,573,959 
Prograf® Capsules 1mg 49,553 £9,272,251 
Genotropin Injection 12mg  6,371 £6,113,058 
Saizen® Click Easy Injection 8mg 8,120 £5,411,801 
Leuprorelin Acetate Injection 11.25mg  24,917 £5,211,130 
Dornase Alfa Solution  2.5mg / 2.5ml Ampoule  9,382 £4,928,483 
 
Table 3.2 lists the top 10 specialist drugs prescribed in England during 2010 / 11 by 
prescription volume (NHS Prescription Services 2012). Commonly prescribed 
specialist drugs include the hormone antagonist goserelin (Zoladex®) and the anti-
androgen agent bicalutamide (Casodex®); both used in advanced prostate cancer, 
the immunosuppressant drugs mycophenylate (Cellcept®), tacrolimus (Prograf®) and 
the anti-rheumatic agent lefluonmide (Arava®). 
 
Table 3.2 Top 30 Specialist Drugs in primary care (GPs) by volume in England 
2010 / 2011 
BNF Name  Total Items  Total Act Cost  
Zoladex® LA Implant 10.8mg SafeSystem  124,048 £29,104,469 
Bicalutamide Tablets 50mg 107,945 £734,205 
Goserelin Acetate Implant 10.8mg  105,815 £24,852,565 
Mycophenolate Mofetil Tablets 500mg 104,075 £15,122,265 
Bicalutamide Tablets 150mg 86,048 £1,276,177 
Leflunomide Tablets 20mg 65,660 £4,049,922 
Leflunomide Tablets 10mg 61,888 £4,126,835 
Tacrolimus Capsules 1mg 53,327 £9,863,894 
Zoladex® Implant 3.6mg SafeSystems 50,962 £3,155,768 
Prograf® Capsules 1mg 49,553 £9,272,251 
Decapeptyl SR Injection 11.25mg  12,290 £2,355,662 
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As a drug group the four immunosupresant drugs ciclosporin, mycophenolate, 
sirolimus and tacrolimus accounted for 31.7% of all specialist drugs prescribed, 
making these the most frequently issued by GPs in primary care. Quarterly 
prescribing rates and expenditure for these four drugs in England are shown in 
Figure 3.2 (NHS Prescription Services 2012).  
 
 
Figure 3.2 Quarterly prescribing rates and expenditure for the 
immunosuppressant drugs ciclosporin, mycophenolate, sirolimus and 
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During this period, annual prescription items for these four drugs rose by 109,442 
(27.0%) with annual expenditure up by £17,314,418 (35.8%). These four drugs are 
licensed for the prophylaxis of acute organ rejection (renal, hepatic or cardiac) with 
ciclosporin also indicated in bone marrow transplantation, nephrotic syndrome. 
However specialists may also recommend these drugs in number of unlicensed 
conditions, such as ciclosporin in acute ulcerative colitis or mycophenolate in 
rheumatic disease (Joint Formulary Committee 2014).  
 
3.1.1.1 Data limitations 
The specialist drugs list is maintained by NHS Prescription Services and included 90 
drugs as of the last quarter (Oct – Dec 2011), and although periodically reviewed is 
not exhaustive. With area prescribing committees or equivalent forums basing drug 
policy on local health economies there may be variation in which specialist drugs are 
recommended for use only in secondary care or those suitable to be prescribed by 
GPs. For example the “traffic light classification” produced by Derbyshire Medicines 
Management Forum included 147 drugs, 105 classed as either “red”; where 
prescribing responsibility was retained in secondary care and 42 as “amber” where 
drugs were  designated as suitable for primary care prescribing under a shared care 
protocol (Anon 2010b). In addition only 49 of these drugs (41 red, 8 amber) were 
included on the specialist drug data base maintained by NHS Prescription Services.   
 
3.2 Organ transplantation  
In 1933, the first real attempt at transplanting a human kidney to a human recipient 
was performed in Russia, (Klintmalm 2004). Interest soon grew into transplant 
immunology culminating with the first ever successful human kidney transplant 
performed in 1951. It was in 1971 that scientists identified ciclosporin as having 
immunosuppressant properties (Bryan 2008). The drug transformed organ 
transplantation with one year survival of kidney transplants soon rising to 80%. With 
further advances in technology heart, heart and lung, and liver transplants became 
more widespread and successful. The expanding immunosuppressant market meant 
that, in the 1980s and 1990s, pharmaceutical companies became more interested in 
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Organ transplantation services are available from 32 specialist centers spread across 
the UK. Table 3.3 shows all organ transplantations conducted in the UK by organ 
type between 2008 and 2013 (adapted from NHS Blood and Transplant 2013). The 
total number of organ transplants carried out each year has steadily increased from 
3516 in 2008 to 4210 in 2013. Kidneys were by far the commonest organ 
transplanted accounting for 67% of all procedures during 2013. 
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Table 3.3 Organ transplantations conducted in the UK by organ type 2008 – 2013 (adapted from NHS Blood and Transplant 2013) 
Organ Transplant 2008 / 09 2009 / 10 2010 / 11 2011 / 12 2012 / 13 
Deceased donor (DD) transplants by organ type      
Kidney 1403 1482 1502 1599 1750 
Pancreas 54 40 41 37 38 
Kidney / Pancreas 152 160 156 173 166 
Pancreas Islets 3 13 13 30 30 
Heart 129 121 131 141 142 
Lung (s) 143 145 169 175 188 
Heart / Lung 3 5 3 5 3 
Liver / Lobe 651 666 668 726 775 
Other (Multi-Organ) 24 21 16 27 21 
Total DD transplants 2562 2563 2699 2913 3113 
Living donor (LD) transplants by organ type      
Kidney 927 1038 1021 1009 1066 
Liver 27 20 21 38 31 
Total LD transplants 954 1058 1042 1047 1097 
      
Total organ transplants 3516 3711 3741 3960 4210 
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3.2.1 Immunosuppressant drugs 
These agents are used to suppress rejection in organ transplant recipients and to 
treat a variety of chronic inflammatory and autoimmune diseases (Joint Formulary 
Committee 2014). In solid organ transplantation the principal aim of 
immunosuppression is to promote organ survival through the prevention of acute 
rejection. Immunosuppression is required for as long as the transplanted organ 
functions; if it is stopped, then rejection occurs and the organ is lost (Watson and 
Dark 2012). Immunosuppression is normally given as a combination of drugs each 
with different sites of action with regimens varying on the perceived 
immunosuppressive challenge that the transplanted organ poses; with more powerful 
immunosuppression used where the risk of rejection is greater.  
 
In the UK a number of drugs are available for use in transplantation such as the 
antiproliferative agents (e.g. azathioprine, mycophenolate), corticosteroids (e.g. 
prednisolone); calcineurin inhibitors (e.g. ciclosporin, tarolimus); non- calcineurin 
inhibitors (e.g. sirolimus); mono-clonal antibodies (e.g. basaliximab) and 
immunoglobulins (e.g. rabbit antithymocyte) (Joint Formulary Committee 2014). In 
2004, NICE guidance made a number of recommendations on the use of specific 
drugs in managing organ transplantation including recommendation for the use of 
some of these drugs in unlicensed indications (NICE 2004).   
 
3.2.2 The National Reporting and Learning Service  
The National Reporting and Learning Service (NRLS) was one of three divisions of 
the National Patient Safety Agency (NPSA).  The NPSA was an arm's length body of 
the Department of Health, established in 2001 with a mandate to identify patient 
safety issues and find appropriate solutions. Table 3.4 lists medication incidents by 
stage of medication process in both primary and secondary care for the period 2005 
– 2010 in relation to ciclosporin, mycophenolate, sirolimus and tacrolimus (NPSA 
personal communication 2011). Of the total 1103 incidents 282 (25.5%) were directly 
related to prescribing, 11 of which occurred in primary care. In addition to this 44 
incidents were classed as moderate, 1 as severe and 2 resulted in fatalities.  
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Table 3.4 Medication incidents involving ciclosporin, mycophenolate, sirolimus and tacrolimus by stage of medication process 
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0 57 1 0 0 3 0 1 0 0 52 
 
Total 
10 1014 8 3 7 42 3 12 1 3 1103 
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3.2.3 Generic prescribing  
In recent years patent expiry in recent years of three immunosuppressant drugs, 
ciclosporin, mycophenolate and tacrolimus has allowed the introduction of generic 
formulations (Johnston 2011). The introduction of both new formulations of 
tacrolimus and less expensive generic formulations has had a profound effect not just 
on the potential savings in drug costs but the associated risks and hazards with their 
use. In January 2009 the MHRA released a safety warning highlighting that 
medication errors with Advagraf ® and Prograf ® had been reported in seven 
European Union countries; with most reports from the UK (MHRA 2009). These 
reports fell into three categories, prescribing errors by either hospital doctors or GPs, 
dispensing errors at pharmacies or administration errors. In addition in some cases 
these errors resulted in patients being dosed incorrectly, leading to serious adverse 
reactions including acute rejection of transplanted organs.  
 
Generic products are not licensed on the basis of clinical assessment in the relevant 
patient group but on bioequivalence assessment in healthy volunteers (Johnston 
2011). Ciclosporin was introduced in the 1970s and is well established as a critical 
dose drug where brand prescribing and dispensing is recommended. With the 
growing numbers of generic oral tacrolimus products and the increased potential for 
inadvertent switching between these products the MHRA in the UK recommended 
that prescriptions for oral tacrolimus products be written by brand name only (MHRA 
2010). In 2012 the MHRA issued a further alert following reports that graft rejection 
reactions and tacrolimus toxicity had resulted from a small number of unintended 
switches between products, and that where a prescriber intended to switch between 
any tacrolimus brand, careful medical supervision and therapeutic monitoring would 
be required (MHRA 2012). The annual cost of treatment following transplantation is 
around £5,000 per year, and higher in some cases depending on choice and 
combinations of agents used. Figure 3.3 shows the costs of originator brands and 
current generic formulations of tacrolimus, ciclopsorin, sirolimus and mycophenolate 
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3.3 Shared care protocols 
Six UK studies have either evaluated the characteristics of shared care protocols or 
the attitudes or views of clinicians towards their use and these are summarised in 
Table 3.5. Overall these studies have shown that despite the best attempts to 
develop and implement shared care protocols to support the use of specialist drugs 
these efforts have been in vain particularly from the perspectives of GPs. Key 
barriers to implementation have included the lack of GP involvement in their 
development (Gerada and Tighe 1999, Duggan et al 2001, Crowe et al 2009), and 
the general quality of shared care protocols including a lack of standards and 
availability (Duggan et al 2001). Iilife et al (2006) investigated the views and 
perceptions of GPs and specialists about the potential for shared care in the 
management of patients with dementia. Broad themes identified as barriers to 
successful implementation included risk reduction or avoidance, and concerns about 
competency and resources for shared care. In addition the authors described 
resistance from GPs in accepting shared care protocols citing issues in relation to 
time constaints and practice workload. Salt et al (2005) also highlighted concerns 
with the level of training that GPs received in managing conditions that required the 
use of specialist drugs.  
 
Horne et al (2001) reported that GPs would be more likely to participate in shared 
care prescribing if they felt hospital doctors were supportive and more understanding 
of their position. In addition the authors identified key quality indicators relating to the 
prescribing of specialist drugs in relation to shared care to include clinical 
responsibility, cost shifting, availability of medicines, GP satisfaction, and the nature 
of the prescribing relationship. Crowe et al (2009) identified additional factors in 
relation to prescribing specialist drugs but these were specifically based around the 
decision making process that GPs needed to go through in managing requests to 
prescribe specialist drugs. Suggested improvements in the use of shared care 
protocols have included the need for joint agreement between primary care and 
secondary care (Salt et al 2005) and having a clearer definition of roles and 




Chapter 3: An exploratory study using key informants to investigate the use of computerised decision support software (CDSS) within UK general practice 
100 
 
Table 3.5 UK studies of shared care protocols 
Authors Design Results  Outcomes 
Gerada and 
Tighe (1999) 
A national survey of all of the former 120 Health 
Authorities to provide details of shared care 
protocols. This was conducted on behalf of the 
Royal College of General Practice and 
Psychiatrists Working Party in relation to shared 
care protocols for drugs used in substance 
misuse. 
Review criteria included patient suitability, 
guidelines for initial assessment, prescribing, 
continued care and the extent of GP 
involvement. From 89 responses received only 
26 Health Authorities had shared care 
arrangements. In only 9 cases was a GP 
involved in their development. 
Few Health Authorities involved GPs in 
developing shared care protocols even though 
they were expected to adhere to them. The 
Working Group concluded that shared care could 
be achieved if there was close contact between 
GPs and specialists, integrated training, audit 
and agreed protocols to include prescribing 
responsibility. 
Duggan et al 
(2001) 
A national survey of hospital pharmacists, 
pharmaceutical and medical advisers in the former 
120 Health Authorities. Qualitative interviews with 
8 health care professionals including GPs, 
prescribing advisers and hospital based clinicians.  
A total of 321 shared care protocols were 
identified that described 99 different specialist 
drugs and treatments. Shared care protocols 
were found to vary considerably with no apparent 
standard either within or between regions; with 
GPs were commonly excluded from their 
production.   
The authors reported that although a large 
number of shared care protocols had been 
produced in the UK, the actual benefits to 
patients was unclear. There appeared to be no 
formal evaluation of their use or mechanisms for 
their implementation and that distribution was 
found to be erratic. 
Horne et al 
(2001) 
To investigate the views and experiences of GPs 
and hospital doctors about arrangements for 
shared care in relation to the prescribing of 
specialist drugs.  Semi-structured interviews with  
London based GPs (n = 48) and hospital doctors 
(n = 13)  
Key themes formed the basis of 8 quality 
indicators relating to prescribing specialist drugs 
and shared care to include clinical responsibility, 
cost shifting, availability of medicines, GP 
satisfaction; and the nature of prescribing 
relationship. 
GPs appeared dissatisfied with shared care 
protocols for prescribing specialist drugs whilst 
hospital doctors appeared satisfied. GPs were 
more likely to participate in shared care 
prescribing if they felt hospital doctors were 
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Table 3.5 UK studies of shared care protocols (cont.) 
Authors Design Results  Outcomes 
Salt et al 
(2005) 
An investigation of perceptions of GPs about 
the prescribing of the specialist drug 
methylphenidate in the management of 
Attention Deficiency Hyperactive Disorder 
(ADHD). Semi structured interviews with 13 
London based GPs and a questionnaire survey 
of 179 GPs based in the same London area 
from which 93 responses were received.  
Whilst GPs had differing views of the aetiology of 
ADHD, there was a consensus view about the 
division of responsibility in the treatment of those 
diagnosed with ADHD. GPs felt uncomfortable 
initiating the prescribing of methylphenidate and 
stressed the importance of ongoing specialist 
involvement in the management of ADHD. There 
was also a feeling of inadequacy in terms of the 
training that GPs had received 
The authors suggested that once guidance on 
the initial diagnosis of ADHD was made available 
to GPs, shared care protocols could be agreed 
between primary care and secondary care so 
that the ongoing division of labour in the 
management of ADHD was made explicit, 
ensuring continuity of care.  
Iilife et al 
(2006) 
An investigation of the perceptions of GPs and 
specialists about the potential for shared care 
in dementia. Semi-structured interviews with 39 
GPs and 30 specialists in 3 inner city and 2 
rural areas. 
Broad themes were identified as barriers to 
successful implementation such risk reduction or 
avoidance; concerns about competency and 
resources for shared care. Resistance to shared 
care mostly came from general practice 
reflecting concerns on staffing, time constraints, 
lack of experience and confidence in making and 
disclosing a diagnosis. 
The authors suggested that roles for primary and 
secondary care professionals were 
inappropriately distributed and required clearer 
definition. Developers of shared care protocols 
were advised to address obstacles including risk 
management and clinical competence. 
(Crowe et al 
2009). 
An investigation of the influences on how GPs 
evaluated requests to initiate a specialist drug 
and whether to go on and prescribe. Semi-
structured interviews with 47 health 
professionals in the North West of England 
including 14 GPs. Other participants included 
prescribing advisers, GP practice managers 
and strategic leads representing prescribing 
committees.  
Six diverse factors were identified as having a 
crucial bearing on how GPs evaluate initial 
requests and subsequently decide whether or 
not to prescribe. These included GPs’ lack of 
knowledge and expertise in using specialist 
drugs, the shared care arrangement, the 
influence of a locally agreed advisory list, 
financial and resource considerations, patient 
convenience and GPs’ specific areas of interest. 
The authors highlighted a number of recurrent 
themes with reference to previous studies such 
as concerns with knowledge and experience of 
using specialist drugs levels by GPs. The 
authors identified factors that influenced GPs’ 
acceptance and prescribing of specialist drugs 
including the importance of an increased 
understanding of GPs’ decision-making process.   
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The use of shared care protocols has been identified as one way of reducing some 
the risks associated with the prescribing of specialist drugs by GPs including the on-
going management of patients. However the outcomes from published studies that 
have investigated the use of shared care protocols has shown a number of 
drawbacks in their use. Four of the six studies that have investigated the use of share 
care protocols in the UK used qualitative methods by way of semi-structured 
interviews with a range of health care professionals (Horne et al 2001, Salt et al 
2005, Iilife et al 2006, Crowe et al 2009). Duggan et al (2001) adopted a mixed 
method approach combining interviews with healthcare professionals with a national 
survey. Although using information technology has been suggested as a possible 
solution to some of the problems associated with the primary care and secondary 
care interface (Hampson et al 1996) and more recently with increased expectations 
following the introduction of the single electronic health record and the greater 
electronic transfer of information (Khambh and Barnick 2007) to date no published 
studies have evaluated the potential for a CDSS to support prescribing in this area.  
 
3.5 Aims and objectives 
The aim of this study is to assess the feasibility of developing a CDSS to support 
GPs at the point of prescribing in the use and management of specialist drugs. The 
objectives for this study were the following:   
 
 Gain an understanding of current usage, system types and characteristics of 
CDSS within primary care.   
 Build a practical understanding of current NHS management systems in 
relation to information technology, general practice  and CDSS  
 Explore how current financial constrains with the NHS may impact the 
delivery of CDSS in primary care  
 Understand from commercial suppliers both historic, current and future 
strategy with regards to CDSS particularly in light of current NHS reforms  
 Explore with secondary care clinicians the shared care protocol development 





Chapter 3: An exploratory study using key informants to investigate the use of computerised 




Oppenheim (1992) described exploratory interviews as the basis of initial research 
that can go on to develop large scale standardised data collection in the form of 
surveys. In addition Oppenheim (1992) described exploratory interviews as heuristic, 
as a way of developing ideas and research hypotheses rather than to obtain statistics 
or facts and that the role of the interviewer is not data collection but idea collection. 
Spradley (1979) identifies three key requirements for interviews as having explicit 
purpose, ethnographic explanation and ethnographic question. Explicit purpose 
requires recognition between the researcher and the informant that the interview as 
an aim and that the discussions are intended to meet this aim. Ethnographic 
explanations require the researcher to ensure that the informant is fully aware of 
every aspect throughout the interview process. Ethnographic questions describe the 
nature of the question being asked by the researcher and can be descriptive, 
structural or contrasting.  
 
Britten et al (1995) described the continuing shift in the focus of primary care 
research through a response to changes in socio-demographic and health 
environment leading to an increased dependence on a variety of research methods 
of which qualitative methods as central. Conducting research within healthcare 
settings has been described as difficult due to a range of factors such as having to 
deal with people, measuring outcomes, time constraints, ethical issues and dealing 
with a range of disciplines or professions (Crombie and Davies 1996). However with 
many of the answers to research questions in healthcare often only available from 
individuals either patients or clinicians, this lends to the use of qualitative methods 
such as direct observation, interviews and focus groups. The reality of health 
services research, including examples of prescribing research is that evidence is 
rarely complete and a systematic approach to gathering consensus including expert 
opinion is often required (Campbell et al 2001).  
 
In this study key informant interviews were the best method in order to meet the aims 
and objectives of the research study. Traditionally established within anthropology 
and sociology research key informants have increasingly been used within medical 
research often to complement other qualitative approaches with the principle 
advantage of obtaining the quality of data in a relatively short time period. A key 
informant is an expert source of information and usually but not invariably occupies a 
position of responsibility and influence (Marshall 1996). 
 
Chapter 3: An exploratory study using key informants to investigate the use of computerised 
decision support software (CDSS) within UK general practice 
104 
 
3.6.1 Selection criteria for the key informants 
A review of the published literature of CDDS usage in the UK identified the 
stakeholder groups who would provide insight into the requirements of a CDSS to 
support the use of specialist drugs within general practice. These key informants 
represented general practice (GPs), NHS management, general practice, secondary 
care clinicians, commercial CDSS suppliers and industry experts. Sixteen individuals 
were identified as potential key informants. With kidney transplants accounting for 
67% of all organ transplantations carried out in the UK (NHS Blood and Transfusion 
2013) renal units were selected as the best suited sites to identify potential contacts. 
Secondary care clinicians with a specific knowledge of specialist drugs and 
immunosuppression were based in tertiary care centres providing transplant 
services. Two GPs known to the primary researcher to have specific interests in the 
research area were approached. Local NHS IT managers and commercial CDSS 
suppliers across the UK were also approached.  
 
3.6.2 Interview schedules  
The interview schedules were used as a topic guide and emerging themes were used 
to formulate further questions during each interview. Hancock et al (2009) explained 
that topic guides should not just be a schedule of questions and should not restrict an 
interview, which needs to be conducted sensitively and flexibly to allow follow up of 
points of interest to either interviewer or interviewee. Interview schedules 
incorporating a range of open and semi-structured questions were developed for 
each of the four stakeholder groups (see Appendix 3.1, 3.2, 3.3 and 3.4). The 
schedules were tailored to each stakeholder group with specific questions reflecting 
the aims and objectives of the study.  
 
 Each schedule included an opening statement that outlined the purpose of 
the study, confirming consent to participate and for the interview to be audio 
recorded. 
 Each informant was asked about their background, past and current role in 
relation to the research study. 
 Both the GPs and secondary care clinicians were asked specific questions in 
relation to the views and experiences specialist drugs, immunosuppression 
and shared care protocols. 
 All of the informants were asked about their views and experiences of IT and 
the feasibility of a CDSS to support the prescribing of specialist drugs.  
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3.6.3 Audio recording 
A Sony digital audio recorder (ICD PX312) was used to record the interviews. Each 
interview schedule had an introductory statement to remind the informants that the 
interview was being audio recorded.  
 
3.6.4 Ethical approval 
Ethical approval for the study was granted by Kings College London Biomedical 
Sciences, Dentistry, Medicine and Natural & Mathematical Sciences Research Ethics 
Subcommittee on the 28th May 2012 (Reference BDM/11/12-82). 
 
3.6.5 GP pilot 
The GP interview schedule was piloted prior to the first interview. A GP known to the 
researcher was approached and agreed to participate. The interview lasted 20 
minutes and was transcribed verbatim into Microsoft Word (Version 10). Following a 
review of the transcript no changes were required to the GP interview schedule.  
 
3.6.6 The interviews 
The flow diagram (see figure 3.4) summarises the methods used in this study. Each 
potential key informant was first sent a cover letter (Appendix 3.5), participant 
information leaflet (Appendix 3.6) and a consent form (Appendix 3.7) either 
electronically and or by post. Any non-responders and any participants declining 
consent were exited from the study and further informants were considered. 
Participants who agreed to take part were then sent a confirmation letter (Appendix 
3.8) and contacted to arrange a suitable time and venue. All interviews were 
arranged at locations convenient to each participant e.g. office. Additional notes were 
taken during each interview which included observational data such as work-place 
environment.  
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Figure 3.4 Summary of methods followed during this research study 
 
3.6.7 Interview transcripts 
Following each interview the recordings were transcribed verbatim onto Microsoft 
Word (version 2010) and each document was checked for accuracy saved as a final 
transcript with an individual anonymous participant code. The software NVIVO 
(version 10) was used to support data analysis.  
 
3.6.8 Data analysis 
Qualitative research uses analytical categories to describe social phenomenon, 
derived either inductively, i.e. gradually from the data obtained or deductively either 
at the beginning or part way through data analysis (Pope et al 2000). A review of the 
literature had identified specific themes which pre-determined the analytical 
categories such as the experiences of individuals of CDSS, specialist drugs and 
shared care protocols. Specific techniques that have been developed to support the 
analysis of data generated from qualitative research to include grounded theory and 
framework analysis (Lacey and Luff 2009). Framework analysis is an inductive 
process of identifying analytical categories developed in the 1990s by UK by social 
policy researchers (Ritchie and Spencer 1994).  
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Although the approach to framework analysis shares many features of grounded 
theory, this approach allows categories and themes to be set at the beginning of 
analysis, but also allows for the generation of new ideas during data analysis.  
Framework analysis was chosen as the method that best supported data analysis 
and would allow for identification of additional theory or the generation of new ideas 
or concepts. 
 
As each interview was conducted and transcribed, initial analysis was conducted 
manually through a process of iteration of the text to allow the researcher (NC) to 
identify emerging themes and sub-themes. These emerging themes were then 
categorised both manually and using the software NVIVO (version 10). These 
themes were used to further develop each interview guide in order to explore key 
areas and amend existing or to add further questions for the subsequent interviews. 
Emerging themes and sub-themes were categorised and charted to identify patterns, 
relationships, contrary statements and conflicting issues. Themes and categories 
were continuously reviewed and re-coded as new data emerged from each interview.  
 
3.6.9 Data quality analysis  
On completion all 12 interviews were re-checked for accuracy. NVIVO trainers (BW, 
TM) were consulted to check coding methodology and data mapping. In order to 
provide more accurate reports and enhanced analysis. A second round of coding 
was completed, and validated with the trainers. A number of iterations of the data set 
were completed and agreed with the research team (NC, CW, BD). 
 
3.7 Results  
Twelve interviews were completed between July 2012 and February 2013. The 
interviews lasted between 30 minutes (GP1) and 65 minutes (DS3) with a mean 
interview time of 50 (49.75) minutes. A summary of the interview schedules and key 
informant background profiles are shown in Table 3.6 
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Table 3.6 Profile summary of the 12 key informants 
Month  Stakeholder Group  Informant Code Interview Duration Profile Summary 
July 2012 GP GP1 30 minutes Recently qualified and worked as a salaried GP based within a large 
health centre 
 
August 2012 NHS IT Manager IT1 49 minutes Recently appointed to the NHS and was working across 3 PCTs on a 
GP practice refresher project. 
 
August 2012 CDSS Industry DS1 55 minutes Pharmaceutical consultant specialising in health informatics. 
 
August 2012 GP GP2 49 minutes Qualified for over 8 years and a partner within a five doctor practice.  
 
September 2012 CDSS Industry DS2 62 minutes CDSS supplier representative. 
 
September 2012 NHS IT Manager IT2 43 minutes GP practice manager with over 20 year experience in NHS IT roles 
including senior management  
 
September 2012 Secondary care 
clinician 
NHS1 49 minutes Lead pharmacist on behalf of a specialist commissioning group 
 
October 2012 CDSS Industry DS3 64 minutes CDSS supplier representative and qualified GP 
 
December 2012 Secondary care 
clinician 
NHS2 50 minutes Lead directorate pharmacist NHS renal unit 
 
December 2012 Secondary care 
clinician 
NHS3 47 minutes Consultant in renal medicine 
 
February 2013 CDSS Industry DS4 61 minutes CDSS supplier representative and a qualified GP 
 
February 2013 Secondary care 
clinician 
NHS4 38 minutes Consultant in renal medicine 
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The research area specifically focussed on primary care and GP prescribing however 
a number of features of secondary care based systems and clinical practice emerged 
in relation to the research area. Three primary themes were identified from the data 
from which a range of secondary themes and sub-themes emerged and these are 
shown in Table 3.7. 
 
Table 3.7 Summary of primary, secondary and sub-themes 
Primary 
Theme  









 Communication: Problems specifically between 
primary care and secondary care (interface) 
 Clinical responsibility: For GPs when prescribing 
specialist drugs  
 Monitoring of patients receiving specialist drugs 
 Experiences of specialist drugs (adverse 
experiences such as drug interactions, generic 
prescribing, repatriation)  
 Experiences of shared care protocols 
IT Systems Operational 
features of IT 
systems (primary 
care)  
General usage of computers in general practice and key 
characteristics of IT systems  
 Regulation (current NHS management systems, 
GP system vendors and shifting to hosted 
systems) 
 Data quality (read coding, accuracy, accreditation) 
 Integration of systems 
 Implementation of systems  
 CDSS and experience in general practice (current 
profiles, usage and characteristics)  
 Current and future developments in CDSS 
 CDSS and specialist drugs (views and attitudes , 
enablers, barriers) 
Cost Drug costs, service 




 Prescribing budgets (primary care) 
 NHS service costs and use of homecare 
 GPSOC (License fees), CDSS funding streams 
 CDSS and specialist drugs: Funding models 
(barriers and enablers) 
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3.8 Primary themes 
Three primary themes emerged from the data analysis and a number of sub-themes. 
The primary themes were safety, IT systems and costs.  
  
3.8.1 Safety 
Aspects of safety were raised throughout the interviews particularly from specific 
experiences of using specialist drugs in terms of prescribing and in the on-going 
management of patients receiving immunosuppressant drugs. The experiences of 
the informants described key concerns, difficulties and having to deal with adverse 
situations or outcomes.  
 
3.8.1.1 Communication  
Issues with communication between primary care and secondary care were 
described by the GPs and secondary care clinicians. A lack of documentation coming 
from secondary care was a specific issue for the GPs and for the secondary care 
clinicians. Problems with communication were described in terms of differences in 
medication records between primary and secondary care (see Box 1).   
 
Box 1: GPs and secondary care clinicians’ experiences of communication  
GP1: “Relatively frequently, if I see a prescription for mycophenolate and 
tacrolimus on the whole, I think they are the only ones I have prescribed, I look to 
try and repatriate the prescribing to secondary care, because frequently we have 
minimal documentation.” 
 
NHS2: “We start blood pressure tablets......we stop blood pressure tablets….we 
change blood pressure tablets……..we withhold drugs because of side 
effects….we communicate this to GPs….but the patient......X months later are still 
on the same drugs.” 
 
NHS4: “Well I would say that the actual transcription errors are relatively rare in 
relation to the drugs, but not unknown……more often just simply it’s what I think 
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3.8.1.2 Clinical responsibility 
Clinical responsibility was described from a range of experiences by the informants 
highlighting a number of concerns (see Box 2). The issue of clinical responsibility and 
its effect on the willingness to prescribe was described by both the GPs and 
secondary care clinicians. One initiative described was the use of traffic light 
schemes whereby certain drugs would remain hospital only based on their 
classification but could be prescribed under certain circumstances by GPs. However 
even under such conditions one secondary care clinician empathised with the difficult 
position that a GP may face when asked to prescribe specialist drugs that they were 
not familiar with.   
 
Box 2: GPs and secondary care clinicians’ experiences of clinical 
responsibility 
GP1: “I think you know about where the responsibility lies, at what stage in therapy 
the patient is, because often the letters come weeks after the clinic, that’s no good, 
they come to us 2 weeks later, we don’t know what their dose is, we don’t know if 
have they completed a dose escalation, you know......we are......basically operating 
in the dark, but we are being asked to prescribe these drugs.” 
 
GP2: “Anxious……you are often being asked to take responsibility for something 
that actually we don’t have the authority or the control over where the consultant in 
a hospital would.” 
 
NHS3: “I didn’t feel particularly strongly that they either should or shouldn’t be 
prescribing I can see their point, they are not drugs they are used to….if you make 
me prescribe some drug for hepatitis which is something out of my expertise I 
would be uncomfortable about it as well.” 
 
3.8.1.3 Monitoring 
The overall clinical management of patients was described by both the GPs and the 
secondary care clinicians. This management included specific aspects about patient 
monitoring and are described in Box 3. The GPs described experiences where 
patient monitoring around blood test results posed practical difficulties. In contrast to 
the GPs, the secondary care clinicians described positive aspects to the clinical 
monitoring of patients receiving immunosuppressant drugs. In addition clinical 
monitoring was described as a key aspect of hospital based reviews.   
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Box 3: GPs and secondary care clinicians’ experiences of the monitoring of 
specialist drugs 
GP1: “Similarly we might get a blood result, that’s potentially very worrying for 
somebody on mycophenolate, but not worrying at all for somebody with slightly low 
neutrophils, you wouldn’t panic……somebody who is not taking mycophenolate you 
would just call them in……but if that was somebody taking mycophenolate they 
need to have a blood test and hospital admission immediately.”  
 
GP2: “Only 2 days ago I had a patient who wanted their medication but no blood 
test been done for 6 months, I tried to ring them…….no answer……..so what do 
you do in that scenario?”  
 
NHS2: “For the frequency that you would need to monitor levels once they are 
stable they only need to be done whenever they come up to clinic so there is no 
point for the GPs doing their bloods anyway so as long as they keep an eye on their 
blood pressure.” 
 
NHS4: “It’s got a lot more complicated in the modern world......in the old world when 
all there was branded ciclosporin it was straight forward, as a general rule in those 
areas where local primary care had agreed to do the prescribing it was generally 
expected that the renal unit would be in charge of the level and the GPs would 
adjust the does as requested by the renal unit.” 
 
3.8.1.4 Experiences of specialist drugs 
A key aspect to medication safety were citations and examples of adverse effects 
linked to the prescribing of immunosuppressant drugs by GPs and the secondary 
care clinicians. These related to two key areas drug interactions and the introduction 
of generic formulations of tacrolimus. 
 
3.8.1.4.1 Drug interactions 
Shown in Box 4 were specific adverse experiences with drug interactions with 
immunosuppressant drugs. One practical difficulty in relation to drug interactions 
faced by GPs was that when hospitals prescribed specialist drugs that information 
was not able to be made available electronically within the patient medication record 
held within the GP clinical system. Without such drugs recorded on a GP held 
medication record there is a potential for other prescribed drugs to interact. 
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The secondary care clinicians described adverse experiences of drug interactions 
including examples when patients were given drugs prescribed by their GPs whilst 
taking immunosuppressant drugs. 
 
Box 4: GPs and secondary care clinicians’ experiences of drug interactions 
with specialist drugs 
GP1: “One of the practical difficulties for us is that often it’s not logged on our 
computer system, that if they are receiving the drugs from somewhere else…. the 
HIV drugs, the TB drugs, mycophenolate, tacrolimus, they might be prescribed by 
specialist clinics, we get clinic letters that tell us, but it does not automatically 
appear on our prescribing system, so potentially drugs that we prescribe might 
interact with that, unless we have put some sort of alert on the system.” 
 
NHS3: “I think drug interactions is one of the major headaches that we have with 
immunosuppressants, you know mainly penicillin allergic patients come in with a 
fever and a chest infection and they get clarithromycin and then the next thing you 
know their tacrolimus levels have doubled.”  
 
3.8.1.4.2 Generic prescribing 
The patent expiry of ciclosporin, mycophenolate and tacrolimus has allowed the 
introduction of generic formulations of these drugs. However the secondary care 
clinicians described a number of adverse events involving generic formulations, 
particularly with tacrolimus, due to differing bioequivalence between these products. 
Examples of inadvertent switching of formulations are shown in Box 5.   
 
Box 5: Secondary care clinicians and experiences of generic prescribing of 
immunosuppressant drugs.  
NHS1: “When the primary care data was analysed it appeared that patients had 
been getting different formulations…...well inappropriately………so basically no 
decision had been made to change it but it had been changed so there was a 
patient safety imperative around bringing patients back.” 
 
NHS2: “So that’s the other thing they did we said specifically you have to give 
Prograf and the GP was going oh well that’s too expensive and I will give you 
Vivadex instead......well they killed the patient.” 
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NHS3: “There is a huge variation in bioequivalence, we had one patient who had 
the wrong brand of tacrolimus and came in and rejected due to lower levels of 
tacrolimus......we had another patient who came in who had a recurrence of herpes 
zoster because she had received a different brand and had been over 
immunosuppressed.” 
 
3.8.1.4.3 Repatriation  
The introduction of generic immunosuppressant drugs and the associated number of 
number of adverse incidents was a key factor that led to the decision to revert GP 
prescribing back to renal units across the country. The secondary care clinicians 
described this process as repatriation with the added benefit of making use of 
homecare services to provide patients with their supply of immunosuppressant drugs 
(see Box 6). A specific service development was the introduction of pharmacist 
prescribing within one of the renal units. 
 
Box 6: Secondary care clinicians and experiences of repatriation and use of 
homecare Services. 
NHS1: “There are cost advantages to using the generic products, but there are big 
issues about when you need to stabilise the patient, if you’re going to do this then 
patients need further work up to enable it this to happen and then you have to be 
consistent afterwards with the choice of products, so the process has been that 
patients have been if you like……..migrated back to the specialist centres, had 
these changes made and then continued to be under the care of the specialist 
centre with the medicines reaching them through homecare.” 
 
NHS2: “Three of us are prescribing pharmacists so we spend a morning a week 
each in the transplant clinic doing all the prescribing for them......the prescriptions 
are on a proforma we have developed......what we do then is that we take them 
downstairs and the bods in the offices scan them, encrypt them and they can then 
send them via NHS mail to the homecare companies.” 
 
NHS4: “As I said earlier on all my life as a consultant, worked in units where the 
prescribing was central, whether it was home delivery or not......so the home 
delivery or not issue to me is seeing that it is convenient for the patient, and the 
VAT gain for the ultimate payers and that is good as well......I think repatriation is a 
good thing......with transplant immunosuppression that is the rational way to do it.” 
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3.8.1.5 Shared care protocols 
The informants described mixed experiences of shared care protocols and 
highlighted some of key concerns in relation to safety such as communication 
between secondary and primary care. The views and experiences of the GPs in 
relation to shared care protocols were particularly negative. The secondary care 
clinicians reported a greater experience of shared care protocols describing some 
positive aspects to their use such as the developmental and approval process. Two 
of the CDSS informants were practicing GPs and shared their experiences and 
opinions in this area. Figure 3.5 shows the views and experiences of the informants 
of shared care protocols by stakeholder group.  
 
 
Figure 3.5 The views and experiences of the informants of shared care 
protocols by stakeholder group. 
 
3.8.1.5.1 Development and approval of shared care protocols 
The secondary care clinicians provided specific insight on the developmental process 
of shared care protocols and these are shown in Box 7. These included writing, 
updating and the approval process including the relationship with primary care based 

























GPs (n = 2) NHS Secondary Care Clinicians (n = 4) CDSS Suppliers (n = 4)
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Positive aspects related to the developmental process however some drawbacks 
were described in relation to the approval process and engagement with primary 
care. Although GPs were involved at the approval level neither of the GP informants 
had any experience in the writing of or development of shared care protocols. 
 
Box 7: Secondary care clinicians and the developmental process of shared 
care protocols 
NHS 1: Generally they take a good deal of effort to create........the challenges again 
around….you often work with a partner, say a primary care partner to develop the 
thing, so it meets everybody’s  needs, so you think you can than lift that model and 
apply it to the next commission group or PCT......to make these things happen and 
often there is a two part process so there may be a pharmacist in the Trust leading 
on it and working with a particular head of medicines management or a PCT 
colleague and that is usually ratified through processes of the PCT and the drug 
and therapeutics committee of the hospital.” 
 
NHS2: “I have written quite a lot of them......usually renal drugs......once I have 
written it I send it to our formulary pharmacist......and then she goes to meetings 
with the local PCTs......rather than the individual PCTs now we deal with the Sector, 
so it’s all the old PCTs in sort of one lump, she goes to meetings with them and 
that’s where these things get thrashed out and they come back for comments.” 
 
NHS3: “We have always had a shared care protocol for immunosupressants, we 
updated it with the idea that generics were coming along, we updated it with the 
idea that Advagraf was coming along too” 
 
NHS4: “Historically it has tended to be slightly one sided from the secondary care 
end......the secondary and tertiary sector is where the experience and expertise 
is…so that’s not totally unreasonable......and it will depend on the certain extent on 
the energy, knowledge and desire from the representatives form primary care who 
are involved.” 
 
3.8.1.5.2 Quality of shared care protocols  
Despite the positive description in terms of developing shared care protocols and the 
approval process involving PCT medicines management teams the opinions and 
experience of the GPs raised doubts on whether these systems were effective with 
the most widely cited problem being the quality of shared care protocols.  
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A number of examples were given describing specific issues such as inappropriate 
drug selection, variability, and the ease of use in general practice. The views of the 
GPs on the quality of shared care protocols are shown in Box 8. 
 
Box 8: GPs’ views on the quality of shared care protocols  
GP1: “I never had any awareness of shared care protocols, I think they are 
universally pretty useless and I think they are a significant area of potential danger.” 
 
GP1: “I understand there are some shared care protocols which exist which I think 
are routinely flouted and are probably quite silly, for example around acetyl - 
cholinesterase inhibitors......yet we are being asked to prescribe things like 
mycophenolate and ciclosporin which I don’t think are benign at all and have 
significant risks and I don’t think are appropriate for  primary care, and It just seems 
to me there is no sense to it.” 
 
GP2: “My normal first response is no we won’t take this on until we get the protocol 
and when it is sent it is not written in my perspective......in the sense that it’s often 
written from how it’s initiated......not terribly helpful or easy to use.” 
 
3.8.1.5.3 Acceptance of Shared care protocols 
The secondary care clinicians described the acceptance of GPs to prescribe 
specialist drugs by way of a shared care protocol as particularly problematic (see Box 
9). Despite having shared care protocols available often supported by local NHS 
medicines management teams or similar authoritative processes, did not specifically 
mean that GPs would use them. 
 
Box 9: Secondary care clinicians and experiences of the acceptance of shared 
care protocols by GPs 
NHS 2: “Well the shared care protocols were out there whether they used them or 
not......I have no idea......the bosses of the PCTs kept saying oh we have to 
update it.……whether that was to make them feel good, or who actually used 
them I have no idea 
 
NHS2: “About 50 / 50 (of GPs)......but it was getting worse…….and even some 
who did prescribe turned around and said no I won’t prescribe.” 
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Box 9: secondary care clinicians and experiences of the acceptance of shared 
care protocols by GPs cont. 
NHS3: “Yes, the request had come from the GP......then you can send out the 
shared care protocol, I have not had an awful lot of feedback from primary care 
about the shared care protocol......sometimes I have had a number of multiple 
requests from a similar GP…...It’s like everything …..a piece of paper that you get in 
the post......oh gosh that’s fantastically interesting, I must remember that the next 
time I see a patient with that......but it gets filed......and then the patient comes along 
and you have to trigger it in your memory that you have that shared care protocol.” 
 
NHS3: “So there were multiple different reasons…..one was the traffic light 
system…..so it would be either red or amber….so they would say that my local PCT 
has said this is red or amber and therefore I shouldn’t be prescribing.” 
 
3.8.1.5.4 Availability of shared care protocols  
Ensuring the availability of shared care protocols and the awareness of their 
existence was a key problem and this is described in Box 10.  The GPs identified the 
absence of shared care protocols when receiving communications from hospitals and 
also identified that often secondary care clinicians were not aware that a protocol 
existed. The secondary care clinicians also described issues with the availability of 
shared care protocols. Difficulties included keeping track of and locating updated 
versions and ensuring dissemination to all GPs to include locums.  
 
Box 10: GPs and secondary care clinicians’ views on the availability of shared 
care protocols.  
GP1: “I think it’s something that we frequently get letters from the hospital 
consultants......you know or this is the drug they are taking, it’s not made clear to us 
if we’re expected to take on prescribing, it’s not made clear to us if there is a shared 
care protocol in place, it’s certainly not clear that they have any idea if there are 
shared care protocols in place.” 
 
GP1: “I am sure they are available on this formulary, somewhere......but the reality 
is this that this data isn’t very accessible to the average GP….. there are so many 
of them that we are just overwhelmed with it, I think most GPs......I certainly shy 
away from prescribing things like tacrolimus.” 
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Box 10: GPs and secondary care clinicians’ views on the availability of shared 
care protocols cont.  
NHS1: “Yes in the sense that I hear that argument, and you know it’s very real if the 
information is not available......wherever it’s getting it embedded in the system….. 
obviously it’s whether it is there but not findable.” 
 
NHS 4: “I think that we do sometimes get sort of howls of protest if we try to set up 
something too complicated......“Listen we are drowning in paperwork!”...... Protocols 
are forms......things get updated, you have to keep track of the version, you have to 
have them easily available, every time a new one comes out you have to update 
everything, you have it set up so locums and other people coming in to the 
environment knows where to find them………it’s  big pain in the neck!” 
 
3.9 Information technology: Systems and functionality 
IT systems within the NHS were described from both historical and current 
perspectives in both primary and secondary care settings. The majority of experience 
as expected was in primary care and general practice. All of the informants were able 
to relate to their experiences of IT systems with emerging themes highlighting key 
aspects not just in relation to operational functions and features but key relationships 
between system suppliers, end users and NHS IT management.  
 
3.9.1 Computer use in general practice 
The use of computer and IT systems were described from end users perspectives 
(GPs and practice staff) and from a management perspective in terms of the 
technical support that was required (see Box 11).  A range of operational issues 
emerged that highlighted a mixture of experiences around computer usage, however 
it was overwhelmingly clear that computer systems were central to the management 
of GP practices and were being used for a wide range of both clinical and non-clinical 
activities. Features from a non-clinical perspective highlighted the increasing 
workload of general practice over time and hence the importance placed on 
computer systems to manage the practice on a day to day basis. Overall, a mixed 
picture was portrayed of computerised systems and acceptance of new technologies. 
Positive benefits were expressed particularly from a clinical aspect such as 
prescribing support and supporting the running of GP practices. Some of the 
problems cited described technical issues with GP practice IT systems and the level 
of aptitude of end users including GPs.  
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Box 11: Informants’ experiences of computer use in general practice  
GP1: “I think our computer system is central to pretty much everything we do, all of 
our records are electronic so past medical history is electronic, all our pathology 
and radiology results are sent to us electronically, and all of our letters are scanned 
on to our computer system.”   
 
GP2: “All of our records, our prescriptions are electronic, anything that comes into 
the practice that isn’t electronic......you know letters will be scanned......our 
business is almost entirely reliant on it.” 
 
IT1: “Yes, we cover right the way through from the PC itself, the server......and 
applications so the day to day tools such as office products......and a lot of admin 
work that goes on, which we were quite taken back at how much work is actually 
happening in a GP practice” 
 
IT2: “It depends on how IT literate they are to start with, obviously there are the 
ones that can do everything from consulting to all the way through to all the 
comprehensive searches, right down to the ones that struggle to even put a 
consultation on......they are getting better, it was the older GPs that seemed to have 
more hassle than younger GPs.” 
 
3.9.2 Key characteristics of IT systems   
The informants described key characteristics of IT systems primarily from a primary 
care perspective and general practice. The informants described how IT systems 
were both regulated and managed from both supplier and NHS management 
perspective. In the UK all IT systems including CDSS are provided by commercial 
organisations, there is no NHS provider as such. The experiences of the informants 
portrayed a heavily monitored and regulated framework around primary care and 
general practice IT systems with overall responsibility resting with NHS Connecting 
for Health and local NHS commissioning organisations.   
 
3.9.2.1 Regulation  
NHS regulatory systems for general practice were described by the informants and 
are shown in Box 12.  Key aspects to regulation included the level of conformity of 
GP clinical systems in relation to core contractual standards with NHS Connecting for 
Health. The high level of conformity was described not just for current GP clinical 
systems but in terms of any additional extensions or enhancements.  
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The NHS IT managers described their roles in terms of providing technical support to 
GP practices. The CDSS informants described operational aspects to software 
systems including aspects of conformance with regulatory standards set by NHS 
Connecting for Health.  
 
Box 12: NHS IT managers and DS3 experiences of NHS IT regulation 
IT1: “All of the clinical application providers, they have to adhere to Connecting for 
Health (CFH) standards, so CFH are in that loop when it comes to any kind of 
procurement......CFH are involved, the PCT is involved......these are all external 
companies, they are not owned in any way shape or form by the NHS, they are 
completely independent; they have to go through a number of criteria to make sure 
they can supply their products to NHS bodies.” 
 
IT2: “What used to be Connecting for Health used to regulate all the clinical 
systems and it would all go through beta testing and so would any bolt on 
applications, and any further enhancements to the clinical systems have to go 
through clinical testing and be signed off by Connecting for Health.” 
 
DS3: “Well sort of test packs and conformance testing of our software and every 
change we make to it has to be re-conformed to ensure that we are sending the 
right message at the right time for the right patient and that the message that we 
send is conforming......it can be consumed at the other end......these are computer 
to computer messages......they are not designed for humans to read they are 
designed for the computer system to interact with another computer system......so 
they are in compacts......HL7 messaging standard format in XML......computer 
talk.” 
 
DS3: “Yes that travels through the spine......and so do all the EPS messages, the 
prescription messages, GP to GP record transfer and all the rest of it......that’s 
highly conformed and tested.” 
 
The financial constraints with the NHS and current reforms were also explored 
particularly with the impact on NHS Connecting for Health and these are shown in 
Box 13. Current and historical difficulties were described including prospects for the 
future in terms of the provision of a regulatory framework for NHS IT systems 
including those for general practice.  
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Box 13: NHS Connecting for Health and future regulation.   
Researcher: “With the current situation with the NHS where do you see Connecting 
for Health in the next 5 years?” 
 
DS3: “Dead, gone......DH Informatics will continue......it will certainly have a 
reduced role in terms of power compared to Connecting for Health...... we need it 
for standards......it’s just going through its death rows, trying to wrap itself up in the 
best possible way......I think it’s proved to be failure, I think it needs to be gone.” 
 
DS3: “At the end of the day the programs they have established will continue, 
those programs are not going to die......I think those programs will persist it will be 
the end of Connecting for Health, but there will be a DH Informatics, they won’t 
embark on any new ones for a long time......It’s not a lack of money it’s a lack of 
focus.” 
 
DS3: “If you look back at the history of the CFH it primarily was a legal contract 
negotiating body, it was not anything else, it had no clinical input, didn’t know what 
it was doing......what it was doing was tying up huge contracts to deliver something 
that was poorly defined.” 
 
3.9.2.2 Hosted GP clinical systems 
Shown in Box 14 were aspects around a trend to move GP clinical systems from 
practice site based models with computer terminals connected to a server, to hosted 
systems with terminals connected to a remote server. Some of the advantages of 
such a move were described including quicker response times from the system 
vendor and improved data security.  
 
Box 14: The shift to hosted GP clinical systems 
IT2: “If the server died on us today we would have to wait for EMIS to come out to 
us which is why they want to move everyone over to hosted systems....... they are 
regulated data centres, there are always two data centres so if one gets damaged, 
blown up, whatever, fire………they will switch over to other data centre so there is 
always the backup….there is no backup with the GP surgeries, there is no server, 
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Box 14: The shift to hosted GP clinical systems (cont.) 
Researcher: “So are hosted systems the way forward and is that happening 
nationally? 
 
IT2: “Yes, because they are phasing out servers......because the life of a server is 4 
– 5 years.” 
 
3.9.2.3 Data quality 
The accuracy of data recorded and or data presented within computerised systems 
was a key theme from both a prescribing perspective and the management of health 
records. A specific problem and area of concern was the process of managing paper 
based information and specifically ensuring relevant data was electronically recorded 
and coded. 
 
3.9.2.3.1 Read coding  
The process of read coding was described from a technical perspective highlighting 
strengths and weakness including how inaccuracies can have a significant effect on 
end users in both prescribing and general patient management (see Box 15). 
Problems were described with coding accuracy such as in drug nomenclature and 
the interpretation of alerts or warnings. In addition difficulties included dealing with 
hospital communications which required manual uploading and read coding on to 
patient’s electronic record held at the GP practice.  
 
Box 15: Informants’ experiences of read coding 
DS2: “A number of drugs prolong the QT interval, by a specific precaution or 
contraindication, if we strictly look at the hierarchy, bring back other cardiac 
arrhythmias which are less relevant, and there are two sides to that 
historically......when doctors started coding, some of the coding was possibly less 
concise than it should have been......we now and particularly in the Snomed 
solution and moving towards it in our Read Solution we are definitely trying to 
narrow the terms which get more granular, more precise coding.” 
 
DS2: “We had an end user who complained that the pregnancy alerts were 
showing for his 80 year old patient because he had never told the system she was 
no longer pregnant......if you have an episode that has completely finished in the 
past and is no longer relevant and I suspect in a lot of cases it is still coming up.” 
 
Chapter 3: An exploratory study using key informants to investigate the use of computerised 
decision support software (CDSS) within UK general practice 
124 
 
Box 15: Informants’ experiences of read coding (cont.) 
GP2: “Where feasible, if we had the man power we would read code everything in 
that letter but in reality we read code as much as we can, so as all the information 
comes in so hopefully we get onto it as a single record and we essentially try and 
run the business as paperless as we can but it’s fairly impossible with prescriptions 
being based on paper” 
 
3.9.2.3.2 Accuracy  
The CDSS informants described key processes around the quality and robustness of 
data (see Box 16). The quality of CDSS alerts were described in relation to the 
reliability of data and ensuring specific standards were maintained. These were 
described in terms of both references used to support CDSS and also the authorising 
process that was followed. In addition legal aspects around authoring alerts and 
warnings provided by CDSS and whether a GP system supplies its own or it is 
provided by a third party were also emphasised. 
 
Box 16: CDSS informants and views of data accuracy  
DS1: “The drug data is obviously quite complex, there are lots of drugs available 
and doses......many suppliers get their drug data from third party data 
suppliers......the system supplier instantiates that into the system, the drug data 
supplier has legal responsibility for the quality of the data  which takes a burden off 
the system supplier, and the system supplier can then go to their customers and 
say this is the level of decision support we provide around allergies, drug 
interactions, precautions and dose checking” 
 
DS3: “Yes and certainly we have evidence for all our authored drugs, those tend to 
come from standard sources so the SPCs for the drugs, the BNF, Martindale etc. 
so that’s where they come from, we don’t make them up.” 
 
DS4: “So there is a whole range......the majority of messages are actually authored 
by the CCGs and the PCT......so the tool basically enables that process and we do 
provide guidance and support for people on that and we provide lots of feedback 
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Both GPs emphasised the importance of being able to trust alerts (see Box 17). 
Being able to trust data being presented was a key area for end user of computerised 
systems for a range of areas to support prescribing including drug information, costs 
and aspects around safety. 
 
Box 17: GPs and experiences of data accuracy  
GP1: “I think that’s possibly a danger, but......you know in most of the prescribing I 
do, it does it in a very conservative way, it still requires you to acknowledge the 
change, it only makes the change temporarily, and I mean, I suppose there is a risk 
with it, but I think in simple things like Script-Switch it’s fairly negligible, it’s not like a 
change of category of drug, you’re just changing formulation, and the dosing 
conversion is fairly accurate.” 
 
GP2: “Personally I like it (Scriptswitch), it’s entirely reliant on the quality of the 
database behind it......I know if it’s up to date, contemporary and being updated I 
will pay attention to it, once I read a message twice or If I start reading a message 
which is out of date, then I start losing faith in the entire product.” 
 
3.9.2.3.3 Accreditation  
A key aspect in relation to data quality was the accreditation of CDSS which was 
described from a range of perspectives by the CDSS informants (see Box 18). 
Although GP computer system suppliers are required to meet strict regulatory and 
conformity standards set by NHS Connecting for Health, such levels of quality 
management for CDSS were described as lacking. One of the informants reported 
that a specific CDSS was ISO accredited, and described an application for 
accreditation with NICE. In addition the informants described recent European 
legislation that classified stand-alone software including CDSS used in healthcare 
within the regulatory framework of medical devices. The informants described 
concerns with aspects of this legislation such as interpretation, implementation and 
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Box 18: CDSS informants and views of accreditation  
DS1: “Well that’s a very good question, and the situation at the moment is that 
there are no specific guidelines......now there are organisations like Intellect, which 
is like a sort of trade body for the system suppliers, and they certainly help with a lot 
of issues around implementation of new requirements, but in terms of actually what 
decision support is required there are no specific regulatory requirements.” 
 
DS2: “We are a fully ISO accredited company, so we are audited by an external 
auditor annually and all the work on the database is fully underpinned by editorial 
policies and work instructions which are regularly reviewed......we are the only 
clinical decision support system that has got NICE accreditation at the moment.”   
 
DS3: “The MHRA are lost completely in the medical devices directive with the 
proposition from Europe that software can be a device, and they don’t know how to 
do this......we are going through the process of registering our decision support 
elements of the software as a device under that Directive yes, because we believe 
that that’s what we are being told we must do, I think it will make no difference to 
anything other than avoid us being fined for not doing it......so we would have to 
declare it......and if we don’t declare it we are likely......it is possible......there is the 
potential for us to get fined under European Law for not declaring it......but no one is 
going to test it......the testing is ours.” 
 
DS4: “Yes there are laws......there is very heavy regulation......and there are fairly 
heavy fines, potentially imprisonment and I don’t think there has been anyone who 
has developed anything that does not comply as the penalties are too high.” 
 
3.9.2.4 Integration of systems 
The NHS IT managers described examples where problems with integration of 
systems caused difficulties for GP clinical system suppliers (see Box 19). Integration 
was described as key to both improving current systems and the way future CDSS 
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Box 19: NHS IT managers and experiences of software application integration  
IT1: With all of these clinical applications they will only provide functionality for what 
they are in business for, so if they are looking at the prescribing side of things that’s 
all they will be interested in, so If you want to integrate something else in then both 
parties need to look at the software application and integrate it in such a way so 
that it is completely seamless, and it works transparently and the way it should 
work......at the moment a lot of these third parties are going out and developing 
products and tools that do not integrate and that’s where a lot of these are failing.” 
 
IT2: “Knowing the clinical systems to start with and knowing how to integrate with 
them......if it was part of the same system that would not be a problem so 
(integration)......it’s the key thing......you don’t want to be doing all that......and then 
you go back to EMIS again......it all has to be integrated into one clinical system.” 
 
3.9.2.5 Implementation of systems 
The informants described mixed experiences of how either new systems or 
enhancements of current systems were implemented both from an IT management 
perspective and from end users. The NHS IT managers described specific 
experiences where the implementation of systems and projects were problematic 
(see Box 20). Key issues raised included a lack of planning, training and engagement 
with end users and were described in relation to a range of systems and applications.  
 
Box 20: NHS IT managers and experiences of IT project implementation  
IT1: “Looking at the work we have done in the last 2 - 3 years I think it has been 
the most challenging for us as department to deal with.....we have to roll out new 
hardware, a lot of these GPs are using machines that are no longer supported by 
Microsoft, no longer supported by clinical service providers, so they have to be 
upgraded......when you roll out new kit it just comes with the new applications and 
you can’t run the old applications on new devices.” 
 
IT2: “Time constraints......a lack of training......that is the norm......they will 
implement something but they will not be a full training package in place......health 
numerics for example they did the training for health numerics months ago......they 
have got a drop in session available but they told us about that on Thursday, so 
people have got things booked and you can’t go, but there doesn’t seem to be 
another training session, there was a training session today and that was it.” 
 
Chapter 3: An exploratory study using key informants to investigate the use of computerised 
decision support software (CDSS) within UK general practice 
128 
 
3.9.2.5.1 Implementation of IT systems and the needs of end users  
The relationship between end users of GP clinical systems and suppliers was 
described from a range of perspectives by the informants. These experiences were 
mixed and highlighted issues arising from system use and in on-going development 
of products. Some of these experiences were in relation to new or existing IT roll out 
and implementation. A key aspect was engagement with end users of GP clinical 
systems through end user groups. Box 21 shows the experiences of the CDSS 
informants with end users. The informants described a range of mixed experiences 
and perspectives between the IT industry and end users. It was acknowledged that 
over alerting was a problem with CDSS and that was from feedback from GPs 
though user groups and also described how end users were involved with product 
development.  The interaction between GP system vendors and user groups in 
particular detail was described as complex with problems arising between users of 
the clinical system, both GPs and practice staff.  
 
Box 21: CDSS informants and experiences with end users 
DS2: “All of our system vendors have their own support desks, so certainly they 
field particularly technical queries from the end users if they tend to be clinical 
queries on the database they come through to us, we also attend some of their user 
groups and certainly some of the system vendors have what they class as super 
users so they can try their new developments on a small group before rolling them 
out to much wider users.” 
 
DS3: “We have user groups we interact with frequently, we have national user 
groups......there are on-line forums......we take lots of feedback from our users of 
our products......be careful about the fact that anybody thinks they can influence a 
product….so we have got have 2,500 practices, 10,000 GPs, 30,000 receptionists 
who all think they have the answer to how you should change it for everybody.” 
 
DS3: “So they both have phenoxymethylpenicillin 250mg tablets......but one says 
250mg tablets but the other says tablets 250mg......trivial you might think, but it’s 
not, because it is change......end users do not like change......what was working OK 
has been changed and that can be disruptive and they don’t like it......so user 
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3.10 CDSS in primary care 
In total 25 CDSS were referred to as either in use in general practice or respondents 
were aware of as being used or available to GPs, of which 9 were active CDSS and 
16 passive and these are shown in Table 3.8. Each of the five current GP clinical 
system providers provided in built active CDSS to support performance in relation to 
the current Quality and Outwork Frameworks (QOF) component of the national 
General Medical Services (GMS) contract in the form of reminders and prompts. 
Integration allows data capture to a national database known as QMAS (Quality 
Management Analysis System) which gives GP practices and PCTs reports on 
achievement against QOF indicators and calculates QOF payments Drug databases 
providing active CDSS were available from the five GP computer system suppliers. 
Two provided their own active CDSS whilst the other three hosted third party CDSS 
provided by the company First Databank Europe. In addition all of the GP clinical 
systems allowed users to add electronic manual reminders or alerts to a patient 
record that would appear when a patient record was accessed. These alerts could be 
authored with free text to reflect a specific clinical intervention or to add a simple 
reminder or message. 
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Table 3.8 Current profiles, usage and characteristics of CDSS available to use by GPs 




Drug Database: CDSS for drug interactions, warnings, 









Point of prescribing decision support tool providing locally authored 
messages via prompts to inform on cost effective drug choices, safety 
warnings or other relevant prescribing related information 
INR-Star Supporting anticoagulation management and therapeutic 
dosing of warfarin 
Prescribing Plus  Point of prescribing support tool when initiating acute and repeat 
prescriptions by suggesting safe, appropriate and cost efficient 






Summaries of the current evidence base and practical 
guidance on best practice in respect of over 300 common 
and / or significant primary care presentations 




Drug Database: CDSS for drug interactions, warnings, 
contraindications, dose checking, allergies and duplicate therapy 
NICE Guidelines  Independent, authoritative and evidence-based guidance 
on the most effective ways to prevent, diagnose and treat 
disease and ill health, reducing inequalities and variation 
INPS (System 
Vendor) 
Drug Database: CDSS for drug interactions, warnings, 






A comprehensive resource to provide details about disease 
presentation, diagnosis, investigation and management. A 
portal for education, research and personal development.  
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Table 3.8 Current profiles, usage and characteristics of CDSS available for use by GPs (cont.) 
Active CDSS  Characteristics Passive CDSS  Characteristics 
Micro-Test (First 
Data Bank)  
Drug Database: CDSS for drug interactions, warnings, 
contraindications, dose checking, allergies and duplicate therapy 
DXS Enables recommended content such as care pathways, 
medicines, referrals, patient education and support groups 




Drug Database: CDSS for drug interactions, warnings, 
contraindications, dose checking, allergies and duplicate therapy 
BMJ learning Provides accredited, peer-reviewed learning sessions in 




Drug Database: CDSS for drug interactions, warnings, 
contraindications, dose checking, allergies and duplicate therapy 
CHADS 2  
 
Simple audit tool used in primary care to aid the risk 
stratification and effective management of Atrial Fibrillation 
(AF) patients, in order to reduce the risk of stroke 
 
QOF Alerts for 
QMAS data 
collection  
QMAS is a national web-based software tool developed for 
implementing the current GP contract. Data from GP practices is 
aggregated to maintain patient confidentiality, and a set of quality 
(QOF) scores is calculated. An alert appears when a patient record is 
accessed reminding the user only where specific clinical interventions 
are required to meet requirements as stipulated in the GP contract.   
Q-Risk  Calculator to work out the risk of having a heart attack or 
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Table 3.8 Current profiles, usage and characteristics of CDSS available for use by GPs (cont.) 
Active CDSS  Characteristics Passive CDSS  Characteristics 
  PCT Extranet 
website 
 
Extranet site that provides access to prescribing support 
produced by the medicines management team such as 
prescribing newsletters, guidelines and links to external 
websites. 
  
  Health Numerics An analytical tool that combines disparate data sources to 
provide a single view of healthcare activity at patient and 
population level. 
 




Supports the optimisation of care by providing access to 
comprehensive, evidence-based guidance, and clinical 
decision support at the point of care 




Electronic access to some of the world's leading drug and 
healthcare references from both the publishing organisation 
and selected partners 
  General Practice 
Notebook 
An online encyclopaedia of medicine that provides a trusted 
immediate reference resource 
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Table 3.8 Current profiles, usage and characteristics of CDSS available for use by GPs (cont.) 
Active CDSS  Characteristics Passive CDSS  Characteristics 






The NPC (now part of NICE) is an on line resource that 
provides a wide range of resources (including e-learning) 
and arranges activities and events to support and promote 
evidence-based medicines management across the NHS, 
to help improve patient care and service delivery 
  Patient.co.uk On line resource that provides evidence based information 
on a wide range of medical and health topics to patients 
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The actual numbers of passive CDSS available was described by one informant as 
“countless”. Internet access and availability to all GP practices has meant traditional 
paper based resources such as journals and guidelines are now available 
electronically. In addition primary care organisations have made available to general 
practice local extranet portals for dissemination of a wide range of resource and 
support information for general practice to include prescribing and medicines 
management support. Passive CDSS that were identified offered a range of features 
aimed to support decision making in range of clinical situations and points within care 
or treatment episodes. These included support at the point of prescribing, during 
patient consultations, clinics or non-clinic situations e.g. personal learning. 
 
3.10.1 Views and experiences of CDSS in primary care 
Overall mixed or negative perceptions and experiences outweighed positive ones for 
the GPs and NHS IT managers compared to the CDSS informants. Figure 3.6 shows 

































GPs (n = 2) NHS IT Managers (n = 2) CDSS System suppliers (n = 4)
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3.10.1.1 GPs’ views and experiences of CDSS  
Overall both GPs expressed mixed opinions of CDSS citing both positive and 
negative views and experiences and these are shown in Box 22. A number of 
positive experiences aspects to CDSS were cited, included cost saving alerts, 
reminders about drug interactions and monitoring, and the on - going alerts and 
reminders provided within GP systems to support QOF. However a major problem 
that was specifically described was CDSS and over-alerting, and that most active 
alerts were ignored.  
 
Box 22: GPs’ attitudes towards CDSS 
GP1: “I certainly find it very useful,  simple reminders to check......for liver function 
tests for example, or if somebody is on methotrexate, you know an alert that warns 
you about that is extremely useful......drug interactions......a lot of the alerts I think 
are probably fairly routinely ignored because they are recognised interactions or 
they are beneficial interactions so for example if you add one anti-hypertensive to 
another and the alert tells you it’s going to cause hypotension that’s exactly the 
intention, and I think that can lead to......perhaps a sort of malaise really you know 
then people don’t not pay enough attention when they really are significant, like 
LFTs or methotrexate.”   
  
GP1: “You know I think active is more, is more useful, I think in terms of 
commencing new medication, then the passive I think systems are  
appropriate......but repeat prescribing I think active methods would be, would be 
because it’s simply you know the speed, the time that it takes, If I am starting a new 
medicine I would look it up, look at the monitoring requirements, look at its dose, 
make a decision, but it’s around repeat prescribing, where the active alerts are 
much more useful I think.” 
 
GP2: “So within the clinical systems in use they have all got it to an element and I 
have to say that most of them implement far too many messages to the point that I 
ignore most of them......so there some times when the message becomes overly 
laborious especially if you get it several times and that would be an example where 
I think the information becomes less useful so I often wish that the messages that 
you know where you can turn off for the next 10 times so you only get it one in 
10......just so you don’t get flooded by it.” 
 
 
Chapter 3: An exploratory study using key informants to investigate the use of computerised 
decision support software (CDSS) within UK general practice 
136 
 
Box 22: GPs’ attitudes towards CDSS cont. 
GP2: “I have colleagues who definitely just ignore the whole process......actually I 
don’t think in practice, I know I just talk to people that say I hate that Script-Switch 
and it’s just a delay in issuing that drug.” 
 
GP2: “It produces you know prompts we use for QOF which essentially is decision 
support, which reminds us of all the stuff to do, and without that I am convinced our 
QOF target would slip by 20%......I think they are fantastic, and I use that now......I 
will add reminders into that for other things, perhaps they need a colonoscopy 3 -
yearly......we use the same system to remind us.” 
 
3.10.1.2 NHS IT managers’ views and experiences of CDSS 
Overall the NHS IT managers described mostly negative or mixed experiences of 
CDSS in relation to both technical aspects of CDSS and also practical difficulties 
such as the effect on the running of GP practices and these are shown in Box 23. 
Some of the problems with CDSS were the way systems were used by GPs, 
management issues, over alerting and technical difficulties such as integration with 
the GP clinical system. In contrast positive aspects to CDSS included their use to 
provide safety related warnings and alerts.  
 
Box 23: NHS IT managers attitudes towards CDSS 
IT1: “The problem with something like that is that the user needs to change their 
mentality or the way they are thinking or using the application......the training side 
of it is simple, it is very easy to use; but if they don’t want to use it they can 
override it and if they switch it off what happens is they continue to work as 
normal......at the moment a lot of these third parties are going out and developing 
products and tools that do not integrate and that’s where a lot of these are failing or 
not working” 
 
IT2: “They (GPs) find them (pop up boxes and warnings) annoying, some of them 
do, because they just want to do the prescription and get the patient out of the 
door, they’ve got ten minutes......I don’t think they pop up too much, they pop up at 
the relevant time but it’s just down to the fact that GPs only have a certain length of 
time......you can’t have too many of these if it’s a contradiction for a medication for 
a patient......it’s far better to get too many boxes than for someone to miss it 
because they have had only one box pop up.” 
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Box 23: NHS IT managers attitudes towards CDSS cont. 
IT2: “If they have a contraindication for penicillin......it might be on the record but 
they are so busy doing the consultation and then suddenly it flags up...... do you 
realise that you have prescribed something that the person is allergic to?......it’s 
patient safety at the end of the day.” 
 
3.10.1.3 CDSS informants’ views and experiences of CDSS 
The CDSS informants described considerable experiences of CDSS in primary care 
and although limited some experiences within secondary care. In primary care a 
range of positive features were described in relation to the benefits of both active and 
passive CDSS and these are shown in Box 24. These included the provision of 
clinical information to support prescribers, ease of implementation, and time saving 
for end users. Good examples were provided highlighting clear advantages of both 
active and passive CDSS. Some drawbacks were described such as promoting wider 
usage particularly with passive systems. 
 
Box 24: CDSS informants and positive experiences of CDSS in primary care.  
DS1: “There are some very good passive resources in terms of websites, internet 
resources that are used in a lot of settings but of course they do rely on the clinician 
going to them......I can see that passive systems have real benefit for dissemination 
of local information that would be of benefit to prescribers, the question of how to 
promote their use is a difficult one.” 
 
DS2: “In primary care I don’t think there is a doctor that doesn’t have a clinical 
decision support system, how much they rely on it and how much they use it and 
how far they take it is more individual, but I think they are all using it to some extent 
at least......dose and dose range check......the normal dose of this drug is within this 
range, the dose you have prescribed is too low so it is likely to be ineffective or the 
dose you have prescribed is too high.” 
 
DS3: “So interactions, contraindications, precautions, prescriber warnings, drug 
doubling, allergy checking and so on......so that work was done primarily in the 
1990s......all the GP system suppliers do very similar sorts of things there is not a 
big difference between us and anyone else.” 
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Box 24: CDSS informants and positive experiences of CDSS in primary care 
cont. 
DS4:” Yes so the key thing around Script-Switch is that it is an active process it 
pops up automatically, it interrupts your workflow......and presents you with choices 
you have to think about, but it is a very quick process......so the second group of 
messages are the information messages......for example it can say this drug is not in 
the formulary and here is the formulary and give you a html link to the formulary so it 
is presenting context and information to the clinician.” 
 
As with the GPs and IT managers a specific area of concern was the problem with 
over alerting and having to override alerts. Box 25 shows experiences of the CDSS 
informants in relation to CDSS and over alerting. DS4 described changes in attitudes 
towards CDSS from a GP perspective in terms of being challenged around decision 
making and the clinical freedom to prescribe and that over time this situation has 
improved and CDSS is now seen as beneficial. 
 
Box 25: CDSS informants and experiences of over-alerting 
DS1: “You know there are two ends to the spectrum......are you to provide no 
decision support at all, so for example one electronic prescribing implementation in 
this country that chose to do that......they said we are not going provide any 
decision support because then our users will know there is no decision support, 
they will use their brains rather than rely on the computer......and if they miss 
it......it’s their fault but on the other hand you can provide a system that provides an 
alert for every single clinical detail, every minor interaction, every possible allergy to 
an excipient and so forth, in which case you know you end up with clinicians 
ignoring most of it simply because there’s just too much.” 
 
DS3: “Feedback from GPs is that they get too many prompts and they override 
them......they override most of the prompts, occasionally they will take notes of the 
prompts but most of the time they override the prompt......you get alert 
overload......and you ignore all of them and that’s the danger.” 
 
DS4: "So I think there has been quite a transition, over the years, when they first 
came in......it mirrors actually I think the conversations that are going around what is 
the role of the clinician......so when they first came in I remember conversations 
with my colleagues of mine......what’s this piece of software telling me how to do my  
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Box 25: CDSS informants and experiences of over-alerting (cont.) 
job?......I think it used to be seen as that whereas there is an acceptance now that 
the clinical variation was seen as a quirk but know it is seen as an issue, but people 
now see decision support as a way of protection and for the patient......and now I 
see people who say......that saved my bacon.” 
 
3.10.2 Developments and improvements of CDSS in primary care  
In addition to drug safety warnings and alerts some of the informants described a 
range of current developments supporting both prescribing and disease management 
in general practice to include:  
.   
 Drug dosage information (dose setting and clinical indication) 
 Drug dosage management (dose optimisation) 
 Disease management and care pathways to include diagnostics and 
investigations 
 Electronic prescribing systems in secondary care 
 Supporting linkages between GP clinical systems and community pharmacy 
clinical systems 
 
The informants described specific examples where they felt current CDDS could be 
improved. These areas included improvements in the management of blood test 
results, provision of patient information leaflets, and prescribing support in the use of 
high risk drugs. In addition one of informants described how one CDSS available in 
the USA that could potentially be developed further in the UK, specifically to prioritise 
the importance of QOF alerts in relation to specific therapeutic conditions.  
 
3.10.3 Specialist drugs and CDSS 
The concept of developing a CDSS to support GPs in the use of specialist drugs 
instead of the current paper based model using shared care protocols was explored 
with all of the informants. Overall the concept was met with positive responses 
across all stakeholder groups and these are shown in Figure 3.7.  
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Figure 3.7 Views and attitudes for a CDSS to support the use of specialist 
drugs by stakeholder group 
 
3.10.3.1 Views of GPs 
Both GPs provided positive feedback to the concept and as potential end users 
described potential operational models and this shown in Box 26. Although a 
preferred model was an active alerting system based on the QOF model a concern 
was raised over being able to trust the system.  
 
Box 26: GPs’ attitudes towards CDSS to support the use of specialist drugs.   
GP1: “I think it would have to be cross boundary......I think a true shared care 
protocol should be that, and it’s okay us having our own primary care system, but it 
would be much better probably if something like INRstar, if it was web accessible 
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Box 26: GPs’ attitudes towards CDSS to support the use of specialist drugs 
cont.   
GP2: “So the advantage is if it was an independent module, it would remind you 
because it only comes up with these drugs of the importance of what you were 
doing, it would focus the mind which I think is good......I think the advantages 
hopefully that it would reflect a standardised protocol, although that might not reflect 
the protocols in the shared care agreements, I often look at the shared care 
agreements and often wonder why there can’t be a standardised shared care 
protocol.” 
 
GP2: “An alert, it would come with my other alerts, the QOF alerts as they are the 
ones we used to interacting with and working with as opposed to, let’s say if you 
went in the screen with drug interactions that’s the one I know that none of us ever 
read as there is too much there......yes you would over trust it......you have just 
issued the azathioprine without a second thought because the box was yellow.” 
 
3.10.3.2 Views of CDSS informants  
All the CDSS informants were positive towards the concept of a CDSS supporting 
GPs in prescribing specialist drugs and these views are shown in Box 27. It was 
accepted that from a technical perspective that the concept was ahead of the current 
capabilities of IT systems. A number of examples were described of how 
operationally the concept could support end users. Overall an active alerting CDSS 
was the preferred model that would benefit end users particularly built around key 
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Box 27: CDSS informants and attitudes towards a CDSS to support the use of 
specialist drugs.   
DS1: “What would be really good is for someone to do some work on the 
development of a shared care protocol in an electronic format that is hyperlinked in 
such a way that if there were routines running behind that would be absolutely 
brilliant, but that represents something a bit of a way ahead of where we are at.” 
 
DS2: “Eventually moving towards active formats will become safer for patients 
because if you say you had been asked to prescribe Mr Smith repeat tacrolimus 
and he has not had a blood level for 3 months, I need to see him......the system can 
alert if he has not got a current blood level and it can also then alert......using INR 
as an example say it has to be between 2 and 3......it can flash an alert up to say 
it’s 3.4 make an appointment......it’s 10 ring the patient immediately.” 
 
DS3: “I don’t think any of the systems actually do that today, though they may have 
the potential to do it if they are individually customised by the end users......with any 
national guidance for how to do that......you could set up reminders and alerts for 
the patient based on the fact that they are taking this drug, so support prompts for 
the user would appear.” 
 
DS4: “In an ideal world you would actually have an electronic shared document that 
goes between primary care and secondary care and until that document flag is on 
the record you as a GP can’t prescribe it......I would always go for an active format 
for the simple reason that it reduces the number steps that can go wrong......so if 
for example you had an active block on that drug unless there was a shared care 
process in place and you physically had to override that and sign that put an 
explanation to why you were overriding it that process it would add a level of safety 
around it.” 
 
3.10.3.3 Views of NHS IT managers  
The NHS IT managers were also supportive of the concept of CDSS to support use 
of specialist drugs and their views are shown in Box 28. Both NHS managers 
preferred an active system and also highlighted the need to ensure adequate training 
and that the CDSS would need to be integrated within the GP clinical system.  
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Box 28: NHS IT managers and attitudes towards CDSS supporting the use of 
specialist drugs   
IT1: “I think an active system would be better, a passive system......there already is 
information available to them I don’t see the GPs going to use it......it has to be 
active, it’s got to be easy to use......because these guys they don’t want to go out 
for training they have not got the time, they are very negative towards any kind of 
training......if it’s structured in the correct way and organised with the right people 
and the relationship is there with the GPs themselves, that’s what makes it 
successful......and I think......I would be quite positive about it......I think it’s a very 
good move.” 
 
IT2: “If it’s part and parcel of the clinical system (integrated)......let’s say if it’s a 
different type of drug, then you haven’t got the problem......it will flag up there is an 
issue, but if you go in separately it may not flag that up for that person necessarily 
so it needs to be combined with the clinical system.” 
 
3.10.3.4 Secondary care clinicians 
Box 29 shows the views of the secondary care clinicians towards the concept of 
CDSS supporting the use of specialist drugs. In contrast to the other key informants 
the secondary care clinicians raised some concerns over the concept such as over-
alerting, multi-user access and the ability to amend or delete records. A specific area 
of concern was the level of patient monitoring required including the need to manage 
drug interactions. It was also felt that if GPs were to manage this they (GPs) would 
need to run transplant clinics in primary care.  
 
Box 29: Secondary care clinicians’ attitudes towards CDSS in supporting the 
prescribing and monitoring of specialist drugs   
NHS1: “Thinking of a web based technology......that’s a very neat solution in terms 
of......from what I understand of it you are talking about a single record that all 
parties could access it and understand that would have a lot of merit.”  
 
NHS2: “It would also depend if we could amend it at our end or if it was view only at 
our end......we would need to be able to access it, but also to realise that there may 
be errors in the medication list, especially with the regards to immunosuppressant, 
so we could actually change it ourselves and then we could ping a note to the GP 
to say that we have amended Mrs Smith’s immunosuppression records.”  
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Box 29: Secondary care clinicians’ attitudes towards CDSS in supporting the 
prescribing and monitoring of specialist drugs cont. 
NHS3: “All of the monitoring for our patients gets done within the transplant clinic 
and you know in a way, the GP role tends to be to issuing prescriptions......but I 
think one of the biggest issues is going to be drug interactions.” 
 
NHS3: “The difficulties is setting two defined parameters for the use of these 
medications and also repeat prompts if every time you prescribe mycophenolate it 
tells you to check white cell count or something like that will just be ignored over and 
over and over again......It would be a very good idea if......you could make the two 
databases talk to each other......the question is who would override what?” 
 
NHS4: “In order for it be fair to a GP you would have to build in a very high level of 
supervision in terms of checking......basically calling the patient’s back to have their 
renal function checked and their levels checked after dose changes......you are 
basically asking the GP to run a transplant clinic and I think that would be a lot to 
ask......clearly transplants are about life sustaining organs......livers, hearts and 
lungs if you get that wrong then it’s good night Vienna.” 
 
3.11 Developing a novel CDSS to support the use of specialist drugs 
The informants discussed what would support the development of a CDSS in this 
area and what would be the potential pitfalls that would need to be avoided. A range 
of enablers and barriers were described to include functionality, funding and key 
aspects around the developmental and implementation process. Figure 3.8 
summaries these by stakeholder group. Table 3.9 shows enablers and barriers for a 
CDSS to support the use of specialist drugs by key informant.   
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Table 3.9 Enablers and barriers for a CDSS to support the use of specialist drugs by key informant 
Enablers GP1 GP2 NHS1 NHS2 NHS3 NHS4 DS1 DS2 DS3 DS4 IT1 IT2 
Multi-user access 
 
            
CDSS: Active alert 
 
            
Ease of Use 
 
            
Joint development and 
Implementation 
 
            
Patient involvement 
 
            
Data quality and 
functionality 
 
            
Use of existing systems 
and frameworks 
            
 
Barriers             
Integration and data 
quality 
 
            
Security and regulation 
 
            
Implementation 
 
            
Needs of end users             
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3.11.1 Enablers  
In order to support the development of a CDSS in this area a range of key 
functionality features and characteristics were described by the informants. In 
addition a number of additional developmental aspects were identified to support 
implementation. 
 
3.11.1.1 Multi-user access  
A key aspect to support a CDSS in this area expressed by the informants was the 
need for the availability of access to a single electronic patient record by a range of 
end users based within both primary and secondary care (See Box 30). The 
informants provided specific examples of how this could help such as by having a 
single medication and pathology record, and the potential to extend user access to 
both patients and community pharmacists.   
 
Box 30: Key informant views on multi-user access 
GP2: “So ideally the secondary care clinician and I would have access to the same 
record, and ideally......they would know, we would both know when the drugs were 
issued and we both share that information......actually more immediately possible is 
that we would share the same pathology history.” 
 
NHS3: “The other issue is that some form of accessible electronic data to also allow 
that patient to have access, so when Joe Bloggs pitches up in a hospital in the 
outer Hebrides he can log in and say look there are all my medications and there 
are all my problems and these are all the issues......there are things like over the 
counter medications......the pharmacist also needs to check what they are giving 
out is correct......and that it’s being prescribed from maybe a different system.” 
 
NHS4: “I would want to be notified when changes were made so I could keep track 
of that and the rational thing for us in primary care is to have some shared 
medication management system so I could see what was on their system and they 
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3.11.1.2 Active alerts 
Active alerts were the preferred functionality for a CDSS with a range of advantages 
described by the informants (See Box 31). Both GPs described the need for an active 
alert to appear at the point of prescribing. A number of suggestions of how the alert 
appeared made such as the current QOF alert, a flashing alert as it acted as a 
reminder and a combination, with the initial alert being active but incorporating some 
passive components. 
 
Box 31: Key informants and views on an active CDSS alert  
GP1: “I think the priority for me would be to have......you know if for example if the 
shared care protocol is presented to me at the time of prescribing, at the point of 
prescribing, it’s no good having some dim and distant website, somewhere having 
to trawl though for every drug, every indication, that is useless.” 
 
GP2: “An alert, it would come with my other alerts,  the QOF alerts as they are the 
ones we used to interacting with and working with as opposed to, let’s say if you 
went to the screen with drug interactions......that’s the one I know that none of us 
ever read as there is too much there.” 
 
DS2: “If there is something that needs to be done right now as this blood test has 
come back and it’s flashing up on his screen, it’s much safer for the patient, more 
effective than having to say here are your repeat prescriptions but oh I haven’t got a 
blood test when did I have one?” 
 
DS4: “I think a combination......there has to be active pop up which says that there 
is an issue that you need to resolve, and there could be some passive processes 
that you just tick and go through......you know......I have provided him the leaflet on 
azathioprine, you can have a passive process for that and you just tick the box.” 
 
IT1: “I think an active system would be better......a passive system......there already 
is information available to them I don’t see that the GPs are going to use it” 
 
IT2: “Because you are not logging in separately......if it’s part and parcel of the 
clinical system......let’s say if it is a different type of drug, then you haven’t got the 
problem….it will flag up there is an issue, but if you go in separately it may not flag 
up for that person necessarily so it needs to be combined with the clinical system.” 
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3.11.1.3 Ease of use  
The ease of use of a CDSS was a key feature that was described by the informants 
(See Box 32). This was described in relation to GPs and the individual level of 
aptitude towards IT and time constraints in use during patient consultations.  
 
Box 32: The views of key informants on CDSS ease of use 
GP2: “The other aspect is that it is instinctively usable so that my colleagues who 
don’t like computers are not even aware that anything has changed......so they say 
oh look, oh yes, good I’ll do it, rather than we add another box......a bit of software 
that they have got to configure on the computer, so it will just fail with all those 
important people.” 
 
IT2: “Easy to use......quick to use, easy and quick......and at no cost to the practice.” 
 
DS4: “It has to be intuitive......it has to be minimally intrusive unless where it needs 
to be intrusive, so it shouldn’t take me 15 minutes for me to something where 
previously I would do in 2 minutes.” 
 
3.11.1.4 Joint development and implementation   
Box 33 shows some of the views from the informants that describe gaining support 
from a range of stakeholders in primary care, secondary care and professional 
bodies. The secondary care clinicians described joint development with primary and 
secondary care but also the need for a clear demarcation of roles and responsibilities 
and the importance of a locally developed project that could be piloted.  The IT 
managers described implementation from a primary care perspective in terms of a 
working knowledge of GP clinical system suppliers. A specific aspect to support 
implementation was to work alongside GP clinical system suppliers rather than 
developing anything independently.   
 
Box 33: Key informants and views on joint development and implementation  
DS2: “It’s getting all the people who are going to be stakeholders, so the secondary 
care initiator and the primary care continuer and possibly the community 
pharmacist or whoever is going to be looking after the clinics.” 
 
DS4: “The key thing would be engagement with the end users......yes the end 
users, so how is it going to impact them, and how is it going to benefit them?” 
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Box 33: Key informants and views on joint development and implementation 
cont. 
NHS2: “I think the whole system would have to be developed between primary and 
secondary care with input from both sides so it would do want we wanted it 
to......and I think both sides would have to sign up to still who has responsibility for 
what.” 
 
IT2: “You would have to approach each of the individual system suppliers and say 
this what we want to......can you do it for us......and then they will decide, and of 
course as soon as the one has done it the others will follow suit because if it’s got 
something the others will want to offer it to their customers.” 
 
3.11.1.5 Patient involvement  
The need to engage with patients was described in relation to both the development 
of and eventual use of a CDSS in this area and this is shown in Box 34. The 
informants described that patients would need to be convinced of the advantages of 
any new system, and that a CDSS may only be suitable for certain clinically suitable 
patients. Patient involvement was also described in terms of service developments.   
 
Box 34: Key informants and views on patient involvement 
DS2: “So it is patient perception, you have to be able to convince patients that this 
in their best interest.” 
 
DS4: “I think you need to go one step back, patient eligibility, which is you need to 
be able to demonstrate that you have picked the right patient......I think the key is 
how you engage with the patient on that, and actually I am keen that you actually 
have that debate with the patient.” 
 
NHS3: “So bottoms up and also patient centric......a lot of the changes we have 
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3.11.1.6 Data quality and functionality  
The quality of clinical data to be presented to end users was described by the 
informants as a key issue in terms of CDSS functionality. The informants described 
the importance of key safety features specifically around drug interactions, dosages 
and clinical support for end users and are these shown in Table 3.10. In addition two 
key expert functions were described that would support GPs to include symptom 
management and organ graft management. 
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Table 3.10 Key functionality for a CDSS to support the use of specialist drugs  
Key Functionality  Key Informants 
Drug interactions DS1: “I think the key things would be to ensure that the patient pathway is as smooth as possible in terms of prescribing and supply and 
to ensure top line safety around major drug interactions.” 
 
NHS3: “I think that the issue of interactions and alerts for both patients and for GPs and secondary care as well….you know because it’s 
not just the consultant adding in its other people in the hospital adding on drugs.” 
Drug dosing, side effects and 
toxicity  
DS3: “They will need to know dose information, how it interacts with other drugs the patient is taking, they need to know information 
about its toxicity, and what monitoring they have to do as a result of that and so on.” 
Drug monitoring GP1: “Safety really......safety and monitoring, we trust our colleagues in the hospital to choose the drug appropriately, the  indication you 
know, they make the decision about the commencement of therapy, the indication and GP’s role I see it maintain safety and monitoring.” 
 
NHS1: “Probably all things we talked about in terms of what is a good shared care protocol......when to do tests, what actions need to be 
taken as a consequence of those......those monitoring parameters, support that would stop you making errors in terms of prescribing 
doses….that kind of thing.” 
Symptom linkage to use of 
specialist drugs 
DS4: “So if you had a symptom finder, so if you had a record that said OK, the GP had just read coded sore throat, temperature......and it 
was flagged up and it came up with a proactive alert to say......oh, shortness of breath......anti-TNFs are you aware that this is a 
complication......then I think GPs would be a lot happier.” 
Knowledge of graft function  NHS4: “It would need to know about graft function......there would need to be a connection through to a clinical module......so other drugs 
we check levels of say digoxin......it’s not just to adjust the dose to keep the digoxin within a certain range so imagine a system that knew 
what the patient’s heart rate was......so you got to keep the drug within this range but you also have to keep an eye on what the heart rate 
is.” 
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3.11.1.7 The use of existing systems and frameworks  
Box 36 shows some of the views of the NHS IT managers that suggested that one 
way forward was to make better use of current IT systems and frameworks and to 
work with GP clinical system suppliers particularly with the current movement to 
hosted systems.   
 
Box 36: NHS IT managers and views on the use of existing systems and 
frameworks 
IT1: “There has been a huge investment in this core network that ultimately BT 
own......N3, it’s one of the biggest networks in the UK, so it’s just not being used to 
its advantage, we are only using 10%......if the right applications come to the 
table......EMIS and SystmOne are making use of it but where you are going in and 
installing it things locally in isolation it’s a backward way of working now, these guys 
should be making better use of this network, putting something here which allows 
all parties to talk to each other.” 
 
IT 2:”Yes because that’s where we are moving away from (non-hosted systems) 
and there is no point trying them.” 
 
Box 37 shows some of the views of the CDSS informants that highlighted previous 
attempts to develop CDSS and the existing technologies that could be utilised. It was 
identified that two GP clinical systems were now able to allow multi-user access that 
could potentially be explored as a way of incorporating a CDSS in this area.  
 
Box 37: CDSS informants and views on the use of existing systems and 
frameworks 
DS3: “There have been lots of attempts at this......this is not revolutionary 
thinking......there is a HL7 standard called Arden Syntax which is about this precise 
thing which enables you to encapsulate this decision stuff in an electronic 
messaging format that you could transfer between systems.” 
 
DS3: “This is a very specialist area and the investment required for which there is 
very little payback for the customer......it becomes a financial question it does not 
become a technical question......these things are achievable and they are 
achievable with the technology we have today.” 
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Box 37: CDSS informants and views on the use of existing systems and 
frameworks cont. 
DS4: “So EMIS Web has a distinct primary care record that is held by primary care 
and it’s able to communicate certain packets of information with other 
people......whereas with SystmOne there is a single record and the ability is to view 
parts of that single record depending on your context, so it is context sensitive 
viewing......there are pros and cons when you get into both.” 
 
3.11.2 Barriers  
A range of barriers to both the development and implementation of a CDSS were 
described by the informants. These barriers highlighted key concerns around safety, 
data quality, clinical responsibility, IT issues, medico-legal issues, communication, 
relationships with secondary care and cost. 
 
3.11.2.1 Integration and data quality  
Concerns around the quality and accuracy of clinical data were raised by the 
informants and are shown in Box 38. These included problems with consistency and 
standards around prescribing terminology and the accuracy of records held in 
hospitals compared to GP systems. GP1 also raised the issue of integration with 
secondary care systems and for hospital based clinicians accessing a single record.  
 
Box 38: CDSS informants and views on integration and data quality  
DS1: “I know there a lot of people sweating on how you deal with consistency and 
standards for prescribing terminology......and it is not an easy problem to solve...... 
one of the potential risk areas, and it shouldn’t be the case but I know certainly it 
has been the case in the past, but quite often products initiated in hospitals have 
not found themselves on the GP clinical system.” 
 
DS2: “It depends if you wanted it to be used stand alone or integrated with the 
whole patient record......If you wanted it integrated with the current patient record, 
the problem becomes that the current GP record and the hospital record are not at 
the moment going to be identical.” 
 
GP1: “Disadvantages would be the usual IT burden, you know how you could 
integrate with primary care systems, how you could allow consultants to access the 
record.” 
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3.11.2.2 Security and regulation  
Box 39 shows concerns raised by the informants around security and regulation. The 
CDSS informants highlighted issues in relation to the design of the database, 
confidentiality and potential problems such as medico-legal issues. The secondary 
care clinicians also described issues around security with patient data and also with 
the ability to override database entries. Neither of the GPs expressed concerns over 
security and regulation.   
 
Box 39: Key informants and views on security and regulation  
DS1: “Security and information governance, using appropriate algorithms and 
terminology, how you deal with communication from secondary care and you 
instantiate that into systems that are familiar......or how this presented in ways that 
are acceptable to the end user either in primary care or in secondary care.” 
 
DS2: “There are always risks about the other data, patients won’t be very happy if 
they have had a renal transplant.....the concept on the spine around a brown paper 
envelope......don’t say I have got HIV......but I am taking ritonivir, saquanavir......and 
the others......so you are not going to have anything else.” 
 
DS4: “There are going to be some issues and there are some medico legal 
things......so for example if I am viewing the record and someone else is updating it 
at the same time and then I go back and somebody says well you missed 
something in that record.” 
 
NHS2: “I can think about some of my patients who get a bit funny about anybody 
accessing their records, I have got one guy even when I tried to sign up for 
homecare......he succumbed eventually......that would mean there is a company out 
there that would know what tablets I am on……but people can break in and 
interrogate the system and I am a transplant patient.” 
 
NHS3: “The only issue is would they want me to override their database......would I 
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3.11.2.3 Implementation  
The informants described a range of potential barriers for a CDSS in this area form 
an implementation perspective and these are shown in Box 40. The CDSS 
informants highlighted financial constraints, a lack of political support from 
stakeholders and a reluctance from secondary care due to the vastly different uptake 
and level of IT infrastructure compared to primary care.  In addition another issue 
identified was establishing a working relationship between third party or external 
providers of CDSS with GP clinical system providers. The secondary care clinicians 
also highlighted a problem with IT infrastructure in secondary care and gaining 
widespread support from GPs as not all GPs would have renal transplant patients 
registered at their practice. 
 
Box 40: Key informants and views on implementation 
DS1: “The real issue is the political will to do it......we have this huge issue around 
diabetes, or people being admitted with hypos, and this huge issue around falls, 
they will say woo!!...yes!!.....but actually......the extent of monitoring 
immunosupressants is not sexy enough and not political enough.” 
 
DS2: “Primary care is very adapt to electronics......so if the hospital that is initiating 
the care is reluctant and is heavily paper based and particularly if the team working 
in that area, in that hospital......convincing them could be difficult.” 
 
DS3: “Because everyone would say yes and would definitely want one, because it 
is a really difficult area and you would need help......you are not going to have a 
problem with demand so how much?” (cost) 
 
IT1: “The barriers would be there from the big players the clinical applications out 
there in the practices, EMIS, Vision, SystmOne......the barriers would for them for 
allowing these new guys, this company coming along with this product to talk to 
them and say yes we can make it work with our product, if that link is not there it is 
going to be very difficult for it to work.” 
 
NHS1: “I think the barriers would......around Trust IT architecture......I mean in the 
sense that some Trusts take a very hard line on bespoke software packages you 
know......so it’s quite hard to introduce specific technologies.” 
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Box 40: Key informants and views on implementation cont. 
NHS4: “Those 1500 patients that I talked about we are talking about the whole 
region......it’s an awful lot of people and an individual GP practice will not have a 
dozen renal transplant recipients.” 
 
3.11.2.4 Needs of end users 
A number of concerns were described in relation to end users and potential 
difficulties that could arise and these are shown in Box 41. The NHS IT managers 
described issues such as training requirements, GP time and a lack of engagement 
with support services. The secondary care clinicians described potential problems 
with the overriding of alerts and messages and where end users may start to use the 
system incorrectly.  
 
Box 41: Key informants’ views on the needs of end-users.  
IT1: “Time is completely the key......they don’t have time to go out to training, and if 
you think about a practice as soon you take out a GP, they have to back fill with a 
locum......because where I see a lot of these things falling, or a lot of tenders not 
even getting pass the starting block, is the question will be asked how will you 
support it, and a lot of the time they say we will wait for the user to contact us, but 
the mentality of the users is that if they can get away without using it they won’t log 
a call.” 
 
IT2: “Resistance......the GP, even if it’s been incorporated into their clinical system 
they may not use it even if it’s there.” 
 
NHS1: “It would really be interesting to talk to some prescribers about how they feel 
about for example alert messages, whether they are things that just cancel and 
ignore or whether there are things they take very seriously and then you get into the 
discussion about which......you know, if we are going to wear people out with too 
many alerts coming on, which are the important ones that need to stay?” 
 
NHS2: “It's all well having the support system there but if people don’t know quite 
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Financial aspects were described from a range of perspectives reflecting each 
stakeholder group and informant background. Some aspects of finance were specific 
such as expenditure on drugs or IT systems and software; however other aspects 
were service related and linked to funding for both primary care and secondary care. 
In addition both GP system and CDSS suppliers are all commercial organisations 
and therefore costs would be important in order to maintain profitability.  
 
3.12.1 Drug costs 
The four immunosuppressant drugs used in transplantation ciclosporin, 
mycophenolate, sirolimus and tacrolimus, until recently were all high cost patented 
medicines. Box 42 illustrates the views of the secondary care clinicians in relation to 
drug expenditure and renal transplantation. A specific issue raised was whether the 
actual costs involved had an effect on the decision to prescribe these drugs.  
 
Box 42: Secondary care clinicians and experiences of drug expenditure  
NHS 3: “You know they never actually said that it was too expensive, it was always 
a clinical reason or something, you know and I can understand that, they are 
expensive drugs......if you have one patient on tacrolimus or mycophenolate that’s 
probably blowing a £7,000 to £8,000 hole in your budget instantly for the patient 
and if they are Afro-Caribbean and they have got an adverse set of genotype you 
may be blowing £12,000 to £15,000 on one single patient.” 
 
NHS2: “It is interesting, sorry for being cynical......there seems to be a correlation 
between the cost of the drug and the willingness or not to prescribe it, the get out 
clause is always that that it needs monitoring.” 
  
Drug costs were an important issue for the GPs and CDSS informants. Some of the 
advantages and benefits of GP clinical systems and CDSS were described in relation 
to promoting cost effective prescribing (see Box 43). The CDSS informants described 
the importance of drug costs in relation to GP prescribing budgets and how CDSS 
could support the management of this expenditure. A mixture of opinion was 
described in relation to the functionality of one specific CDSS, in terms of fully 
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Box 43: GPs and CDSS informants’ views of drug expenditure.  
 GP 1: “I think certainly there are cost effectiveness benefits, for example yesterday 
I tried to prescribe orlistat, and the NICE guidance on orlistat was presented to me 
at the time a very quick exert, about one paragraph was presented at the time I 
tried to prescribe it.” 
 
GP2: “So the other thing to say that in Synergy, it gives a very good overview over 
pricing, much better than the other products out there, and I think in that 
perspective I get less out of it from a price perspective......it’s quite easy within 
Synergy to tell the different costs.” 
 
DS2: “They are more concerned with cost, whereas our future product that we are 
working with many customers at the moment including some of our competitor is 
not just based on cost, but is based on medicines optimisation.”  
 
DS3: “We know Script-Switch very well, they work with us, their functionality is 
designed to switch patient’s prescriptions to, generally to PCT preferred 
options......it’s not done on safety grounds......it’s done on economic grounds so the 
PCT will say we want to stop GPs prescribing all these expensive drugs so they put 
on all these hooks, every time you prescribe one of those expensive drugs you get 
offered a cheaper alternative, you don’t get offered something safer.” 
 
DS3: “Their business model is to sell their services to PCTs to reduce their 
prescribing budget, that’s their economic model......they can call it a decision 
support system, I would agree with that......I would dispute the fact that it is clinically 
driven.” 
 
DS4: “I have a very strong interest in clinical and information governance and to me 
the education aspects of the tool and the safety aspects of the tool are just as 
important….. but in terms of the number of  messages presented, if you are 
measuring it by that method, then cost saving is the largest utilisation and that will 
vary from dropping one drug to another drug or changing the formulation or the 
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3.12.2 Service costs  
In the NHS in England the commissioning and providing of healthcare for patients are 
separate functions carried out by different types of organisation underpinned by a 
tariff based payment system for the provision of hospital based care and services. 
Introduced over a decade ago this system replaced the previous arrangements 
whereby hospitals were paid according to block contracts, and fixed payments based 
largely on historic funding patterns. A specific aspect of NHS service funding was 
described in arrangements to provide homecare services.  
 
3.12.2.1 Homecare services 
The cost of providing NHS services was an important feature not just from a safety 
perspective in relation to the use of immunosuppressant drugs, but from a financial 
position in terms of service delivery. The secondary care clinicians described the 
background to homecare services from both a financial and strategic perspective and 
some of the complexities involved in the decision making process (see Box 44). This 
initially proved difficult despite the problems with generic formulations. It was not until 
a national tender for immunosuppressant drug provision was announced that 
Homecare services were eventually agreed as a preferred supply route.     
 
Box 44: Secondary care clinicians’ views of the financial aspects of homecare 
services.  
NHS2: “Yes, Healthcare at Home and Evolution are the two we use......so Mrs 
Bloggs......tacrolimus and mycophenolate......dose is blah, blah......20 weeks supply 
please and within 2 weeks they are delivered to their home.” 
 
NHS3: “Yes we then said OK we can try and use the homecare model….. there 
would be a small delivery charge for it but it would probably balance itself, but again 
they said no……they wouldn’t and it was not until the national tender came along 
and we all sat around the table and we said right what we can do is bring everyone 
back into secondary care, we can convert our patients to a generic brand and we 
can get everything at the national tender price and then all of a sudden it had to 
happen overnight for a benefit of about £2.5 million locally for our patients.” 
 
3.12.3 Funding of GP computers and IT Systems 
The current funding arrangements for general practice and IT systems, including 
CDSS were explored with the NHS IT managers and CDSS informants. With the 
backdrop of the current financial constraints in the NHS the impact on some of these 
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arrangements were explored in respect to funding arrangements for IT hardware and 
software. Box 45 shows current funding models as described by the NHS IT 
managers. The current funding model for GP clinical systems and CDSS were 
determined on local contractual arrangements with the NHS. A key feature that 
emerged was the reliance on NHS funding for GP IT system suppliers. Current 
financial pressures were also described as a key factor in the decision for changes 
whereby practices across a locality would be changing over to one GP clinical 
system. 
 
Box 45: Informants views on the funding of IT in general practice 
IT1: “I think a lot of that is funded by GPSOC, and by the PCT......running costs, 
support maintenance, it does vary, certain products are supported......some GPs 
have to contribute a percentage of the full amount, things like Docman, it does 
vary from Borough to Borough, it depends on what the GPs agree to as part of 
their framework with the PCT, funding does vary, from what I can see a lot of it is 
paid for by the PCT.” 
 
IT1: GPs are reluctant to pay or contribute towards anything to do with 
IT......whenever they have asked for equipment they have expected the PCT to 
deliver, and the majority of the time they do, but where the PCT may feel that the 
request say it is to their advantage they ask the GPs to contribute they say no.” 
 
DS3: “GP practices who use our systems pay us a license fee and a maintenance 
fee for the software......and that’s what funds it......very few of them pay us directly 
anymore, most of them get paid under a NHS contract with GPSOC to the PCTs 
and we get reimbursed in that respect......so the site is registered as using our 
software and we get a fee usually via the PCT from them......so it is all wrapped up 
in the software licensing fee.” 
 
DS3: “Script-Switch is not funded this way, Script-Switch is paid for by the PCT 
through prescribing budgets, DXS is funded primarily through pharmaceutical 
advertising......so they sell their services to pharmaceutical companies so that 
when you go to prescribe something a little tiny advert, that big appears on the 
screen for the drug......but the majority of the funding of any of these systems 
comes through the software licensing of our product.” 
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3.12.4 Funding models for CDSS and specialist drugs  
Overall the informants had mixed attitudes towards funding arrangements for a 
CDSS in this area and these are shown in Box 46. The sums of money involved were 
described as considerable and a specific aspect that would require close examination 
particularly in light of current financial constraints facing the NHS. The informants 
described some of the broader aspects to funding arrangements highlighting the 
complex strategic relationships between stakeholder groups including central 
Government.   
Box 46: Key informants and views on funding  
DS3: “Hundreds and thousands of pounds......probably several million by the time 
you have finished the project......this is a very specialist area and the investment 
required for which there is very little payback for the customer......it becomes a 
financial question it does not become a technical question......these things are 
achievable and they are achievable with the technology we have today.” 
 
DS4: “You either go down a commercial route or you don’t, and if you don’t go 
down a commercial route then......the history of the NHS is that it has tried lots and 
lots of things on a non-commercial route and they have either not been particularly 
robust, or they have not had buy in.”  
 
DS4: “And there are substantive costs, not just development but on-going 
maintenance of the product and the NHS has not always been able to do that 
particularly well......and I think it is very telling......that the NHS has not chosen to 
be one of the GP Systems of Choice.”  
 
NHS3: “You know I spend most of my week sitting in meetings with people 
saying......who is going to pay for this......it’s a very difficult question......I think there 
would probably be resistance from Trusts to pay for it......I am sure if you pitched 
up at the hospital and said look we have this great system we want to implement 
but it would cost you......I think they would say thank you very much but don’t call 
us” 
 
IT1: “Fundamentally a lot of these GPs work in the same way, and they have the 
same tools available to them, but to introduce an application like this, it needs to be 
affordable for whoever is going to fund it whether it’s the PCT, the GPs, it’s got to 
be the right price, the price is one of the biggest things.” 
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Different funding models were explored including GP funding and the current NHS 
funded models with commercial CDSS suppliers including GP clinical system 
providers. On the whole the consensus was that either central funding from the 
Department of Health or an extension of current arrangements with local NHS 
organisations would be best suited. None of the informants supported a GP funded 
model. In addition the informants described the potential use of savings generated by 
moving transplant clinics from secondary care to primary care as possible source of 
funding. Key informant and suggested funding models are shown in Table 3.11.  
 
Table 3.11 Funding models of a CDSS to support the use specialist drugs by 








GP funding Other funding 
GP1     
GP2     
NHS1     
NHS2     
NHS3     
NHS4     
DS1     
DS2     
DS3     
DS4     
IT1     
IT2     
 
3.12.4.1 Central funding 
The views of the informants that supported central funding are shown in Box 47.  
Funding was described in relation to both technical and regulatory requirements that 
would need to be fulfilled if new systems were to be developed. In addition the costs 
involved in both piloting and wider roll out were described as considerable and not 
possible without central funding. Central funding was in reference to the Department 
of Health (DH), rather than from local NHS budgets that would be managed at a local 
level with NHS organisations such as CCGs and IT teams. 
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Box 47: Key informants and views on central funding  
DS3: “So go to the DH and say you know prescribing tacrolimus needs several 
million pounds spent on implementing a shared care protocol to ensure the safety 
of patients and win that business case, and then you can do it and actually 
technically it is not that hard as there is already existing stuff you can pick off the 
shelf that would help you.” 
 
NHS1: “The real issue here then is around who potentially can fund that in the 
future you could be looking at the Commissioning Board, if it’s a service that’s in the 
description of those that are going to be handled in the future…….presumably there 
would be the patient safety focus, that would be the argument to fund it….on the flip 
side it might be a CCG………I think that funding through the Commissioning Board 
might be more successful if the service is based in that set of commissioning 
requirements.” 
 
NHS2: “Whether the Government themselves given that the central spine system is 
not going to work would send any central funding in this direction so it might be 
worth trying it out.” 
 
NHS3: “So it would be getting buy in…….so more likely to be a central funding 
issue rather than a local funding issue and then you can say well this will improve 
patient safety globally and then you can turn around and say well it is going to 
improve patient safety locally so either the two groups have buy-in to it, or it has to 
be centrally funded.” 
 
3.12.4.2 Extension of NHS funding arrangements 
The views of the informants that supported an extension of current NHS funding 
arrangements are shown in Box 48. The informants described this in relation to the 
emergence of CCGs and how different operating models could affect decision 
making in terms of supporting implementation, including liaison with secondary care. 
Both GPs supported NHS funding and utilising existing systems more effectively. The 
NHS IT managers described either direct CCG funding or through a GP systems 
supplier business case. In addition one suggestion was for emerging CCGs or 
groups of CCGs could take this on with agreements with local hospitals. 
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These local funding arrangements could be tailored and managed at a CCG level 
rather than a central DH model and depending on the range of stakeholders involved 
could lead to a number of different models that would require locally agreed 
management frameworks.   
 
Box 48: Informants and views on NHS funding arrangements 
DS1: “In the new NHS this firmly sits with the CCGs, at the CCG wallets really, and I 
think the multi-million dollar question is which of the CCGs is going to see this as a 
prescribing safety issue, big enough to tackle and you can say to the CCG we need 
to deal with.” 
 
DS2: “So then it can be an extension of the system the GP already has......which 
depending on the exact complexity of what you want it is not going to be that 
expensive......if you wanted a stand - alone system that was used by the GP for 
these drugs and by hospital clinicians that initiated the drug it becomes a different 
cost model altogether, particularly if the hospital records are still paper.” 
 
NHS2: “It might be you have to take it to individual CCGs or groups of CCGs and 
say this is the system......you know would you and your user hospitals sign up to it 
and it might be different funding agreements in different patches.” 
 
GP2:”There is a real sense to me that this can actually can come out of the 
products……implementing the products in a more intelligent kind of way.” 
 
IT1: “Yeah, I don’t know what the system suppliers charge…it would be something 
that would be taken into account......they will probably do a business case.” 
 
IT2: “You wouldn’t get the system suppliers to do it or the GPs either; it would have 
to be the CCG.” 
 
3.12.4.3 Other funding models 
The informants described alternative funding models and these are shown in Box 49. 
Suggestions included the possibility of a primary care based service rather than a 
hospital based one to support on-going care to include monitoring post 
transplantation. Primary care based clinics cost the NHS considerably less than 
secondary care clinics and were identified as a potential funding stream.  
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Investing in a CDSS was also described in relation to the cost of patients suffering 
adverse events and the cost of receiving a transplant.  
 
Box 49: Key informants and views on other funding models 
DS4: “What you have to look at is not just the system implementation cost but also 
the net savings......or the net cost......so if somebody falls through the net and does 
not have their azathioprine or any other immunosuppressant and if they reject as a 
result of that......what is the net cost to the NHS, probably hundreds of thousands 
or millions and if the patient survives let alone the cost if he doesn’t......then you 
then have to look at the incidence of that complication, so actually each time he 
misses azathioprine it costs us a £1 million.”  
 
DS4: “A consultant appointment is £220......but actually what I would like to see if a 
patient had tacrolimus that they would be given a 20 minute appointment with the 
GP rather than a 10 minute appointment......and the GP would have to be able to 
demonstrate that everything is safety netted properly, and that should be 
remunerated.” 
 
NHS4: “Sure, what we are talking about is a shared effort by the primary care and 
secondary care sectors to move something from secondary care to the primary 
care sector, the cost would have to borne by the two of them together, so they 
would both have advantages they would both stand to benefit from it.” 
 
NHS4: “So secondary care would have a relatively straight forward but time 
consuming task off its hands, the primary care sector could then repatriate the 
appropriate funding......the secondary care sector is relatively unlikely to stump up 
the money for an initiative whose purpose is to repatriate something to primary 
care......so clearly secondary care needs to be involved in the advising and 
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3.13 Discussion  
 
Of the primary themes safety and the use of IT systems were the predominant areas 
that emerged from the key informant interviews. Safety was discussed not just in 
terms of prescribing and the use of specialist drugs but also in the way patient care 
was being delivered through clinical services. IT systems within the NHS were 
described from both historical and current perspectives in both primary and 
secondary care settings although the majority of experience as expected was within 
primary care and general practice.  
In terms of costs, financial aspects were described from a range of perspectives 
reflecting each stakeholder group and the roles and priorities of individual informants.  
 
3.13.1 Safety 
Aspects of safety were raised throughout the interviews either from past experiences 
in prescribing, monitoring arrangements, use of specialist drugs and in attitudes 
towards CDSS and improving current models of care. Medication safety is an area of 
international concern with systematic reviews estimating that 3-4% of all unplanned 
hospital admissions are due to preventable drug related morbidity with the majority 
attributed to shortcomings in the prescribing and monitoring aspects of medicine 
usage (Dreischulte and Guthrie 2012).  
 
3.13.2 Prescribing 
Safety in relation to prescribing was a prominent feature described in a range of 
experiences involving drugs used in various clinical indications. In relation to 
specialist drugs, the predominant aspects to safety were described from adverse 
experiences such as side effects and managing drug interactions. Positive aspects 
described by the secondary care clinicians included the use of immunosuppressant 
drugs in organ transplantation and how services had developed to accommodate the 
growing number of patients. The secondary care clinicians were all highly 
experienced and would clearly be comfortable in all aspects of renal medicine 
including the use of specialist drugs. However, in contrast both of the GPs described 
a range of concerns and adverse experiences in relation to prescribing specialist 
drugs. In the UK a systematic review of prescribing error rates in primary care 
identified key stages of medication management where error rates of over 50% 
occurred, such as repeat prescribing reviews, interface prescribing, communication 
and patent adherence (Garfield et al 2009).  
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The authors identified an overall GP prescribing error rate of 7.5% and also that only 
between 4% and 21% of patients received optimal benefit from their medication. In 
addition an estimated 1 in 15 of hospital admissions were medication related and two 
thirds of these were preventable with this level of risk was greater in certain patient 
groups such as the elderly or those receiving high risk medications.  
 
In a recent UK based retrospective analysis of 6048 prescription items issued to  
1777 patients across 15 GP practices, Avery et al (2013) reported an overall GP 
prescribing error rate of 4.9%. The vast majority of errors were described as of mild 
to moderate severity with 0.2% of prescription items having a severe error. The 
authors reported that prescribing a drug that required specific monitoring including 
the immunosuppressant drugs methotrexate and azathioprine was associated with a 
three-fold risk of error. Slight et al (2013) described the outcomes from a qualitative 
study that explored the causes of prescribing error with staff from 15 GP practices in 
the UK that comprised of semi-structured interviews (n = 34) and six focus groups (n 
= 46). Seven categories of high level error producing conditions were identified; the 
patient, the team, the working environment, the task, the computer system and the 
interface between primary and secondary care. The authors described the underlying 
causes of prescribing and monitoring errors as complex. Key recommendations were 
made in relation to GP training, continuing professional development, clinical 
governance, effective use of GP clinical computer systems and improving safety 
systems.  
 
3.13.2.1 Communication  
Both the GPs and secondary care clinicians in this study described problems in this 
area particularly with the current paper-based system of communication.  The 
accuracy of patient medication was a particular theme that highlighted discrepancies 
in record keeping between primary care and secondary care. A number of examples 
were given where medication was either initiated or stopped within secondary care 
but was not reflected in medication records held at the GP practice. The willingness 
to prescribe specialist drugs was a clear concern for both GPs described in 
experiences where communication with secondary care was either lacking or absent. 
Hampson et al (1996) described a range of issues from the primary care and 
secondary care interface with communication described as fundamental and one of 
the busiest areas of data transfer. Avery et al (2010b) reported that a range of 
adverse outcomes had been attributed to problems with communication at the 
interface between primary care and secondary care including medication errors.  
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In addition the author described problems in relation to communication included 
those not just between individual clinicians in primary and secondary care but also 
between clinicians and patients.  
 
In a pharmacist-led review of 126 medical patients and 51 surgical patients in the 
North West of England, Collins et al (2004) identified a range of discrepancies in both 
medication and dosages prescribed within in-patient settings when comparing 
medical notes to drug charts and comparing discharge information to records held 
within primary care settings. A total of 51 medicines were identified that were not on 
the records of either the GP or nursing home, and these accounted for approximately 
5% of all medicines recorded. The authors concluded that the study supported 
previous findings that there were substantial numbers of discrepancies between 
documented sources of patients’ medicines and what patients reported what they 
were taking. In addition the authors reported that the inaccuracies observed with 
GPs’ records in comparison with hospital records suggested that there was no gold 
standard in medication history available, other than a list of drugs taken from a 
patient who is perceived to be reliable and to achieve such a standard would require 
improved communications between healthcare professionals.  
 
3.13.2.2 Clinical responsibility 
Where specialist drugs are concerned specific continuous management and clinical 
monitoring may be required and not all GPs will have the expertise or experience to 
undertake the full clinical and legal responsibility to prescribe specialist drugs 
(Khambh and Barnick 2007). In a UK national survey of both GPs (n = 1887) and 
hospital consultants (n = 729), Sibbald et al (1992) reported on the investigation of 
some of the problems reported at the hospital and primary care interface.  
Overall, 570 (46%) GPs reported that they had been asked by a hospital to prescribe 
drugs where they had felt unable to take clinical responsibility. The specialist drugs 
reported were those used in fertility treatments, growth hormone, anticancer 
treatments (immunosuppressant and cytotoxic drugs), and drugs used in renal failure 
(fluid for continuous ambulatory peritoneal dialysis and erythropoietin). The principal 
reasons cited for not being able to undertake this responsibility included difficulty in 
detecting side effects, uncertainty about explaining treatment to patients, difficulty 
monitoring dosage, high cost of a drug, and a lack of knowledge about the treatment. 
The issue of clinical responsibility was described by the GPs and the secondary care 
clinicians including the use of traffic light schemes.  
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Overall a level of concern and anxiety was expressed by the GPs in terms of 
prescribing specialist drugs and undertaking clinical responsibility. Horne et al (2001) 
described clinical responsibility as a consistent theme and the need for both GPs and 
hospital doctors to agree respective responsibilities. 
 
3.13.2.3 Monitoring 
Monitoring is a periodic measurement that guides the overall management of either 
acute or chronic illness and can be performed by clinicians, patients or both 
(Glasziou et al 2005). Monitoring can have a positive effect on treatment such as 
improving adherence, selection of appropriate medication, better titration of dose and 
learning about non-medical factors that may affect treatment outcomes.  Managing 
prescribing is often finding the correct balance between therapeutic efficiency and 
adverse side effects of medication (Johnston and Holt 1999). The process of 
therapeutic drug monitoring suited a range of drugs specifically those that exhibited a 
narrow therapeutic index drugs where the differences between drug concentrations 
exerting benefit and those causing adverse effects were small. In the case of 
immunosuppressant drugs such as ciclosporin and tacrolimus, small variations in 
drug exposure can result in reduced immunosuppression or drug toxicity with 
potentially adverse effects on patient outcomes (Johnston 2013). Monitoring 
arrangements were an area of considerable concern described by both GPs in terms 
of on-going management of patients. The GPs described situations where there was 
a lack of either recent blood tests and or knowledge of what specific patient 
monitoring was required. There are a lack of published studies that have specifically 
explored patient monitoring in relation to specialist drugs, although Horne al (2001) 
described some of these activities such as carrying out routine checks such as blood 
pressure, urine analysis and taking blood samples.    
 
3.13.3 Experiences of specialist drugs 
A specific area of concern was the numerous citations by the secondary care 
clinicians of experiences of adverse events in relation to the use of 
immunosuppressant drugs. These related to two key areas, drug interactions and the 
introduction of generic formulations of tacrolimus.  
 
3.13.3.1 Drug interactions  
Drug interactions occur when two or more drugs when taken concomitantly interact in 
such a way that it leads to the effectiveness or toxicity of one or more of the drugs 
being altered (NPC 1999).  
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The drugs that are likely to be involved are those with a narrow margin between the 
therapeutic and toxic dose, those requiring careful dosage control and those which 
either induce or inhibit liver enzymes. The effect and severity of drug interactions 
may vary considerably from one patient to another with the elderly, patients taking 
multiple medications and those with impaired renal or liver function most susceptible. 
Both the GPs and the secondary care clinicians described the importance of drug 
interactions from a range of experiences and perspectives. A practical difficulty 
described was that where prescribing was retained in secondary care the use of 
those drugs would not appear within the electronic health record held at the GP 
practice. Although manual alerts could be added to the GP held record, electronic 
drug interactions provided by CDSS would not be able to alert the prescriber if an 
interacting drug was prescribed. There are no published studies that have specifically 
explored this aspect of prescribing either in relation to improving CDSS and or the 
ways to facilitate on-going prescribing where hospitals continue to prescribe 
specialist drugs. The secondary care clinicians described experiences of where 
patients had presented to clinic having been prescribed drugs that had interacted 
with their immunosuppressant drugs causing either under immunosuppression and 
were at risk of graft rejection or over immunosuppression and were at risk of 
infection. 
 
3.13.3.2 Generic prescribing 
In the UK generic prescribing is acknowledged as desirable and representing high 
quality prescribing (Duerden and Hughes 2010). The benefits of generic prescribing 
include including reducing the risk of error as each drug has only one international 
chemical name rather than many brand names and, usually, reducing the cost of 
prescribing. The informants described a range of adverse experiences following the 
introduction of generic formulations of tacrolimus and newer formulations of existing 
branded tacrolimus, including examples where patients had acute organ rejections 
and in one case a fatality. These experiences correlated well with published alerts 
and warnings issued in the UK and the use of tacrolimus (MHRA 2009, 2010, 2012). 
The secondary care clinicians described some of the difficulties in ensuring that GPs 
prescribed immunosuppressant drugs by specific brand despite stipulation within 
shared care protocols and in communications to GPs. A number of scenarios were 
described where formulations where inadvertently switched either when generically 
issued prescriptions were presented at community pharmacies for dispensing or 
where GPs changed prescriptions for patients between different branded 
formulations.   
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The secondary care clinicians described in detail examples of inadvertent switching 
of tacrolimus formulations due to branded products not being specified on GP 
prescriptions resulting in adverse events including organ rejections and a fatality. In 
addition the secondary care clinicians described some the strategic planning and 
decision making that eventually initiated the repatriation of the prescribing of 
immunosuppressant drugs. In 2011 some UK renal transplant units began to 
commence new patients on Adoport ® following the outcomes of a national tender for 
immediate release formulations of tacrolimus that resulted in significant savings to 
the NHS against the use of Prograf ® (Devaney and Lee 2013). In addition the 
national tender also included oral formulations of mycophenolate however unlike 
tacrolimus bioequivalence problems were not an issue with this drug. Recent reforms 
in NHS commissioning arrangements for specialist drugs and services including 
organ transplantation have meant that repatriation of the prescribing of 
immunosuppressant drugs to secondary care is set to increase across the country 
(Devaney and Lee 2013).  
 
3.14 Specialist drugs and shared care protocols 
A number of published studies had either evaluated or explored the development and 
/ or use of shared care protocols in the UK (Gerada et al 1999, Duggan et al 2001, 
Horne et al 2001, Salt et al 2005, Iilife et al 2006, Crowe et al 2009). The attitudes 
and experiences of the key informants in relation to specialist drugs and shared care 
protocols reflected some of the reported outcomes of these studies. These 
experiences highlighted specific underlying issues such as poor communication; a 
reliance on paper based systems, time constraints and the access and availability of 
shared care protocols.  
 
3.14.1 Attitudes and experiences of shared care protocols 
Emerging themes reflected a mixture of both positive and negative experiences and 
attitudes to shared care protocols, however a key feature was the particular 
negativity towards their use from both GPs. Major themes that emerged from the 
data in relation to shared care protocols described the development process, quality, 
availability and acceptance by GPs. Significantly nearly all of the positive aspects 
around shared care protocols came from the secondary care clinicians, specifically in 
relation to the developmental and approval process. These included examples of 
how aspects of the design process could improve the quality and arrangements for 
monitoring.  
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In contrast however the views and experiences GPs did not reflect this and provided 
a contrasting picture particularly with regards to the quality and availability of shared 
care protocols. These results broadly reflected the outcomes from previously 
published studies in relation to specialist drugs and shared care protocols. Duggan et 
al (2001) reported mixed attitudes towards shared care protocols with the former 
health authority advisers (medical and pharmaceutical) as predominantly negative 
whilst hospital pharmacists as positive. Horne et al (2001) reported on the overall 
dissatisfaction of GPs with arrangements for prescribing specialist drugs in contrast 
to hospital doctors who were generally satisfied. The authors described the negative 
attitudes of GPs in relation shared care protocols including a lack of involvement in 
monitoring, a lack of experience and that protocols were not helpful as they were 
time consuming to develop for small numbers of patients. In terms of the key 
informants both GPs reported that had either personally or were aware of colleagues 
who had been involved in developing shared care protocols. Crowe et al (2009) 
described specific concerns that adversely affected the acceptance of shared care 
protocols including a lack of GP input into development, the authorising process, a 
lack of availability and the on-going monitoring and patient management.  
 
3.14.2 Developing shared care protocols and their quality  
Positive aspects to shared care protocols came from experiences around the 
development process described by the secondary care clinicians. The responsibility 
for developing, maintaining and approving shared care protocols has been described 
as a shared process involving stakeholder groups from both primary and secondary 
care such as local prescribing or medicines management committees with GP 
involvement (Khambh and Barnick 2007). One such example has been the 
development of localised shared care protocols in line with UK National Service 
Framework standards to improve the treatment of mental health (Snowden and 
Marriott 2003). Overseen by a multi-agency steering group, this six-month project 
drew on the results of an initial systematic literature review which were compared 
and contrasted by a facilitated group of primary and secondary care clinicians. The 
authors reported that using local clinical consensus was an effective method for 
adapting clinical guidelines to local circumstances. The development of shared care 
protocols for immunosuppressant drugs in renal transplantation was explored with 
the secondary care clinicians, to include the writing, management and approval 
process in conjunction with primary care organisations.  
The process was described as pharmacist led involving a renal directorate 
pharmacist, formulary pharmacist and final approval by a medicines committee 
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where GPs attended that covered a number of primary care organisations. However 
both GP1 and GP2 described that they had no experience in either writing or in the 
development of shared care protocols. Gerada and Tighe (1999) and Duggan et al 
(2001) have reported on the limited role of GPs in the development and use of 
shared care protocols.  
 
Despite the positive experiences described around the developmental and approval 
process of shared care protocols and the approval process involving PCT medicines 
management teams the opinions and experience of GP1 and GP2 raised doubts 
about whether these systems were effective in real terms with the most widely cited 
problem being the quality of shared care protocols. A wide number of examples were 
given describing specific issues such as inappropriate drug selection, written quality, 
variability, and the ease of use for general practice. Similar drawbacks with the 
quality of shared care protocols were described by Duggan et al (2001), including 
variability and a lack of apparent standards either within or between geographical 
regions. 
 
3.14.3 Acceptance of shared care protocols 
GPs may often lack the relevant skills and expertise to undertake the full legal and 
clinical responsibility for prescribing specialist drugs; hence a shared care 
arrangement including an appropriate protocol will in many cases be appropriate 
(Khambh and Barnick 2007). Although the desired effect of introducing shared care 
protocols was to address this issue this was not reflected from the range of 
experiences described by the informants. A number of issues were cited as barriers 
in the acceptance of shared care protocols that provided some insight into this area 
such as GP workload, complexity of the arrangement and dissemination from 
secondary care. Ilife et al (2006) reported a similar resistance to shared care from 
within general practice with concerns on staffing, time constraints and a lack of 
experience and confidence in making and disclosing a diagnosis. The barriers to 
acceptance of shared care protocols described by the informants differed from those 
cited by Duggan et al (2001), where the main barrier was described as cost shifting. 
The informants described a range of issues such as clinical responsibility, role of 
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3.14.4 Awareness and availability  
Shared care protocols are widely available to download from the websites of 
approving bodies such as area prescribing committees (Department of Health 2012). 
However the actual local awareness and availability of shared care protocols was a 
key problem described by both GPs and the secondary care clinicians. Some of 
these problems highlighted specific issues such as confusion over responsibility for 
dissemination, use of paper based protocols and identifying updated versions. Crowe 
et al (2009) cited similar experiences describing the importance of distributing paper 
based traffic light lists at practice level and failings from a PCT perspective in the 
dissemination of shared care protocols and raising awareness of their existence with 
GPs. Access and availability of resources was a key concern for the informants 
despite the dissemination process now in place in terms of NHS internet and extranet 
access. Being unable to locate shared care protocols was a concern and coincided 
with issues in general regarding accessing to information within primary care. 
Navigating extranet sites was described as difficult even for IT literate individuals and 
in a busy GP consultation time constraints were also considered having an adverse 
effect on access.  
 
3.15 Information technology: Systems and functionality 
The informants described the use of computers and IT systems within general 
practice from both an end user perspective i.e. GPs and practice staff and from a 
technical perspective in terms of functionality including key aspects of management 
and regulation. Overall in terms of usage a mixed picture was portrayed of 
computerised systems and acceptance of new technologies. Computers were 
described as essential in the running of general practices such as in offering 
appointments, processing patient data, pathology links with hospitals, generating 
prescriptions and alert and reminder systems.  A specific aspect was the wide range 
of both clinical and practice administration functionality that was available for use in 
terms of applications provided by the GP clinical system providers and external 
software applications. Internet availability provided access to major resources for 
general practices in terms of communication and operational links to applications 
such as NHS mail, Choose and Book local NHS extranet websites. In terms of 
prescribing support computer usage was described as essential in terms of 
managing health records and medication to include the availability of CDSS.  
However a number of problematic aspects of computer use were described by the 
informants including issues in relation to practice workload, computer maintenance, 
and training requirements for staff. 
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In addition specifically for the GPs a clear problem was time constraints in terms of 
overall computer use including additional software applications during consultations. 
The informants also described specific problems in terms of changes to computers 
and software applications and the impact to general practices and in particular to end 
users. Even small changes could potentially impact on general practice workload and 
were described in terms of the way new software applications were implemented. 
The acceptance and use of new technologies was described as variable with key 
enablers described as the provision of adequate training, targeting slow adopters and 
better use of peer support.   
 
The overall experiences of the informants correlated with published studies that have 
evaluated computer usage within general practice.  An early systematic review of 30 
published evaluations from the UK and abroad Sullivan and Mitchell (1995) reported 
that although computer use during GP consultations had helped improve clinician 
performance the length of patient consultations had increased. The authors later 
repeated this systematic review identifying 61 studies that examined the effects of 
computers on clinician performance, patient outcomes and the attitudes of both 
clinicians and patients (Mitchell and Sullivan 2001). The authors reported mixed 
experiences of usage with computers in primary care, with use reported to increase 
consultation time and whilst reminder systems benefited preventive tasks and 
disease management these improvements were lost when reminders were stopped. 
In addition the authors described other concerns such as the impact on privacy, the 
doctor / patient relationships, cost, time and training requirements.  In contrast 
positive experiences included generating prescriptions, increasing generic 
prescribing and managing investigations and tests. Morris et al (2003) reported from 
a national survey of all Scottish GP practices, that most GPs made frequent use of 
computers for a variety of clinical and practice management activities however other 
staff wishing to make a greater use of computers was unable to due to a lack of 
access.  
 
In a broader study involving London based GPs, practice staff and PCT 
management, Mannan et al (2006) reported that although general practices 
acknowledged the benefits of new technology concerns remained around acceptance 
due to issues such as the mistrust of technology and fears with the increased 
workload levels required. In addition the authors recommended that IT 
implementation teams should focus their attention to those practices that have been 
reluctant to use technology to support both clinical care and practice management. 
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More recent studies have explored computer usage during consultation by use of 
video recording techniques. Chan et al (2007) reviewed 100 patient consultations 
involving 10 GPs and reported on three types users of computers, as either minimal, 
continuous or end users, where end users would only use the computer at the end of 
the consultation. In a broader examination Kumarapeli and De Lusignan (2013) used 
multichannel video to record 163 patient consultations with 16 GPs based in 11 
practices and described usage in relation to proportion time spent on the computer 
but also described 34 different tasks commonly performed classed as either  
continuous, episodic and singleton (one off). In addition the authors reported on a 
range of factors that affected patient interaction including having to multitask, 
interruptions and room layout. 
 
3.15.1 Data quality and read coding  
Computerisation has introduced electronically accessible information supporting both 
clinical and non-clinical practice management. A key aspect has been the ability to 
electronically record patient specific information to an individual health record and the 
ability to recall or retrieve aspects of patient or clinical relevant data. Lawrenson et al 
(1999) has reported on the development of three major national databases 
developed to routinely collect specific data from selected general practices in the UK; 
the Department of Health owned General Practice Research Database (GPRD), and 
two commercially owned databases, Mediplus and the Doctors Independent Network 
Database (DIN). Key to these national databases is the quality and accuracy of data 
that is recorded by use of standardised systems of coding. A specific problem and 
area of concern described by the informants was the process of managing paper 
based information and specifically ensuring relevant data was electronically recorded 
and coded. In addition inaccuracies were cited as a key area that had a significant 
effect on both clinicians and patients. This was described particularly between the 
primary care and secondary care interface where patient specific information was 
reported as often either missing or lacking. A recurrent theme was the accuracy of 
medication lists held by GPs compared to those held in secondary care.   
 
De Lusignan (2005) has described coding as a complex task and suggested that in 
order to overcome difficulties clinician attitude and IT aptitude be addressed in 
addition to identify and technical barriers or organisational factors.   Described by the 
authors as the first systematic review to investigate the measurement of the quality of 
general practice held data Thiru et al (2003) identified 47 studies from the literature of 
which 31 were from the UK.  
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However due to a lack of standardised methods for the assessment of data quality in 
electronic patient records the authors were unable to compare results between these 
studies. The authors reported that  limitations in data quality would remain when 
systems allowing the opportunity to record clinical data in different forms i.e. both 
paper and electronically continued and that the validity and quality of electronically 
held data would improve as clinicians migrated to electronic systems. 
 
For clinicians having electronically available data has huge advantages in that clinical 
and management decisions can be quickly and safely made without the need to 
manually check for information. GP system suppliers are required through 
contractual agreements with the Department of Health and the GPSOC program to 
provide computer systems that meet specific specifications including CDSS to 
provide drug related safety information such interactions and warnings. However 
reports have highlighted safety deficiencies within GP computer systems where 
warnings failed to alert end users when expected (Fernando et al 2004). In addition 
the need for improvement strategies for GP clinical system suppliers have been 
recommended to include human ergonomics in the design of hazard alerts (Avery et 
al 2005, 2007). Being able to trust data being presented electronically was a key area 
for the end users particularly the GPs and thus support the use of IT systems in 
general practice including CDSS for both prescribing general practice management. 
The informants highlighted specific key processes around maintaining the quality and 
robustness of electronic data and in terms of on-going development of products. In 
addition the informants provided a range of examples where inaccurate coding of 
patient data or the perceived irrelevance of prompts and alerts such as with drug 
interactions led to a distrust of the functionality and the subsequent over-riding of 
alerts.  
 
3.15.2 Accreditation  
A key aspect in relation to standards was the concept of accreditation of software 
systems in particular with reference to CDSS. Introduced in 1993, Requirements for 
Accreditation (RFA) ensured that GP clinical systems provided agreed core 
functionality and conformed to national standards to include the provision of CDSS 
(Sugden et al 2008). In addition the Department of Health recommended that health 
authorities should only reimburse GP practices expenditure in respect of GP clinical 
systems if the expenditure related to a system that was accredited to RFA standards.  
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In order to support GP practices move to systems that were compliant with the 
introduction of the single electronic care record and NHS spine, the RFA was 
replaced by the GP System of Choice (GPSOC) initiative which encouraged GP 
clinical system providers to upgrade their systems through a series of compliance 
levels in order to achieve a greater level of standards (Sugden et al 2008). However 
although GP clinical system suppliers were required to meet these regulatory 
standards a specific issue that the informants described was the historic lack of 
regulatory standards in relation to CDSS.  
 
The CDSS informants described recent developments in order to bridge this gap with 
software accreditation. The accreditation of any system confers a degree of quality 
assurance. In the UK the NICE Accreditation Programme recognises organisations 
that demonstrate high standards in producing health or social care guidance with 
users of accredited guidance can therefore have high confidence in the quality of the 
information (NICE 2013). Organisations may publicly display a seal of approval called 
an Accreditation Mark for 5 years after their processes have been accredited. The 
informants described the accreditation for a specific CDSS that provided prescribing 
support within GP clinical systems. However it emerged that the accreditation only 
covered the authoring process behind the product and not the actual clinical content. 
In addition the informants also described mixed attitudes to a recent European 
Directive that stipulated that CDSS were stand-alone software that were to be 
classified as a medical device (EMA 2012). The implications for suppliers were 
described as particularly difficult as the MHRA in UK would have to ensure 
adherence to the European Directive. The informants described the considerable 
investment in terms of time and money in order to meet the requirements of the 
Directive and the financial penalties for not doing so. In addition this would have a 
specific impact for the introduction of any new CDSS in that the product would need 
to meet the requirements of the Directive.   
 
3.15.3 The views and experiences of CDSS in primary care  
The informants described key positive aspects to CDSS specifically in relation to the 
active alert process. Benefits cited included cost saving alerts such as those provided 
by Script-Switch, drug safety alerts such as drug interactions the on - going alerts 
and reminders provided within GP systems to support QOF. In addition CDSS was 
described as supportive around the prescribing process such as repeat prescribing in 
both passive and active formats and allowing engagement with patients during 
consultation.  
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Quality was as a key feature exemplified through robust data checking and authoring 
processes from providers of CDSS and developments such accreditation. In contrast 
some of the problems associated with CDSS were described in relation to a lack of 
integration with GP clinical systems, the implementation process particularly with the 
effects on GP practices such as staff training and having to deal with technical 
difficulties. In relation to IT systems and initiatives that were being introduced by NHS 
Connecting for Health Mannan et al (2006) reported that the majority of practice staff 
expressed concerns with these initiatives such as workload pressures, a lack of 
training and costs of implementation. In addition practice staff expressed fears that 
change would be forced onto them. 
 
A specific theme that the informants described was the need to override alerts 
provided by CDSS particularly during patient consultations with time being a 
significant factor. Similar findings have been reported from studies that have explored 
attitudes and perceptions of CDSS with GPs. Magnus et al (2002) reported that 22% 
of GPs surveyed (n = 220) admitted to frequently or very frequently overriding drug 
interaction alerts without proper checking with possible reasons cited as the 
perception that the alerts were frequently irrelevant. (Rosseau et al 2003) reported 
three main areas of concern with CDSS amongst GPs and nurses (n = 40) included 
the timing of the alert, ease of use of the system, and helpfulness of the content. 
Short et al (2004) reported on practical barriers to the use of CDSS during 
consultations including limitations of practitioners’ IT skills, a lack of  understanding of 
the risk output of systems, concerns about communicating risk sufficiently well to 
patients and time constraints.  
 
A particular theme that emerged was the relationship between commercial system 
suppliers, NHS IT management and the end users of systems including CDSS. In 
terms of CDSS, Delaney et al (1999) reported that despite the huge potential in its 
use, the concept had largely failed due to the failure to examine the needs of 
practitioners more closely. A number of examples were provided where engagement 
with end users was described in specific detail highlighting problems in the 
development, use of and implementation of either new or changes in IT systems 
including CDSS. The CDSS informants in particular described the importance of 
engagement with the end users and how user groups played a pivotal role in 
maintaining and developing products and services.  
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3.16 The views and experiences of CDSS in secondary care 
Although limited compared to primary care, the informants described experiences of 
CDSS in secondary care. Groundrey-Smith (2006) has reported on the limited 
experience of electronic prescribing within UK hospitals and the small number of 
studies that have cited observed benefits including the availability of CDSS as a 
support tool at the point of prescribing. Although none of the secondary care 
clinicians currently used electronic prescribing systems within secondary care there 
was a general awareness and acceptance of its benefits including the use of CDSS. 
A number of references were made to either the imminent or planned implementation 
of electronic prescribing systems within hospitals. A number of examples of CDSS 
were described as either being used or developed locally within specific clinical units 
independently of secondary care information technology systems.  
 
The secondary care clinicians described the establishment of a national network of 
electronic renal databases that were used to collect biochemical and haematological 
information to inform the UK renal registry. These experiences correlate with a recent 
survey of NHS hospitals (n = 101) that has shown that the uptake of electronic 
prescribing within UK hospitals is beginning to rise, with 70 (69%) having at least one 
form of electronic prescribing in use (Ahmed et al 2013). More than half (39;56%) of 
hospitals with electronic prescribing had more than one system in use, representing 
60 different systems with the most common used only for discharge prescribing, used 
in 48 (48%) and specialist chemotherapy used in 34 (34%) of respondent hospitals. 
In addition the functionality of CDSS available was reported as being widely varied.  
In 2013 NHS England launched a £260 million technology fund available to NHS 
providers to support a move from paper-based systems for patient notes and 
prescriptions to integrated electronic care records and the development of e-
prescribing and e-referral systems (NHS England 2013).  
 
3.17 Developments and improving CDSS 
A wide range of both current or proposed developments and improvements in CDSS 
were explored with the informants. For general practice key areas were described in 
the way electronic systems including CDSS could potentially support the 
management of long term conditions. The current GP contract is supported by the 
QMAS electronic alerting system that provides financial incentives and information 
technology through computerised prompts and decision support to achieve evidence 
based quality targets (Gillam and Steele 2013). Some of the positive experiences 
described by the informants were of how QOF alerts had improved general practice.   
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One of the informants described the functionality of a primary care based CDSS that 
operated in the USA whereby aspects to a patient’s medical care could be prioritised 
unlike the current QOF alerting systems in the UK. This this could be a significant 
area for development as more urgent interventions could be prioritised over less 
important ones especially if patients have limited GP appointment times. Other 
potentially significant areas for CDSS development included linking GP clinical 
systems with community pharmacies and in the on-going development and 
implementation of electronic prescribing systems within secondary care.  
 
3.18 CDSS and specialist drugs 
Overall the concept was welcomed by all of the 12 informants. Key enablers that 
were described included data quality and functionality (9), joint development and 
implementation (8), for the CDSS to have an active alerting functionality within an 
electronic patient record (6) and to make use of existing systems and frameworks (5). 
Key barriers that were described included addressing the needs of end users (6), 
security and regulation (5). Of the funding models explored, the majority of the 
informants (7) suggested an extension of the current NHS funded model. Four of the 
informants suggested central funding whilst none suggested that GPs should provide 
funding. One of the informants described a potential funding model whereby shifting 
transplant clinics into primary care could release funds that could be invested into the 
development of a CDSS. A key aspect that emerged was the role of GP clinical 
system suppliers as a point of entry for the development of a CDSS to support the 
use of immunosuppressant drugs. Making use of existing systems and frameworks 
related to both financial and regulatory perspectives. The cost of developing a new 
product was estimated by the informants to run into millions of pounds. Without 
central funding from the Department of Health the only considered option would be to 
extend current NHS funding streams in collaboration with a GP clinical system 




The importance of costs were a specific feature in three key areas; drug costs, IT 
costs and service costs.  
 
3.19.1 Drug expenditure  
The informants provided a mixture of views regarding whether drug costs played a 
significant role in GP decision making in whether to undertake the prescribing of 
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specialist drugs. Safety related issues such as patient monitoring and clinical 
responsibility were described as the predominant factors. It was clear however that 
some of the adverse experiences associated with tacrolimus were linked to primary 
care drug costs and GPs having to manage indicative practice budgets. With clinical 
commissioning groups (CCGs) now responsible for managing primary care 
prescribing budgets, key decision making around commissioning of health services 
rests with GPs. With the drive to bring hospital services out into the community, this 
raises the prospect of a greater level of specialist drugs being prescribed within 
primary care adding additional pressures on primary care prescribing expenditure. 
Cost shifting from secondary care to primary care was a major issue in the 1990s 
with GP fundholding particularly with high cost specialist drugs such as erythropoietin 
in renal medicine (Stephens 2005). Significantly drug cost was not cited as a barrier 
by any of the informants. GP fundholding was abolished in 1997 and replaced with 
prescribing incentive schemes, which were designed to encourage quality 
improvements and cost containment in prescribing (Stephens 2005).    
 
3.19.2 Funding of IT systems and CDSS 
The informants described funding arrangements for general practice and IT systems, 
including CDSS from both a historical perspective and in relation to recent NHS 
reforms. A specific aspect was the role of the NHS in terms of funding IT for GP 
practice in its entirety. The NHS has historically subsidised the cost of GP computer 
systems since the 1990s, initially through facilitation payments to improve standards 
e.g. immunisation and cervical cytology targets and more recently to meet the data 
requirements for QOF and the GMS contract introduced in 2004 (Roland et al 2012).  
In terms of funding arrangements the NHS provides this through the GP Systems of 
Choice (GPSOC) framework. Launched in 2014, “Securing Excellence in GP IT 
Services” announced changes in the operating arrangements including financial 
procedures and associated controls with regards to IT for general practice (NHS 
England 2014). These changes included arrangements for governance, leadership 
and clinical safety assurances including the availability of secure e-mail (NHSmail) 
for all primary care contractors. The document also outlined key repsonbilities for IT 
infrastructure that were to be retained centrally and those for local development.  A 
recurrent theme that emerged from the key informant interviews was the need for 
funding for either existing systems or any future developments in IT to be met by the 
NHS or by central Government and not by GP practices. In addition this also 
extended to additional costs to support implementation such technical support and 
staff training. 
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3.19.3 Commissioning of specialist services 
Important features to the development of renal units were the growing numbers of 
patients receiving transplants and the close affiliation of patients to transplant 
centres. Transplantation was described as a positive intervention both in terms of 
outcomes and quality of life but also cost to the NHS. The annual cost of dialysis is 
£30,800 per year compared to the one off cost of a transplant of £17,000 and annual 
drug costs of £5,000 (Johnston 2011). Costs, including drug costs although not the 
predominant factor were a key feature for driving forward the repatriation of 
prescribing and the supply of immunosuppressant drugs through homecare. Attitudes 
to using homecare providers to supply immunosuppressant drugs in renal transplant 
patients were generally positive particularly from an operational perspective by the 
secondary care clinicians interviewed in this study. Although financial savings were 
described as considerable, particularly once patients were repatriated and converted 
to cost effective generic formulations of immunosuppressant drugs, the safety and 
clinical care of patients was considered just as important.  
 
The treatment at home of patients requiring specialist drugs and treatments such as 
intravenous therapies including chemotherapy and total parenteral nutrition is 
accepted as a safe and effective means of healthcare provision (Short and Norwood 
2003). In the UK the high-tech homecare model of delivery has evolved significantly 
and is regulated by the National Homecare Medicines Committee (NHMC). It was 
recognised that market expansion in homecare required effective management to 
ensure patient safety and clinical effectiveness (Commercial Medicines Unit 2010). In 
2011 the Department of Health commissioned the report “Homecare Medicines – 
Towards a Vision for the Future” (Department of Health 2011). The report made a list 
of recommendations to improve the financial and clinical governance arrangements 
for patients receiving medicines from Homecare providers. The secondary care 
clinicians described their experiences in some of the strategic decision making in 
relation to repatriation of the prescribing of immunosuppressant drugs and the use of 
homecare services. In 2010 the Government White Paper “Equity and excellence: 
Liberating the NHS” outlined key strategic steps in order to achieve financial targets 
to include Quality, Innovation, Productivity and Prevention (QIPP), a national 
program of work streams that included medicines use and procurement (Department 
of Health 2009). In terms of renal transplantation, this led to the development of a 
national “Kidney Care QIPP Plan”, which was incorporated into the strategic 
commissioning plans for renal care (NHS Specialised Commissioning Transition 
2012).  
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A key opportunity identified was the wider use of generic formulations of tacrolimus 
which formed the basis for a national tender in 2011. Transplant centres in the UK 
soon introduced supervised switch programmes in order to move patients to cost 
effective branded generic formulations of tacrolimus (Devaney and Lee 2013). The 
secondary care clinicians described the use of homecare services as leverage in 
order to ensure patients were reviewed and appropriately managed before being 
transferred over to these providers.   
 
From 2013 changes to the commissioning arrangements for specialist drugs in 
England have provided the opportunity for hospitals to further extend the process of 
repatriation of prescribing of immunosuppressant drugs (Devaney and Lee 2013). 
With the continued emphasis on managing expenditure in the NHS and a push 
towards moving secondary care services out into primary care, closer to patients 
NHS commissioners may see other specialist drugs as suitable for consideration for 
wider use in in primary care such as in GP practices or community clinics supported 
by the provision of homecare services (Anon 2012).  
 
3.20 Limitations 
The number of participants that took part was small with only two GPs that were 
purposively recruited to this study, both of whom were younger and very familiar with 
computers and IT systems. This may have introduced a level of bias towards 
attitudes to IT and CDSS. However as two of the CDSS informants were also 
practicing GPs this did allow for further data to be gathered from a clinicians’ 
perspective. In addition only two NHS IT managers were purposively recruited to the 
study. 
 
3.21 Further work  
In principle all of the key informants expressed positive attitudes to the concept of 
developing a CDSS to support the use of specialist drugs. A number of 
disadvantages to the current paper based systems of communication including the 
use of shared care protocols between secondary care and primary care were 
described with the predominant factor being safety. A number of operating models 
were suggested however key to which model would best support clinicians would  
depend on whether the repatriation of immunosuppressant drugs is extended to 
cover other forms of organ transplantation services e.g. liver and or other specialist 
drugs.  
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The secondary care clinicians described the repatriation project in terms of renal 
units as a pan-London initiative and with other areas of the country following suit. If 
prescribing is retained in secondary care an additional factor is the extent to which 
electronic prescribing as a whole develops within secondary care. If a hospital Trust 
embarks on a whole system implementation that incorporates all clinical sites, wards 
including pharmacy this may impact on the implementation process and a different 
approach may be required compared to a ward based or clinical unit based system.   
 
Ahmed et al (2013) reported on the increasing numbers of electronic prescribing 
systems in secondary care in the UK but also added that many hospitals used more 
than one system and that there was wide variability in the functionality of available 
CDSS. In addition the integration with current GP clinical systems will remain a 
concern as the informants described a range of problems at the primary and 
secondary care interface such as inaccuracies in health records including medication 
lists. Developing existing renal databases managed within secondary care to allow 
electronic prescribing is potential area which could be explored, although the 
integration with the GP clinical system would remain key factor. In addition if a 
homecare model is to be the continued system of supply of specialist drugs then the 
integration with the homecare pharmacy computerised system could be a potential 
area for further investigation.   
 
A primary care based model was suggested as a potential model by the informants 
either GP led or specialist led. Current GP clinical systems would be the point of 
entry in order for a CDSS to be developed and potentially introduced to support 
clinicians. The informants described a current model where all GP practices within a 
locality were considering moving to a single GP clinical system supplier. Two 
suppliers have developed clinical systems that allow multi-user access, SystmOne 
and EMIS Web. These are both hosted systems and allow external user access to a 
single record clinical electronic patient record. Potentially these systems could be 
introduced within other primary care or secondary care based clinics with controls 







Chapter 3: An exploratory study using key informants to investigate the use of computerised 




The results of this study have shown that little has changed in terms of the views and 
perceptions of clinicians towards the use of specialist drugs and shared care 
protocols in relation to previously published literature. Khambh and Barnick (2007) 
suggested that proposed developments in electronic prescribing within secondary 
care could improve the situation with paper based systems particularly with the 
problems associated with communication between secondary care and primary care. 
The authors also highlighted that electronic prescribing systems would require 
significant time to become fully established before benefits would be seen. The 
direction of a primary care driven NHS does not appear to be changing, and the 
increasing trend to see a greater range of specialist drugs used within community 
settings either through homecare services or the introduction of other service models 
will continue.  
 
The informants in this study described enablers and barriers to the development of a 
CDSS to support the use of specialist drugs. Six of the 12 informants described a 
failure to address the needs of end users as a barrier. Coiera et al (2006) reported 
that the effectiveness of CDDS should not be judged on performance of the software 
but a better understanding of cognitive and socio-technical interaction in its design. 
Horskey et al (2012) described poor usability as one of the core barriers to the 
adoption of CDSS. In addition the authors suggest that designers of systems needed 
to adopt methods that included user-centred, iterative design and common standards 
based on human and computer interactive research methods.  
 
The key informants described a number of operating models for a potential CDSS to 
support GPs in the use of specialist drugs. In order to understand the actual needs of 
GPs as end users of a potential CDSS a specific additional area was identified for 
further investigation. The following chapter adopts methods used within the field of 
human factors and ergonomics. The purpose of this additional study was to 
understand from a GP perspective from real time scenarios the actual level and use 
of computers and software applications including CDSS at the point of prescribing 
both during and outside of patient consultations. In addition weaknesses or failings in 
existing systems could be identified and be used in the further development of a 









A task analysis of the use of 
computers and computing 
software by GPs





4.1 Human factors and ergonomics 
Human factors and ergonomics apply the knowledge of human abilities and 
limitations to the design of systems with the goal of ensuring that the interaction 
between people and elements of systems enhance safety, performance, and 
satisfaction (Shaver and Braun 2008). Many of the advances in ergonomics 
originated from the needs of the military during both World Wars such as having to 
train pilots to operate and fly newer combat aircraft. Over the years other industries 
have benefited by closely examining and analysing the way humans interact with 
systems including motor, power and telecommunications. The UK National Patient 
Safety Agency (NPSA) reviewed safety critical industries such as the nuclear, rail, 
underground, aviation and air traffic control and identified a set of design principles 
that could be used to identify and evaluate hazards within healthcare settings (NPSA 
2010). This report identified key human factors techniques that could support 
stakeholders involved in the planning, design and development of healthcare 
facilities, such as human error identification, hazard and operability studies and task 
analysis.  
 
Task analysis has been described as a fundamental methodology that can be used 
to both assess and reduce sources of human error (Embrey 2000). Task analysis can 
be used to eliminate preconditions that give rise to errors and to support the design 
of new or to modify existing systems. The methods used can broadly be described 
either as action based approaches or cognitive approaches. Action based 
approaches examine systems from an operational perspective, whereas cognitive 
approaches examine the mental processes behind aspects to behaviour such as 
decision making and problem solving (Embrey 2000). Hierarchical task analysis is a 
systemic way of describing how work is organised and involves a top-down approach 
to identify the goal of a task and the various sub-tasks that need to be carried out in 
order for the goal to be achieved (Embrey 2000). This approach has been used for a 
range of applications such as interface design and evaluation, job aid design, 
workload assessment and error prediction (Stanton 2006). Cognitive task analysis 
yields information about the knowledge thought processes that impact on observable 
task performance (Chipman et al 2000).  In addition cognitive task analysis focuses 
on describing the cognitive elements around decision making and judgements 
required in completing tasks such as situation assessment strategies and identifying 
critical cues and perceptual distinctions (Militello and Hutton 1998).  





Hierarchical task analysis provides a method of examining work by describing human 
activity in the context of understanding the purpose of work in terms of the 
organisations and systems in which it is being carried out (Shepherd 2001).  In 
hierarchical task analysis individual tasks are represented in terms of hierarchies of 
goals and sub-goals based on the concept of plans to show when a sub-goal is to be 
conducted and can be represented either diagrammatically or in a tabular format.  
 
Despite the huge potential of CDSS, Delaney et al (1999) attributed difficulties in 
uptake was largely due to the inability to examine the needs of practitioners more 
closely. Coiera et al (2006) reported that the effectiveness of CDSS should not be 
have been judged on performance but a better understanding of cognitive and socio-
technical interaction in its design. In terms of electronic prescribing, the need to 
present complex information in a straightforward and timely manner makes interface 
design critical in order to provide a balance between the completeness of data 
capture during the prescribing process and the ease of use for the end-user 
(Groundrey-Smith 2008).  
 
In the current study the 12 key informants (see chapter 3.81), all described their 
views and attitudes to a proposed CDSS to support the use of specialist drugs within 
general practice. The key informants all identified both enablers and barriers to the 
concept. Key enablers described included data quality and functionality (9), joint 
development and implementation (8), for the CDSS to have an active alerting 
functionality within an electronic patient record (6) and to make use of existing 
systems and frameworks (5). Key barriers described included addressing the needs 
of end users (6), security and regulation (5). Six of the key informants identified a key 
barrier to implementation as addressing the needs of the end user; in this case GPs. 
 
In a literature review of CDSS and prescribing, Horskey et al (2012) focussed on 
identifying best practices for clinical interventions and described poor usability as one 
of the primary barriers to the adoption of CDSS and a deterrent to routine use. In 
addition the authors identified a range of design recommendations and 
characteristics for CDSS in supporting electronic prescribing. These included the 
active or passive functionality, display features, filtering of frequent interruption and 
prompting for continuous maintenance of the electronic patient record.   
 
 





4.1.1 Error analysis techniques 
Lane et al (2006) reported on the use of hierarchical task analysis to model the drug 
administration process within a UK hospital. The tasks presented were subdivided 
into additional levels of component tasks that identified a detailed description of how 
drugs were being administered to patients. In addition the authors applied an error 
analysis technique based on the systematic human error reduction and prediction 
approach (SHERPA). This technique identifies and classifies errors that can occur 
and at which points during each task at which they may occur. Based on the output 
of the SHERPA analysis the authors were able to suggest design solutions to 
mitigate the errors in the drug administration process. A wide range of predictive 
error analysis techniques have been developed by different individuals from within 
different industries. However most of these are commercial in origin not subjected to 
formal validation and are rarely published in the academic literature (Lyons et al 
2004). In an early evaluation Kirwan (1992) compared SHERPA with eleven other 
error analysis techniques based on a number of criteria including accuracy, 
comprehensiveness, usefulness and the ability to see if the incidents predicted by 
each model matched those that had actually occurred. The author reported that 
SHERPA was the most highly rated by expert users. In a later revised wider 
evaluation of 38 techniques, Kirwan (1998) suggested that no single technique was 
optimal based on all of the qualitative criteria used. In addition the author described 
that few techniques were highly structured thus only aiding the assessor rather than 
being fully prescriptive. Whilst healthcare has increased the awareness of 
retrospective safety assessment techniques, such as root cause analysis, adoption of 
predictive safety assessment techniques has been slow due to the lack of support in 
technique choice and practical knowledge in the published literature (Lyons 2009). 
 
Examples from the UK within healthcare settings where a predictive model such as 
SHERPA has been used or adapted include the use of anaesthesia (Phipps et al 
2008) and during endoscopic surgery (Joice et al 1998). Phipps et al (2008) reported 
on the results from a hierarchical task analysis from the start of a preoperative visit to 
the postoperative handover of patients to recovery staff. This identified the type of 
behaviours involved according to the phase of anaesthesia. The SHERPA analysis 
used in this study identified that errors during preoperative planning and 
perioperative maintenance could have been avoided by the use of measures to 
support information handling and decision making. 





In addition errors during machine checking, induction and emergence could have 
been be reduced by streamlining or automating task steps, or by making changes to 
the physical design of the work environment. In an observational study of 
laparoscopic cholecystectomy, Joice et al (1998) described how an error analysis 
model adapted from the SHERPA model was used to identify aspects of the design 
and use of instruments and surgical training. In addition the study identified the 
differences between tasks performed that required further evaluation in order to 
identify performance related factors and so reduce error rates.  
 
4.1.2 Activity diagrams 
Activity diagrams display a sequence of actions including alternative paths that can 
be followed. These are often organised as swim lanes in order to identify who or what 
is responsible for a specific task or activity (Benson 2010). Activity diagrams have 
been used to model aspects of prescribing and clinician workload. In order to 
facilitate the implementation of electronic prescribing systems Johnson and Fitzhenry 
(2006) described the development of activity diagrams to model workflow patterns 
involved in prescription writing both during and outside of patient clinics within 
primary care settings in the USA. Bell et al (2004) identified distinct functionalities in 
relation to electronic prescribing systems available in the USA. A functional model of 
medication management based around the major activities of prescribing, 
transmitting prescriptions, dispensing, administering medication and monitoring the 
effects was subsequently developed.  
 
4.2 Aims and objectives 
The results from the key informant interviews in the current study identified key 
operational functions and characteristics of a potential CDSS to support the 
prescribing and use of immunosuppressant drugs to include enablers and barriers to 
implementation. However in order to support the operational design of a CDSS a 
closer understanding of the way GPs actually worked and used computers was 
identified as a specific aspect that required further examination. One method of 
supporting this process further was by observing and detailing the way GPs interact 
with computers and computing software. Task analysis can be used to eliminate 
some of the preconditions that can give rise to errors and to support the design of 
new or modification of existing systems.  
 
 





The aim of this study to identify an operating model for a potential CDSS to support 
GPs in the use of specialist drugs in order to ensure high level safety and quality in 
prescribing, with following objectives:   
 
 To determine the actual level and use of computers and software 
applications including CDSS at the point of prescribing both during and 
outside of patient consultations by GPs 
 To identify potential weakness or failings in existing systems that could be 
identified and be used in the development of a CDSS to support the use of 
specialist drugs.  
 
4.3 Methods 
The purpose of this study was to identify the way GPs actually utilise computers 
including CDSS both during and outside of patient consultation, and to assess risks 
and weaknesses in current systems. Hierarchical task analysis was chosen as the 
method because it specifically identifies observable actions to include any functional 
requirements. This is unlike cognitive task analysis where techniques attempt to 
address underlying mental processes that can give rise to errors which is particularly 
important in areas such diagnosis or problem solving (Embrey 2000). Data from the 
interviews and observations was initially used to develop an activity diagram that 
represented the way the GPs conducted their work and used their computers both 
during and outside of patient consultation. A hierarchical task analysis was 
completed specifically on the process of how GPs currently prescribed specialist 
drugs. An error analysis based on SHERPA was then applied to the steps involved in 
prescribing specialist drugs.  
 
4.3.1 Interview schedule  
An interview schedule was prepared by the research team to include specific pre-
determined questions in order to collate information about the individual GP, such as 
experience, specialities and knowledge and use of CDSS (see Appendix 4.1). 
Further questions were in relation to computer use including CDSS both during and 
outside of patient consultation. The interview schedule was used as a topic guide and 
emerging themes were used to formulate further questions during each interview and 
observations. Each GP was asked to demonstrate how the computer and any 
additional software including CDSS were used either during or outside consultation to 
include prescribing medication. 





Case scenarios were discussed with each GP to include where patients either 
presented with or hospitals requested prescriptions for immunosuppressant drugs. In 
addition these scenarios were discussed where shared care protocols were not 
available to the GP. These case scenarios were developed from results of the 
interviews with the 12 key informants (see chapter 3). Written notes were taken 
throughout each interview including relevant observations. These were all later 
checked by the researcher for accuracy.     
 
4.3.2 Selection criteria 
In total nine GPs were purposively selected, with two having participated in the key 
informant interviews (GP1 and GP2). A third GP (GP3) was involved in the piloting 
phase of the key informant interviews. Each GP was sent a participant information 
leaflet (Appendix 4.2), a consent form (Appendix 4.3). Interviews were arranged and 
conducted within each of the GPs’ consultation rooms. Three GPs were each 
selected on the basis that they were each users of the three major GP clinical system 
suppliers in the UK EMIS, Vision and SystmOne. A development within this field of 
primary care that was identified during the key informant interviews (see chapter 3) 
was the national drive for GP clinical system suppliers to move over to so-called 
hosted systems. Benefits from the use of hosted systems include data recovery, 
system management, technical support, integration with other sites and access for 
NHS staff working from multiple locations (Barr 2008). SystmOne is a provider of a 
single hosted system whilst EMIS provides existing traditional GP site based systems 
(EMIS LV, hosted systems EMIS PCS and EMIS Web). Vision currently provides only 
a GP site based system. All of the GPs that were approached agreed to participate in 
the study.       
 
4.4 Ethical Approval 
A modification for ethical approval for the key informant interviews (Reference 
BDM/11/12-82) for this study was granted by Kings College London Biomedical 
Sciences, Dentistry, Medicine and Natural & Mathematical Sciences Research Ethics 












In total 9 GPs participated in this observational study and a summary of their 
demographic profile is shown in Table 4.1. Each interview lasted no longer than 40 
minutes. Six of the GPs were partners at the practices they worked at whilst three 
were salaried GPs. The GPs qualified between 2001 and 2013. All of the GPs 
described themselves as having either a medium or high IT aptitude both in general 
and in the use of the GP clinical system within their practice. The GPs all described 
having additional interests and specialities. In addition one GP explained they worked 
at a practice accredited as being suitable for the training of doctors to become GPs.  





Table 4.1 Demographic characteristics of participating GPs 
Demographic characteristics GP1 GP2 GP3 GP4 GP5 GP6 GP7 GP8 GP9 
Number of years qualified          
< 5 years          
5 – 10 years          
>10 years          
Employment Status          
Salaried GP          
Partner          
Specialty           
Mental Health          
Musculoskeletal          
Diabetes          
Minor surgery          
Paediatrics          
Obstetrics          
Cardiology          
Internal medicine          
Occupational Health          
Anticoagulation          
 





Table 4.1 Demographic characteristics of participating GPs cont. 
Demographic characteristics 
cont. 
GP1 GP2 GP3 GP4 GP5 GP6 GP7 GP8 GP9 
GP Clinical System Used          
SystmOne          
Vision          
EMIS Web          
EMIS LV          
Reported aptitude towards IT          
High           
Medium           
Low          
Reported aptitude towards use of 
GP clinical system 
         
High          
Medium           
Low          
 
 





4.5.1 Consultation rooms 
The GPs all worked in spacious rooms which were well-equipped and all had a desk 
and sat facing their desktop computer terminals. Printers linked to each computer 
terminal were also based on each desk. Both GP2 and GP5 had two monitors linked 
to their desktop computers that sat next to each other which allowed them to view the 
GP clinical system on one screen and other documents and software applications on 
the other screen at the same time. GP2 described aspects to a local IT project that 
provided funding to allow the installation of additional monitors. In addition the layout 
in all of the consultation rooms allowed patients to sit to the side of each GP and 
were able to view the computer screen.  
 
4.5.2 Use of GP computers  
All of the tasks undertaken by the GPs both during and outside patient consultation 
and the extent to which the computer and additional software applications were 
utilised were used to prepare an activity diagram which is shown in Figure 4.1. The 
initial activities undertaken by all of the GPs highlighted steps taken to reach the 
central patients’ electronic health record (EHR) provided by each of the GP clinical 
system providers. After switching on their computers access to each of the GP 
clinical systems was from each desktop terminal by clicking on an icon and then 
using a user name and password. This process was simple in terms of time and ease 
of use for the GPs. Although for the Vision clinical system a greater number of steps 
were required as three separate logins were needed, two for Vision itself and one for 
Docman, an electronic database that managed scanned letters and communications.  
 
All of the GPs used their computers throughout their working day for a wide range of 
both clinical and administrative tasks. In addition all of the GPs used NHS smartcards 
which allowed access to the NHS central care record (CRS). The actual level of use 
of GP practice computers including the GP clinical systems and additional 


















Patient consultation generally 
restricted to 10 minutes, minimal 
use of computer  
Actions include referral, 
pathology requests, advice, 
prescribing but all require 
recording (read coding / 
templates) 
 
Problems: Time constraints e.g. 
to add read codes, completing 
recording templates.  
Other Activities  
Review of paper hospital 
communications (out-patient 
appointments, discharge letters, 
discharge summaries, out-patient 
prescriptions) 
 
Review of other patient specific 
correspondence (letters) 
 
Review of pathology results received via 
lab-links  
 
Clinical audit, patient searches, GMS 
contract management  
 
Signing repeat prescriptions generated 
by staff 
 
These activities may result in patient 
specific actions that require recording of 
relevant details (read coding / 
templates|) or in some cases generating 
prescriptions. 
 
GP Clinical System Main Page 
 Electronic Health Record (EHR) 
Enter login and passwords (depending 
on GP clinical system) 
GP selects clinical system, double click 
using the mouse and then inserts a 
“NHS Smart Card.” 
GP switches computer on and logs in to 
mainframe   
 
Enter patient specific EHR via 
appointment list or by searching 
by following prompts e.g. by 
surname, date of birth. 
 
Problems: Time constraints, if 
possible prior to seeing the 
patient the GP can view the 




Routine booked appointment / 
emergency appointment with 
patient. 





CCG extranet:  








to GP practice 








Patient attends GP practice 
Figure 4.1 Activity diagram representing GPs’ use of computers both during and outside of 
patient consultation. 
 






GP1, GP2 and GP3 all described the available functionalities of SystmOne as 
considerable with many different applications or features. Some of the positive 
aspects to the system included speed, ease of use, and the ability to quickly navigate 
between the various functions. However GP1 described the layout of the screen and 
the use of icons to display the array of functionalities as excessive. GP2 found some 
of the functionality around drug information and pricing particularly at the point of 
prescribing not as good as other GP clinical systems.  SystmOne is a window - 
based hosted system and allows a level of external sharing and access to the clinical 
system and patient’s health record. Once authorised users can access any patient 
held information from any GP practice where the clinical system is installed.   
 
4.5.2.2 EMIS 
GP4, GP5 and GP6 were all positive towards their experiences and use of the EMIS 
GP clinical system. GP4 was a user of EMIS LV, an older disk operated system 
(DOS) whilst GP5 and GP6 were users of EMIS Web, a window - based system. The 
layouts of each of the systems were completely different with users of EMIS LV 
mainly reliant on the keyboard to complete tasks. All of the GPs found EMIS quick 
and easy to use and found locating information a simple task. EMIS Web is a hosted 
GP clinical system and allows a certain level of external sharing and access to other 
users.  
 
4.5.2.3 Vision  
GP7, GP8 and GP9 described mixed experiences of using the window - based Vision 
GP clinical system. GP7 and GP9 found aspects of the system slow and the level of 
available functionality excessive. In addition both GP7 and GP9 described the level 
of training they received on Vision as inadequate. GP8 was extremely positive 
towards all aspects of the system and was a regular user of many of the available 
functions.   
 
4.5.3 Patient consultations 
The GPs described varying levels of use of their computers either prior to or during 
each patient consultation. Prior to a consultation use was dependent on time and 
knowledge of the individual patient. Appointment slots would indicate to the GP which 
patients were due to be seen each day. All of the GPs described the pressures of 
time constraints in relation to patient appointments and consultations.  





Time permitting key areas of the patient’s EHR that were checked were from 
attendance during recent consultations, previous recorded clinical problems or 
diagnosis, medication records, investigations and any hospital communications. 
During patient consultation nearly all of GPs tended to leave any use of GP clinical 
system towards the end of the consultation in order to record relevant details and or 
complete any tasks such as issuing a prescription. GP2 described that there was no 
time to even look at the computer screen during consultation whilst GP6 was definite 
that any use had to be reserved to the end of the consultation so that time was solely 
allocated directly to the patient. GP1, GP4 and GP8 all described being able to use 
their computers broadly to the same level both during and outside a patient 
consultation.  
 
4.5.4 Recording templates and read coding  
During patient consultations the ability of the GPs to utilise many of the electronic 
functions available was limited primarily due to time constraints. All of the GPs 
described the ability to record each consultation using a consultation recording 
template however only GP4, GP5, GP8 and GP9 actually used this functionality 
routinely. The other GPs all tended to record relevant aspects of each consultation 
using free text. Although other recording templates were available to support disease 
management these tended to be reserved where specific clinics such as in asthma or 
diabetes. Read coding was also described as problematic during consultations due to 
time constraints. In addition the GPs also described dissatisfaction with the level and 
accuracy of read coding performed by other users of the clinical systems within each 
of the GP practices.   
 
4.5.5 Prescribing 
All of the GPs described the process of issuing prescriptions for medication during 
consultations as one-off “acute prescriptions” for acute clinical indications with the 
patient present. For patients with long term conditions where regular medication was 
required, prescriptions would be initially generated by the GP on a “repeat” basis. 
Once authorised further repeat prescriptions were generated by practice staff at 
regular intervals for the GP to check and sign without the patient being present. The 
GPs all described prescribing as a quick and simple process in terms of generating 
both “acute” and “repeat prescriptions” and all demonstrated the prescribing 
workflow.  





With the window-based systems (SystmOne, EMIS Web and Vision) a pop up 
template that guided the end user through the prescribing workflow was accessed by 
clicking on either an acute or repeat prescribing icon. Key features that required 
completion were the drug name, formulation, dose, quantity, and prescription type. A 
number of fields required completion either from drop down menus or manual entry 
and selection. The repeat prescribing templates differed slightly with additional fields 
around medication management systems such as numbers of issues permitted and 
when re-authorisation was needed. The prescribing workflow within EMIS LV was 
simpler in terms of visual appearance, data entry and overall completion. In addition 
the GPs who used SystmOne were able to prescribe from an installed prescribing 
formulary that had been approved for use within the local CCG.   
 
All of the GPs described the availability of both active and passive CDSS within each 
of the GP clinical systems. Some of the passive CDSS alerts were available as 
integrated icons and directly visible or electronically available through links. However 
overall use during consultations of CDSS was generally limited to prescribing and 
active alerts linked to warnings such as drug interactions and safety messages. In 
general the decision making around how to treat the presenting condition during 
consultations was GP led and built around the patient rather than referring to the GP 
clinical system or any other additional software applications. Once a decision was 
made to prescribe, in the majority of cases the prescription was issued and although 
CDSS was clearly available during the prescribing workflow most of the active alerts 
generated were ignored. However all of the GPs described the availability of Script-
Switch® and found this a useful resource at the point of prescribing. Drug specific 
information was available during prescribing workflow and could be accessed easily 
from within all of the window - based systems. The GPs who used SystmOne found 
drug pricing information difficult to obtain due to the number of additional steps 
required, particularly within the prescribing workflow.  
 
4.5.6 Referrals  
During consultations all the GPs described being able to refer patients using template 
letters that could be accessed from within each of the GP clinical systems. Electronic 
referrals were made using the national electronic system Choose and Book and were 
sent to a local referral facilitation service for checking and processing. The system 
allowed patients a choice of either NHS or private hospital out-patient appointments 
and was simple to access and use on all the GP clinical systems.  





In addition GP5 and GP6 described the use of an electronic pathology system that 
the practice had recently introduced. The system allowed an electronic blood form to 
be printed and given to patients. This form was also sent automatically to the local 
pathology provider in advance of the patient presenting at the clinic.   
 
4.5.7 Computer use outside of consultation 
The GPs described their individual workload in relation to their clinical roles and the 
need to complete a specific level of administrative tasks each day.  Time was 
generally set aside for each of the GPs to work on these areas at the end of surgery. 
These tasks included checking pathology results received electronically via lab links, 
dealing with letters and communications from hospitals e.g. discharge letters, out-
patient prescriptions and results of investigations. These activities were generally 
conducted within the patient’s EHR, as actions would often require recording and or 
follow up with patients. Paper letters were left for practice staff to scan and record 
into the patient’s EHR. Some activities however required the additional use of 
computerised functionalities outside of the GP clinical system. The GPs described 
using a number of resources such as NHS mail, the internet, Microsoft applications 
and the local CCG extranet. All of the GPs found time to use a range of passive 
CDSS to provide information on specific drugs or diseases, including patient 
information leaflets either from within the GP clinical system, externally from desktop 
icons or by using the internet.  
 
4.5.8 GMS contract and locally commissioned services 
The GPs described varied levels of activities linked to attainment of QOF points and 
performance against enhanced services within the GMS contract. In addition other 
tasks carried out related to additional locally commissioned services. All of the GP 
clinical systems provided on-going data management and reporting facilities to 
provide practice performance in relation to QOF. The alerts provided by QMAS within 
each GP clinical system appeared as on-screen reminders with the patients’ EHR 
highlighting the need for specific interventions. Only GP5 and GP8 described being 
able to process these reminders during the consultation, otherwise these tasks were 
left to be completed opportunistically. GP8 in particular described being an active 
user of this aspect of Vision to support additional work such as clinical audit and 
reporting. Both GP4 and GP8 worked at practices that offered local anticoagulation 
management under an enhanced service and were users of INRstar®.  
 





4.6 Case Scenario: Requests to prescribe specialist drugs 
The GPs described a range of tasks they would undertake in order to reach a 
decision as to whether to agree to requests to prescribe specialist drugs. These tasks 
were used to prepare an activity diagram shown in Figure 4.2. All of these tasks were 
affected by a number of factors such as the availability of relevant information, time 
constraints particularly within patient consultations and patient expectations. The 
GPs described similar approaches to the decision making process in agreeing to 
prescribe a specialist drug. Although there was a general awareness of local traffic 
light lists, this information was not easily available either within the GP clinical system 
or at the practice itself. Having to physically make enquires and locate information 
regarding traffic light lists or shared care protocols particularly during consultations 
was time consuming. GP1, GP3 and GP4 would specifically look for the local CCG 
traffic light list at the outset to check if the drug was a hospital only drug. GP1 
described checking the availability of the traffic light list from the CCG extranet whilst 
GP3 and GP4 would contact the CCG pharmaceutical adviser. 
 
In the absence of a shared care protocol all of the GPs described trying to gather 
drug specific information from a range of sources such as the BNF (paper and 
electronic), drug information portals from either within the GP clinical systems e.g. 
EMIS mentor or external websites accessed from the internet. In addition the GPs 
described difficulties in having to contact consultants in hospitals either by letter, fax 
or telephone. All of the GPs described having to make contact with the CCG 
pharmaceutical adviser for advice either by telephoning or sending an e-mail. Other 
options described were the use of the internet or known websites e.g. CKS to obtain 
either clinical aspects of shared care protocols such as monitoring or examples of 
shared care protocols from other hospitals. In addition any shared care protocol 
located still needed to be checked to determine if it was valid. An additional problem 
cited was the time required to document all of the additional tasks within the patients’ 
EHR. The GPs all described the need to involve and inform patients at all times and 
in many cases patients’ expectations were a key factor in the overall decision 
making. A specific point made by GP3 was that often in such scenarios the overall 
process and decision making was based on previous experiences and memory 
rather than any clear direction or steps to take including either any written procedures 
or computerised functionality within the GP clinical system.  
 
 









































Figure 4.2 Activity diagram representing tasks involved in GPs’ decision making in managing 





Drug selection: drug name, dose, quantity, treatment 
duration  
 
Use mouse and or keyboard to enter text or to select from 
the drop down menus or fields 
 
CDSS: Active and Passive  
 
Repeat Prescribing Management Fields: Number of 
authorised repeats, review date, batch repeats 
Internal to the patients’ 
EHR 
 
CDSS (Active): Allergies, 




CDSS (Passive): Prompts, 
icons (e.g. EMIS Mentor) 
Pathology results, other 
biochemical or physical 
markers 
Hospital communications  
External to the patients’ 
EHR 
 
CDSS (passive) e.g. clinical 
guidelines, Patient.co.uk 
Use of the internet 
Books, journals, paper notes  
Specialist Drugs: Key 
Issues for GP  
 
Is this a hospital only drug or 
a drug that can be 
prescribed under a shared 
care protocol?  
 
Checking the local CCG 
traffic light list 
 
Locating the shared care 
protocol  
 
Clinical responsibility and 
agreeing to prescribe the 
specialist drug: YES or NO  
 
Locating a shared care protocol  
 May be available as a scanned document within the 
patient EHR; how is it located, is it easy to 
navigate the GP clinical system? 
 May be available electronically via a web-based 
resource (e.g. CCG extranet); how is it located; 
external to the patient EHR 
 If unable to locate to contact hospital (e.g. via 
telephone or by letter) 
 If unable to locate contact the CCG pharmaceutical 
adviser (e.g. via telephone or e-mail) 
 Discuss with GP colleagues  e.g. clinical meetings 
 Identifying drug specific monitoring and prescribing 
advice (passive CDSS e.g. CKS) 
 Contact community pharmacist for advice 
 Consider other actions to include adding manual 
alerts to warn clinicians regarding the need for a 
shared care protocol or specific criteria e.g. blood 
tests, drug interactions 
 Patient recall, limit prescription quantity 
 Consider the above in relation to opportunities 






GP agrees to prescribe the 
specialist drug either as acute or 
repeat prescription. If GP does NOT 
agree inform patient 
 
GP 
GP issues prescription and to record any additional 
relevant details in patient’s EHR 
 





4.6.1 Prescribing specialist drugs 
The GPs described limited functionalities within each of the GP clinical systems to 
support in the on-going prescribing of specialist drugs.  All of the GPs described 
being able to add simple alerts or reminders to patient’s electronic health records to 
highlight that the patient was being treated with a specialist drug or that a shared 
care protocol needed to be followed. Additional tasks described were restricting 
prescription quantities of the specialist drug and or creating tasks such as recall in 
order to ensure patients attended the practice on a regular basis. GP8 described that 
in such cases these patients would always be discussed at practice clinical meetings 
to ensure all of the other GPs and staff were aware of any specific issues such as 
regular therapeutic monitoring. Where shared care protocols were available all of the 
GPs reported that they would be scanned and added to a patient’s EHR. However an 
additional problem described was that the GPs relied on administrative staff for 
scanning letters and communications. Although the GPs described using each GP 
clinical system as quick and simple, locating a shared care protocol was not 
straightforward as scanned letters were filed by speciality so a number of documents 
needed to be checked before the shared care protocol was found. 
 
4.7 Hierarchical task analysis   
The GPs described various actions to the case scenarios presented, with the central 
aim of deciding whether or not to accept clinical responsibility for prescribing a 
specialist drug. The Hierarchical task analysis conducted was only applied to the 
physical task of prescribing specialist drugs and this is shown in Table 4.2. 
Essentially the overall task was simplistic with the goal being to prescribe the 
specialist drug. In addition key sub-tasks were identified. Firstly there needed to be a 
check to ensure if the specialist drug was not a hospital only drug In such  cases the 
request to prescribe would be Declined. Secondly there was a check to assess if the 
specialist drug were prescribed by a GP whether or not a shared care protocol was 
required. These checks were made by referring to a traffic light classification of 










Table 4.2 Hierarchical task analysis of the prescribing of specialist drugs by 
GPs  
Prescribing a specialist drug 
Plan 0: Either during or outside a patient consultation the GP needs to consider a 
request to prescribe a specialist drug. Do 1.1 to 1.4 
 
1.1 To check the traffic light list and see if the specialist drug is a “hospital only 
drug.” If “Yes” the GP should NOT prescribe, and should refer back to the 
hospital clinic. If “No” go to 1.2  
1.2 To check the traffic light list and see if the specialist drug can be prescribed under 
a shared care protocol. If “Yes” go to 1.3.   
1.3 GP to locate the shared care protocol. 
1.4 GP reads the shared care protocol and agrees to accept clinical responsibility for 
prescribing the specialist drug 
1.5 GP reads the shared care protocol and declines to accept clinical responsibility 




4.7.1 SHERPA error analysis  
The SHERPA error analysis model categories potential error types as either action 
error, checking error, retrieval error, communication error or selection error. Each 
error type can be further categorised as an error mode and specifically coded. These 
are described in Table 4.3. The application of SHERPA error analysis to the 
prescribing of specialist drugs by GPs is shown in Table 4.4. The SHERPA error 
analysis takes each task identified from the HTA and then categorises the error type, 
consequence, recovery, probability of occurrence (P) and remedial action or design 
solution. The probability of occurrence was described as high (H), medium (M) or low 
(L). The SHERPA error analysis demonstrated that although the specific task of 
prescribing was relatively simple in terms of the number of steps required to 
complete this task, the potential for error was considerable. 
 
Under the description column the potential error that could occur was referenced 
against those specific GPs that referred to or described completing this specific task. 
Other potential errors came to light during that analysis, but were not described by 
any other GPs. 
 
 





Table 4.3 SHERPA error modes 
 
Error Type Code Error mode 
 
Action errors A1 Operation too long/short  
 
 A2 Operation mistimed  
 
 A3 Operation in wrong direction 
  
 A4 Operation too little/much 
  
 A5 Misalign 
  
 A6 Right operation on wrong object  
 
 A7 Wrong operation on right object  
 
 A8 Operation omitted  
 
 A9 Operation incomplete  
 
 A10 Wrong operation on wrong object 
 
Checking errors C1 Check omitted  
 
 C2 Check incomplete  
 
 C3 Right check on wrong object  
 
 C4 Wrong check on right object  
 
 C5 Check mistimed  
 
 C6 Wrong check on wrong object  
 
Retrieval errors R1 Information not obtained  
 
 R2 Wrong information obtained  
 
 R3 Information retrieval incomplete  
 
Communication errors I1 Information not communicated  
 
 I2 Wrong information communicated  
 
 I3 Information communication incomplete  
 
Selection errors S1 Selection omitted  
 
 S2 Wrong selection made 
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Table 4.4 Application of SHERPA to the prescribing of specialist drugs by GPs 
Task step  Error 
mode 
Description Consequence Recovery P Remedial strategy / design solution 
1.1 To check if the 
specialist drug is a 
“hospital drug.” 
C1 Failure by GP to check 
the traffic light list (GP1, 
GP3, GP4, GP7) 
A hospital only 
specialist drug is 






M Add / highlight to the patients’ EHR e.g. 
screen alert or manual reminder 
 
Design Solution: The GP clinical 
system to automatically alert the GP 
that this is a hospital only drug, not to 
prescribe and to refer back to the 
hospital i.e. a hard stop  
 
Community pharmacist informs GP that a 
hospital only drug has been prescribed. 
 
Design Solution: The pharmacy 
computer system to automatically alert 
the pharmacist that this is a hospital 
only drug and not to be issued in 
primary care and to refer back to the GP 
 
 R1 Traffic light list is not 
available at the practice 
(paper list) (GP1) 
A hospital only 
specialist drug is 






H Add / highlight to the patients’ EHR e.g. 
screen alert or manual reminder.  
 
Practice to ensure paper list is available to 
all GPs including locums 
 R1 Traffic  light list  is 
available at the practice 
(paper list), but is out of 
date 
A hospital only 
specialist drug is 






L Add / highlight to the patients’ EHR e.g. 
screen alert or manual reminder.  
 
Practice to ensure updated / current paper 
list is available to all GPs including locums 
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Table 4.4 Application of SHERPA to the prescribing of specialist drugs by GPs (cont.) 
Task step  Error 
mode 
Description Consequence Recovery P Remedial strategy / design solution 
 R1 Traffic light list is 
available at the practice 
(via local extranet) but 
lack of GP awareness 
(GP1)  
A hospital only 
specialist drug is 







H Add / highlight to the patients’ EHR e.g. 
screen alert or manual reminder 
 R1 Traffic  light list is 
available at the practice 
(via local extranet) but 
lack of GP access rights 
(GP1) 
A hospital only 
specialist drug is 






H To make a link available to local extranet 
web-page. Practice to ensure all GPs and 
locums have a user name and password 
 
1.2 To check if a 
shared care protocol 
is required to 
support the 
prescribing of a 
specialist drug 
C1  Failure by GP to check 
the traffic light list (GP1, 
GP3,GP7) 
A specialist drug 
may be prescribed 
without reference 






M Add / highlight to the patients’ EHR e.g. 
screen alert or manual reminder that a 
shared care protocol is required  
 
 
 R1 Traffic  light list  is not 
available at the practice 
(paper list) 
A specialist drug 
may be prescribed 
without reference 






H Add / highlight to the patients’ EHR e.g. 
screen alert or manual reminder. Practice 
to ensure paper list  is available to all GPs 
including locums 
 R1 Traffic  light list  is 
available at the practice 
(paper list), but is out of 
date 
A specialist drug 
may be prescribed 
without reference 







L Add / highlight to the patients’ EHR e.g. 
screen alert or manual reminder  
 
Practice to ensure updated / current paper 
list  is available to all GPs including locums 
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Table 4.4 Application of SHERPA to the prescribing of specialist drugs by GPs (cont.) 
Task step  Error 
mode 
Description Consequence Recovery P Remedial strategy / design solution 
 R1 Traffic  light list is 
available at the practice 
(via local extranet) but 
lack of GP awareness 
(GP1, GP8) 
A specialist drug 
may be prescribed 
without reference 






H Add / highlight to the patients’ EHR e.g. 
screen alert or manual reminder 
 
 
 R1 Traffic  light list is 
available at the practice 
(via local extranet) but 
lack of GP access rights 
(GP1, GP8) 
A specialist drug 
may be prescribed 
without reference 






H To make link available to local extranet 
web-page  
 
Practice to ensure all GPs and locums 
have a user name and password 
 
1.3 To locate the 
shared care protocol 
to support the GP in 
prescribing the 
specialist drug. 
R1 Shared care protocol not 
available to GP (paper 
copy) as not sent by 
hospital clinic.  
 
GP unable to contact 
clinic and or receive 
shared care protocol 
(time constraints) 
(GP1,GP2, GP6, GP7) 
A specialist drug 
may be prescribed 
without reference 






H Add / highlight to the patients’ EHR e.g. 
screen alert or manual reminder 
 
Ensure hospitals send copies of shared 
care protocols to GPs (Action for 
Medicines Management Teams) 
 
 R1 Shared care protocol not 
available to GP (paper 
copy) as filed in patient’s 
paper notes and NOT 




A specialist drug 
may be prescribed 
without reference 






L Ensure paper copy of shared care protocol 
is scanned into patients’ EHR (for practice 
staff). Need to highlight in practice policy in 
handling communications from hospitals 
i.e. scanning in appropriately.  
 
Add / highlight to the patients’ EHR e.g. 
screen alert or manual reminder 
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Table 4.4 Application of SHERPA to the prescribing of specialist drugs by GPs (cont.)  
Task step  Error 
mode 
Description Consequence Recovery P Remedial strategy / design solution 
 R1 Shared care protocol has 
been scanned into 
patients’  EHR, but not 
easily available or difficult 
to locate (i.e. difficulty in 
navigating the clinical 
system) 
A specialist drug 
may be prescribed 
without reference 








M Design solution: The GP clinical system 
to make the protocol easily available 
and or identifiable within the patient’s 
EHR 
 
Training for GP on the use of the clinical 
system 
 R1 Shared care protocol is 
not available via the local 
extranet (GP6, GP8) 
A specialist drug 
may be prescribed 
without reference 






H To ensure that the shared care protocol is 




 R1 Shared care protocol is 
available on local 
extranet but  lack of GP 
awareness  
A specialist drug 
may be prescribed 
without reference 






H Add / highlight to the patients’ EHR e.g. 
screen alert or manual reminder 
 R1 Shared care protocol is 
available via local 
extranet but lack of GP 
access rights 
A specialist drug 
may be prescribed 
without reference 






H To make a link available to local extranet 
web-page (will need user name and 
password).  
Practice to ensure all GPs and locums 
have a user name and password 
 R1 Shared care protocol is 
available via local 
extranet but out of date 
A specialist drug 
may be prescribed 
without reference 







L To ensure that the current shared care 
protocol is available on local extranet 
(Medicines Management Team) 
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Table 4.4 Application of SHERPA to the prescribing of specialist drugs by GPs (cont.) 
Task step  Error 
mode 
Description Consequence Recovery P Remedial strategy / design solution 
 R1 Lack of GP awareness of 
availability of shared care 
protocols from other 
external web based NHS 
resources (GP1, GP2) 
A specialist drug 
may be prescribed 
without reference 






M Add / highlight to the patients’ EHR e.g. 
screen alert or manual reminder – with 
names of external web based NHS 
resources 
 R1 Lack of GP awareness of 
prescribing support from 
other electronic or 
manual resources (drug 
specific e.g. drug 
interactions, monitoring) 
(GP1, GP3, GP9)  
A specialist drug 
may be prescribed 
without reference 









request  for 
prescription 
(1.3) 
H Add / highlight to the patients’ EHR e.g. 
screen alert or manual reminder for checks 
to be made before next prescription due 
date  
 R1 GP unaware of local  
CCG pharmaceutical 
adviser contact details 
(GP1, GP2, GP3, GP4, 
GP5, GP8, GP9) 
A specialist drug 
may be prescribed 
without reference 









request  for 
prescription 
(1.3) 
M Details of local CCG pharmaceutical 
adviser to be made available either at the 
GP practice and or within the GP clinical 
system 
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4.7.2 Remedial Strategies and design solutions 
It was clear that the underlying problem that the GPs faced was dealing with a paper 
based communication system used by secondary care. The risk of prescribing 
specialist drugs in an unsafe manner was increased because of the lack of available 
functionality within all of the GP clinical systems and time constraints. In order to 
resolve these issues all the GPs required time. In addition some GPs relied on other 
staff to provide advice and information. In many cases the next opportunity to resolve 
such problems was when a further prescription was requested by the patient.  
 
The predominant theme that emerged from the SHERPA error analysis was the 
almost complete application of the error mode R1 to each task because information 
required by the GP was not readily available. The potential adverse outcome was 
that a GP could inadvertently prescribe a specialist drug that was either classed as 
hospital only, or prescribe one without reference to an appropriate shared care 
protocol. In addition 11 out of the 20 task steps where an error could occur were 
rated as a high probability of occurrence. The fundamental problems described by 
the GPs related to the lack of awareness or availability of either the traffic light list or 
shared care protocols. In addition, where shared care protocols were required to 
support the prescribing of specialist drugs, a major obstacle was locating them in 
either a paper or electronic format. It was evident that throughout the whole process 
the currently available computerised systems, either from the GP clinical systems or 
from other software applications were unable to provide support or solutions to the 
problems described by the GPs. The easiest remedial solution to the problems 
described by the GPs was to physically add simple alerts or reminders to the 
patients’ EHR. These alerts allowed free text to be added to a pop up box that could 
inform each user of key messages in relation to the prescribing of specialist drugs, 
such as to check the shared care protocol or the need for regular blood tests. .  
 
Other interventions described were manual tasks to contact and liaise with a range of 
individuals such as GPs, practice staff, primary care pharmacists within CCG 
medicines management teams and clinical teams within secondary care. Potentially 
either GP clinical systems or community pharmacy computer systems could 
incorporate active hard stops to alert users of when hospital only drugs were being 
prescribed. However this could also be effectively incorporated within a novel 
prescribing support module i.e. an electronic management of specialist drug CDSS 
inclusive of all specialist drugs.  
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Based on the results from the previous key informant interviews, the hierarchical task 
analysis and SHERPA error analysis a potential operating model for a CDSS to 
support GPs in prescribing specialist drugs was identified. Table 4.5 describes a 
hierarchical task analysis of this proposed model to demonstrate how a GP could 
potentially safely prescribe a specialist drug in primary care.  
 
Table 4.5 Hierarchical task analysis of the prescribing of specialist drugs by 
GPs (Potential operating model supported by CDSS) 
Prescribing a specialist drug 
Plan 0: Either during or outside a patient consultation the GP needs to consider a 
request to prescribe a specialist drug. Do 1.1 to 1.9 
 
1.1 To check if the specialist drug can be prescribed in primary care by a GP 
1.2 Enter the “Management of Specialist Drugs Module” integrated within the GP 
clinical system. 
1.3 Enter the drug name, and confirm if the specialist drug is a hospital only drug or 
one that requires a shared care protocol. If hospital only follow the prompt to 
exit and inform the patient. 
1.4 If a shared care protocol is required follow the prompt to direct the GP to the 
shared care protocol section of the module. 
1.5 Module to automatically update fields for monitoring requirements within 
electronic shared care protocol from a search of patient’s EHR  
1.6 If data not available within patients’ EHR, module to automatically prompt action 
or task e.g. full blood count 
1.7 GP to decide whether to accept clinical responsibility for prescribing the specialist 
drug. If “No” exit and inform patient; if “Yes” go to 1.8. 
1.8 Once satisfactorily completed select the prompt within the module to the 
prescribing functionality, follow the prescribing workflow and issue prescription 
(consider repeat or acute prescription). 
1.9 Module to save all recorded information appropriately and with relevant read code 
within patients’ EHR on exit and automatically update the prescribing 
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4.8. Discussion  
In 2001 the Department of Health established the National Patient Safety Agency 
(NPSA) with a mandate to identify patient safety issues and find appropriate 
solutions. The NPSA has produced key guidance for health professionals in the NHS 
that has introduced both human factors techniques such as to support designing 
healthcare settings (NPSA 2010) and in applying risk assessment methods to include 
predictive safety analysis techniques such as failure mode and effect analysis 
(FMEA) and probabilistic risk assessment (NPSA 2006). Both of these reports have 
cited the wide experience of such methods and techniques from the commercial 
sector particularly critical industries.  
 
This is the first study that has applied both hierarchical task analysis and an error 
analysis model (SHERPA), to the task of prescribing specialist drugs by GPs in the 
UK. Kirwan (1998) described 38 predictive error analysis models which have been 
developed including SHERPA and FMEA. However their use within UK healthcare 
settings has remained limited and reserved to secondary care settings. The results 
from this study highlighted key areas of potential risk in the prescribing of specialist 
drugs and use of shared care protocols. A key aspect that emerged was the risk 
associated with a lack of awareness or access to either traffic light classification lists 
or shared care protocols themselves. Navigating extranet sites was described as 
difficult even for GPs who reported themselves as IT literate, compounded by time 
constraints during patient consultations. Crowe et al (2009) undertook qualitative 
interviews with stakeholders (n = 47), including 14 GPs on the factors that influenced 
GP decision making in prescribing specialist drugs. Of six diverse factors identified 
one was described as a locally agreed advisory lists (red, amber or green). Key 
drawbacks were reported with traffic light classification lists linked to GPs’ lack of 
understanding of these lists, inadequacies in dissemination and communication from 
PCTs and poor distribution at practice level. In addition a specific concern with the 
use of traffic light lists was the amber classification for specialist drugs where a 
shared care protocol did not exist, which in effect meant that these drugs would be 
treated as them red or hospital only drugs. In addition the authors reported there 
were frequent requests asking GPs to prescribe specialist drugs without a shared 
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The 9 GPs who participated in the current study used the three major GP clinical 
systems in the UK EMIS, Vision and SystmOne. The results from the HTA and 
SHERPA error analysis identified barriers in terms of managing requests to prescribe 
specialist drugs. In general the GPs worked in a similar way and the tasks carried 
associated with requests to prescribe specialist were not affected by or dependant on 
the GP clinical system used.  
 
4.9. Limitations 
GP1, GP2 and GP3 participated in the key informant interviews, although GP3 was 
only involved in an initial pilot. In addition all of the GPs worked within a single CCG, 
and were purposively selected as they known to the lead researcher and this may 
have introduced bias. In addition all of the GPs were young with the most 
experienced GP having qualified in 2001. In addition all of the GPs described 
themselves as having either good or high IT aptitude, and this may have introduced 
bias in terms of the level and use of computers, GP clinical systems and CDSS. In 
addition the HTA was only applied to the process of prescribing and was not applied 
to the patient consultation, decision making around agreeing to prescribe a specialist 
drug and the prescribing workflow itself. This would form the basis of further research 
in this area.    
 
4.10. Further work 
Only 9 GPs were recruited although they represented users of the three main GP 
clinical systems available in the UK. Therefore further work should be extended to 
include a larger sample of GPs, randomly selected and with a varied background and 
level of experience of both IT in general and use of GP clinical systems. In addition 
this sample should include sessional GPs and locums. In addition further work could 
include investigating additional aspects of GP workload and use of computers. This 
could include decision making during consultation, supporting diagnosis and 
prescribing workflow.  
 
Although HTA was chosen as the preferred research method in this study the results 
from the SHERPA error analysis identified a need to further explore the decision 
making processes followed by GPs. This would be achieved by adopting a cognitive 
approach to task analysis and should inform the process of further research in this 
area. Published evidence from the UK of the use of cognitive task analysis within 
healthcare settings is limited. 
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In an extension to a previous study Phipps et al (2011) explored some of the 
cognitive aspects in relation to the planning and delivery of anaesthesia by applying 
two alternative extensions to the standard hierarchical task analysis. The authors 
described the value of generating insights in the way anaesthetists handled 
information and their own cognitive performance. In terms of GP decision making and 
the use of CDSS to support the prescribing of specialist this is as yet an unexplored 
area, and would form a clear basis for further research.  
 
4.11. Conclusion 
A study of human ergonomics was used to further investigate GPs and the actual 
level and use of computers and software programs including CDSS at the point of 
prescribing both during and outside of patient consultations. The application of an 
analytical approach to these processes through a task analysis framework and 
specifically a predictive error analysis (SHERPA) identified failings in existing 
arrangements for GPs to safely prescribe specialist drugs. The lack of specific 
functionality within GP computer systems including CDSS adversely affected the 
ability for GPs to resolve problems associated with the prescribing of specialist drugs. 
Time constraints during patient consultations compounded these problems. A 
potential operating model to support GPs in the prescribing and use of specialist 
drugs has been identified based on the use of hierarchical task analysis and the 















This thesis investigated developing a novel CDSS to aid GPs in the prescribing and 
management of specialist drugs in primary care. One of the aspects to this investigation was 
to explore this concept with a range of stakeholders. This work was further extended with 
GPs, as end users of a potential system. The background to this thesis was GP prescribing 
in the UK with a focus on the principles that defined and measured prescribing quality. 
Based on a literature review (Barber 1995) and findings from the World Health Organisation 
(WHO 2002), the National Prescribing Centre (NPC) defined prescribing quality as a balance 
of the traditional teaching of safety and efficacy with the need to be cost-effective and 
involving the patient in treatment (NPC 2007). Duerden et al (2011) reported that definitions 
of prescribing quality were elusive and that any description was guided by the stakeholder 
groups involved in the prescribing process.  
 
From a NHS management perspective regulation in the use of medicines has been 
influenced by the emergence of national bodies and agencies that have been tasked to 
address key aspects that have had a major influence GP prescribing. Cost containment has 
consistently been an issue for the NHS ever since its inception in 1948. In the last 20 years 
prescribing has been under the scrutiny of the National Audit Office (NAO), Published 
reports from the NAO highlighted potential savings in expenditure from inappropriate 
prescribing (NAO 1994), increasing cost pressures linked to quality standards from National 
Service Frameworks (NSFs) and NICE (NAO 2003) and initiatives to improve prescribing 
efficiencies and reducing wastage (NAO 2007).  Launched in 1999 as a Special Health 
Authority, NICE was made responsible to disseminate clinical guidelines on the relevant 
evidence of clinical cost effectiveness with the associated audit methodology and information 
on good practice (Stephens 2005). The UK Chief Medical Officer’s report “An Organisation 
with a Memory” (Department of Health 2000) set out a challenging agenda for improving 
care by reporting and learning from adverse events, which later saw the establishment of the 
National Patient Safety Agency (NPSA).  In the UK attempts to implement measures to 
improving prescribing quality have included the use of prescribing formularies, prescribing 
indicators and financial incentives through prescribing incentive schemes and clinical 
elements within the GMS GP contract. Developments in IT and the potential for CDSS to 
improve prescribing quality were identified as a research area. This was explored further by 
firstly scoping the evidence base of CDSS, and then investigating the potential of developing 








5.2 Scoping review 
One of the aims of this thesis was to identify the evidence base in relation to the use of 
CDSS in primary care. From the scoping review conducted experience of CDSS was 
identified in a wide range of clinical areas such as disease management, drug dosing, 
therapeutic control and prescribing. In the UK CDSS was found to be extensively available to 
GPs, particularly through GP clinical systems. However robust evidence in terms of 
randomised controlled trials were limited to use in anticoagulation management or 
evaluations of CDSS that were either prototypes or are no longer in use. In addition key 
problems associated with CDSS were identified including low usage rates, over-alerting, and 
to ensure that future developments were made by engaging closely with end users. In this 
study time constraints and a lack of resource meant engagement with stakeholders was 
limited. Other scoping reviews have demonstrated the benefits of wider engagement with 
stakeholders such as interviews, surveys and focus groups (Bissell et al 2008, Duerden et al 
2011). This aspect was a key element in the research described in this thesis by identifying 
key informants and ensuring relevant stakeholders were identified and invited to participate.  
 
5.3 Key informant interviews  
The aim of this study was to assess the feasibility of developing a CDSS to support GPs at 
the point of prescribing in the use and management of specialist drugs. Twelve key 
informants participated in this research study and represented four stakeholder groups. The 
informants described a broad range of views and experiences of information technology, use 
of computers and of specialist drugs. Three primary themes emerged from these interviews; 
safety in relation to the use of specialist drugs, information technology and costs. In terms of 
specialist drugs safety concerns were clearly evident and correlated with the published 
literature particularly with the use of shared care protocols (Horne et al 2001, Duggan et al 
2001). All of the informants were positive towards the potential of a CDSS to support the use 
of specialist drugs and described potential operating models including enablers and barriers 
to implementation. Costs were described as a factor in terms of drug expenditure, NHS 
services and in funding arrangements for general practice to include CDSS. In principle key 
elements of operation and implementation for a potential CDSS were identified. Further 
evaluation of the potential CDSS was identified which required more detailed examination of 










5.4 Task analysis  
This is the first study that has applied both hierarchical task analysis and an error analysis 
model (SHERPA), to the task of prescribing specialist drugs by GPs in the UK. Previous 
examples where these methods have been used within UK healthcare settings have been in 
secondary care (Joice et al 1998, Lane at al 2006, Phipps et al 2008, Phipps et al 2011). 
Operating within a paper based communication system form a secondary care was a 
fundamental obstacle for the GPs. Risks associated with the use of specialist drugs were 
compounded by the lack of available functionality within all of the GP clinical systems. 
Almost all of the error modes for each task were classed as retrieval errors due the 
unavailability of the required information. There was a lack of functionality within GP clinical 
systems to resolve the problems associated with the prescribing of specialist drugs. Based 
on the results of the SHERPA error analysis the hierarchical task analysis was repeated and 
an operating model for a potential CDSS to support GPs in the use of specialist drugs in 
order to ensure high level safety and quality in prescribing was identified.  
 
5.4.1 Extending the evidence base of CDSS 
The key informant interviews and follow up task analysis were conducted between May 2012 
and February 2015. During the analysis of the results of these studies new emerging data 
was identified in relation to the evidence base of CDSS. Some of this data was identified as 
a direct result of these studies. The key informants described key developments in terms of 
accreditation of CDSS, both in the UK (NICE 2013) and within the European Union (EMA 
2012). One CDSS supplier introduced new products for use within primary care settings in 
the UK. In addition a number of published studies have reported on evaluations of CDSS in 
use, CDSS in development and of the literature including systematic reviews.  
 
In the UK, medicines optimisation has been defined as a “patient-focused approach to 
getting the best from investment in and use of medicines that requires a holistic approach, 
an enhanced level of patient centred professionalism, and partnership between clinical 
professionals and a patient” (Picton and Wright 2013 p3). This national initiative is 
underpinned by four principles; to understand the patient’s experience, evidenced based 
choices of medicines, ensure medicines are used safely and to incorporate medicines 
optimisation into routine practice. In order to support the implementation of medicines 
optimisation a recent development has been the introduction of a new CDSS in the UK by 
First Databank. OptimiseRx® is a system that is fully integrated within the workflow of 
SystmOne and can provide patient specific alerts based on a range of read coded health 
data (Anon 2015b). 




Whereas OptimiseRx® is available at the point of prescribing, AnalyseRx® is a retrospective 
analytical tool also recently introduced by First Databank that provides a clinical reporting 
system based at both population and patient level to support CCGs, GP practices, 
prescribers and patients (Anon 2015c). At patient level the tool supports interventions in 
terms of case finding, clinical audit and patient specific medication plans.  
 
CDSS such as OptimiseRx® and Script-Switch® provide decision support at the point of 
prescribing in the form of alerts which can also be tailored to the needs of the end user. An 
advantage of OptimiseRx is that alerts can take into account specific read coded elements of 
the patient’s electronic health record. Both of these tools allow information messages to be 
authored in relation to safety warnings, including local traffic light classification of specialist 
drugs and the ability to add electronic links to websites or electronic portals where shared 
care protocols are available. Although this can provide an element of support in the decision 
making process as to whether a GP decides to prescribe any drug, including a specialist 
drug (see Fig 4.2), in the case of shared care protocols links within alerts will only take the 
end user to an electronic paper or PDF document. In contrast the HTA (Table 4.5) provides 
a potential solution in the form of a wholly electronic integrated management of the 
prescribing and use of specialist drugs. 
 
In the UK Hayward et al (2013) used video recordings of patient consultations to examine 
the use of CDSS during patient consultations with GPs. This study used video recording of 
112 patient consultations involving eight GPs based in three practices. During 73 of these 
consultations 132 prescriptions were issued which also generated a total of 117 CDSS 
alerts. However these alerts only resulted in the GP making a check on the prescription in 
only 3 cases and in each case no change was made to the prescription. The authors 
described the poor impact made by CDSS during consultations and suggested this was 
because by the time an alert had appeared the majority of the work required by the GP had 
already occurred because the GP has already consulted with the patient and formulating a 
decision around treatment options. The authors concluded that CDSS would be more 
acceptable and effective if the prescribing support was made much earlier during the 
process of prescription generation.  
 
In the first published study of the views and or perceptions of GPs towards Script-Switch® 
Hire and Rushforth (2013), reported on the findings from semi-structured interviews with 8 
GPs across 5 practices in the North of England. Key themes identified from a thematic 
analysis included acceptance, impact, external control, disruption to workflow and 
willingness to switch medication from either a GP or patient’s perspective.  




Despite general acceptance of Script-Switch® in terms of enhancing cost effective 
prescribing, its impact was perceived as limited compared to other existing cost effective 
prescribing initiatives. Key drawbacks cited included alert content, inability to filter alerts, a 
lack of GP control and a lack of integration with other clinical information held in the patient’s 
electronic record. Despite these findings the uptake of Script-Switch® has increased since 
the scoping review and is now installed in over 7,500 GP practices (Anon 2015). A recent 
Dutch study has reported on the development of a CDSS to specifically focus on supporting 
medication reviews in elderly patients within nursing homes (De Wit et al 2013). The authors 
described five phase study to include the development of a CDSS, clinical rules to 
incorporate laboratory and pharmacy data, CDSS validation, randomised trial and feasibility 
for implementation.  
 
In a recent literature review of all systematic reviews in relation to CDSS (Cresswell et al 
2012) identified 41 systematic reviews of CDSS published between 1997 and 2010 that met 
their inclusion criteria which included impact on safety, quality or organisational, 
implementation or adoption consideration. Ten of the 41 systematic reviews had been 
identified from the scoping review conducted for this thesis. In addition the authors had used 
additional databases such as the Cochrane Library and personal databases which provided 
additional data. The authors reported on the improving evidence to support CDSS such as in 
clinical performance, but also highlighted risks with disruption to clinical workflow and the 
need for development to also be tailored towards the needs of end users. In a meta-
regression of 162 randomised trials of CDSS, Roshanov et al (2013) evaluated the 
effectiveness of systems as reported outcomes of process of care or patient health. CDSS 
that presented advice in electronic charting or order entry system interfaces were less likely 
to be effective. Better outcomes were produced where CDSS provided advice for both 
patients and clinicians, where clinicians were required to supply a reason for overriding an 
alert or where a CDSS was evaluated by their developers.         
 
5.5 Limitations 
There were a number of limitations with the studies that were conducted as part of this 
thesis. The main limitation of the scoping review was the availability of resources to further 
engage with stakeholders. This was a particular problem as other sources where evidence 
could have been obtained were not accessed such as attending conferences or seeking the 
views or experiences individuals either from interviews or surveys. In terms of the key 
informant interviews of the 12 key informants only two were GPs and only 2 NHS IT 
managers were recruited to the study.  




Three of the GPs that participated in the final task analysis also took part in the key 
informant phase although one was only involved in a pilot phase. Overall the two studies that 
involved participants for this thesis were small and would have benefitted with having a 
larger and more diverse range of specific individuals based across a wider geographical 
area, particularly the GPs and secondary care clinicians. The stakeholder groups in the key 
informant interviews were not equally balanced. Additional senior NHS IT managers, 
including those working for the former NHS Connecting for Health, could not be recruited to 
participate in this study. In both the key informant interviews and the task analysis study the 
GPs were generally younger and more familiar with computers and IT systems  
 
5.6 Implications for clinical practice and policy  
The results from this study have highlighted key safety concerns and issues with the use of 
specialist drugs, particularly when prescribed by GPs in primary care despite the availability 
shared care protocols. The secondary care clinicians involved in this study described from 
their first hand experiences with patients who had been prescribed immunosuppressant 
drugs and had suffered adverse effects following inadvertent switches in brands of 
tacrolimus. Clinical practice and policy key themes that emerged from the key informants 
were the repatriation of prescribing of immunosuppressant drugs and use of homecare 
services to deliver medication. Devaney and Lee (2013) have described the repatriation of 
immunosuppressant drugs in renal transplantation but it is not clear whether this may be 
extended to other transplant services and or other specialist drugs. This may have an impact 
on a potential CDSS if prescribing responsibility remains with secondary care clinicians, 
particularly with the extended roll out of electronic prescribing systems in secondary care. 
Going forward constraints in the UK economy are shaping the design and provision of a 
greater primary care led NHS. If GP commissioning is to continue with these increased 
pressures there are implications for the individual stakeholder groups such as commercial 
providers of CDSS in terms of future funding streams either for existing services or for future 
developments.  
 
A range of potential funding models were explored with the key informants including GP 
funding, central funding and the current NHS funded model. The consensus was that either 
central funding from the Department of Health or an extension of current arrangements with 
local NHS organisations would be appropriate. None of the informants supported a GP 
funded model. One source of funding which could be explored was the potential use of 
savings generated by moving transplant clinics from secondary care to primary care.       
 




5.6.1 Implication for GPs  
If GPs were to undertake the prescribing of specialist drugs fully supported by an integrated 
clinical module with CDSS, there would be implications on prescribing expenditure and 
increased workload for practices. This would be related to patient management such as 
more appointments and monitoring. There would also be a number of additional factors to 
take into account such as, accepting both clinical responsibility and the associated workload.  
 
5.6.2 Implications for Clinical Commissioning Groups 
For CCGs there would be implications for overall financial management based on associated 
cost shifting from secondary care to primary care. In addition there would be requirements 
associated with clinical risk and governance arrangements around prescribing specialist 
drugs at practice level. In addition other financial implications would involve funding 
arrangements for a CDSS and whether it would be an associated cost linked to GP clinical 
system providers. The transfer of services from secondary care would require scrutiny for 
any savings generated could be linked to the development costs of a potential CDSS.  
 
5.6.3 Implications for CDSS suppliers 
There would be a number implications for the CDSS suppliers, and this would be dependent  
on whether this would be an independent clinical module provided by a third party supplier or 
something developed by an existing GP clinical system provider. Key aspects would be IT 
governance, maintenance, updating and funding streams. The key informants described 
some of the current funding models for both GP clinical system providers and third party 
CDSS providers. The informants described a number of current funding streams where 
payment was outside the GPSOC licence fee arrangement with GP clinical system 
providers. These included through pharmaceutical industry advertising for DXS® and from 
cost savings generated by prescribing budgets for Script-Switch®. The informants described 
a number of initiatives for either planned developments or potential improvements in current 
CDSS including drug dosage management, disease management and care pathways to 
include diagnostics and investigations and supporting linkages between GP clinical systems 
and community pharmacy clinical systems.  
 
5.6.4 Enablers and barriers to implementation  
The key informants all identified both enablers and barriers to the concept. Key enablers 
described included data quality and functionality, joint development and implementation, for 
the CDSS to have an active alerting functionality within an electronic patient record, and to 
make use of existing systems and frameworks. Key barriers described included addressing 
the needs of end users, security and regulation, and funding.  




Although costs were not cited as a specific issue, recent NHS financial constraints may still 
have an impact depending on Government plans following on from the recent general 
election NHS Connecting for Health ceased to operate in 2013, and the longer term plans for 
electronic prescribing in secondary care are not known despite recent commitment (NHS 
England 2013).  
 
5.7 Further Work 
A range of opportunities for further work were identified to extend the knowledge base of 
CDSS. These included wider evaluations of the CDSS available within GP clinical systems 
included those provided via links and or arrangements with third part suppliers. One clear 
area identified was the need for further evaluations of existing CDSS such as Script-Switch® 
and INRstar.® A specific area would be to investigate not just the views of end users but also 
the commissioners who decide funding arrangements for the provision of these systems, 
including lead pharmacists from medicines management teams. The key informants 
described a number of operating models for a CDSS. These included primary care and 
secondary care together with homecare services. This would need to be further evaluated 
particularly with the anticipated increased uptake in the UK of electronic prescribing systems 
in secondary care (Ahmed et al 2013).  
 
One of the enablers identified to support implementation was better use of existing 
frameworks. With primary care GP clinical system providers moving to hosted with wider 
external user access this would be a potential research area. Thistlethwaite et al (2010) 
described decision making in prescribing as complicated, involving both patient and doctor 
with a range of factors that influence this process including the use of a patient centred 
approach to prescribing. The results from the SHERPA error analysis identified a need to 
further explore the decision making processes followed by GPs. In terms of task analysis, 
this would be in the form of cognitive approaches. Any additional work in this area would 
need to involve a larger sample involving GPs including both GPs employed on a sessional 













5.8 Overall Conclusion 
The three aims of this thesis were to identify the evidence base in relation to the use of 
CDSS, to assess the feasibility of developing a novel CDSS and to identify an operating 
model for a potential CDSS to support GPs in the use of specialist drugs. In terms of 
outcomes all of these aims were met.   
 
In addition on two key areas of new knowledge in relation to the subject area were identified 
which were: 
  
 A potential operating model for general practice to support GPs in the prescribing 
and use of specialist drugs 
 Key enablers and barriers to support the implementation of such a model 
 
Safety was a primary focus of the research described in this thesis and the research 
conducted. The better use of information technology and CDSS may provide a solution but 
the results of this research suggest any new developments need to be carefully planned with 
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Exploratory study using key informants to investigate the use 












Thank you for agreeing to participate in this study which aims to explore the views, 
perceptions and experiences of individuals in the use of CDSS. I will be grateful if you could 
confirm that you have seen and read the information sheet and that you have read and 
signed the consent form. During the interview I will be taking written notes but will also be 
using an audio tape recorder to help me write up a transcript. The recording will be 
destroyed after the completion of my doctorate. Please explain things to me as if I am one of 
your colleagues. I may ask you for clarification and examples of the topics discussed. Feel 
free to stop me if you have any questions or need anything explained.   
 
Background 
CDSS can function as either “active” whereby it interacts within a host clinical system or 
“passive” whereby the end user decides when and where to use it. Firstly we will be 
discussing your use of CDSS in your practice   
 
Evaluation of CDSS  
Now I’d like to discuss your views and perceptions of CDSS in terms of likes and dislikes as 
well as your opinion of the advantages of systems and disadvantages of different systems. 
 
Consider the following questions and scenarios:   
 Describe your experience of using computers in general practice and using electronic 
health records. 
 What are your views and experience of “active” CDSS where software interacts with 
the GP practice computer system at the point of prescribing or using other areas of 
electronic health records? 
 What are your views and experience of “passive” CDSS where the user decides 





 Which CDSS have you used please give details  
 Which type of CDSS do you prefer and why? 
 In your opinion what are the advantages that CDSS provides during consultations. 
Please give examples  
 Are there any advantages for CDSS in other areas of your work in general practice? 
 In your opinion what are the disadvantages of CDSS?  
 Are there aspects of prescribing or clinical areas where you find CDSS particularly 
helpful and why?  
 In your opinion what are the does CDSS improves the quality of care or medical 
advice that you provide? Please give examples 
 Have you any experiences where CDSS has had any adverse effect on patient care 
or clinical outcomes and if so what happened? 
 Describe any other resources, other than CDSS, which you use to aid prescribing 
and your work in general practice. What advantages and if any do they confer and 
what are they? 
 Are aware of any CDSS in development, please provide details on patients groups, 
medicines etc.? 
 
Shared care protocols, Specialist Drugs, and CDSS 
In the UK there has been a growing trend for some specialised hospital initiated treatments 
to be managed within primary care.  Often this is within so called “shared care 
arrangements” using “shared care protocols”. In addition I will asking you about your views 
and experiences when dealing with requests from hospital clinicians to prescribe specialist 
drugs, and using shared care protocols. 
 
In England during 2010 / 11 over 1.6 million prescription items were issued by GPs for 
specialist drugs at a cost of £250 million, 3.13% of the total £7.98 billion national primary 
care drugs bill. Of this £65 million (26.3%) was spent on the immunosuppressant drugs 
ciclosporin, mycophenolate, sirolimus and tacrolimus. In addition these four drugs 
accounted for 31.7% of all specialist drugs prescribed, making these the most frequently 
issued by GPs in primary care. Shared care protocols are designed to support the 
management of specialist drugs that are initiated by secondary care clinicians and then 





 Are you familiar with shared care protocols and if so describe your experience of 
using them? 
 Have you ever been asked to comment on or been involved in developing a shared 
care protocol and if you have please provide some details? 
 
As a potential area for development this study will be looking to explore if CDSS could have 
a role in helping GPs prescribe and manage specialist drugs in primary care. Based on your 
experience of general practice, primary care and taking account of current NHS policy I will 
like to discuss with you the following:  
  
 Describe your experiences of prescribing specialist drugs in primary care 
 Which specialist drugs have you prescribed in the past or are currently prescribing 
and were you able to use shared care protocols for these drugs?  
 Have you experienced any problems or difficulties in prescribing specialist drugs, and 
if so how could they have been avoided? 
 What experience do you have in the prescribing and management of patients with 
any of the four immunosuppressant drugs ciclosporin, mycophenolate, sirolimus and 
tacrolimus? 
 What do you think of the idea of a CDSS; specifically designed to support the 
prescribing of specialist drugs?  
 If such a CDSS was developed, what do you think would be the advantages and 
disadvantages for GPs? 
 What do you think are the disadvantages of using a CDSS to support the prescribing 
of specialist drugs? 
 Describe how you think such a CDSS would best operate including any specific 
characteristics or features? 
 
Finally one last question; in your opinion should funding come from any or all of the following 
to develop and or implement such a CDSS: NHS, CDSS suppliers, GP practice computer 
suppliers or GPs? 
 
Conclusion 
Thank you for your time and I am very grateful that you have given me an insight into your 
views and perceptions of CDSS and its potential role in supporting the prescribing of 
specialist drugs. I would like to remind you that if you wish to withdraw from the study you 









Exploratory study using key informants to investigate the use computerised 
decision support software (CDSS) within UK general practice.   
 
SECONDARY CARE CLINICIAN VERSION 
 
Introduction 
Thank you for agreeing to participate in this study which aims to explore the views, 
perceptions and experiences of individuals in the use of CDSS. I will be grateful if you could 
confirm that you have seen and read the information sheet and that you have read and 
signed the consent form. During the interview I will be taking written notes but will also be 
using an audio tape recorder to help me write up a transcript. The recording will be 
destroyed after the completion of my doctorate. Please explain things to me as if I am one of 
your colleagues. I may ask you for clarification and examples of the topics discussed. Feel 
free to stop me if you have any questions or need anything explained.   
 
Background 
Specialist drugs have been defined as those that have significant pharmacological 
complexity and or rarity of use which make prescribing them in community relatively 
uncommon. In addition patients receiving these drugs may require particular complex 
monitoring requiring specialist knowledge for interpretation and management. Guidance from 
the NHS Management Executive issued in 1991 outlined core principles and responsibilities 
associated with prescribing particularly with the transfer of treatment between secondary and 
primary care. Where this involves new or rarely prescribed treatments, including unlicensed 
drugs, shared care arrangements should be proposed in the form of a “protocol” outlining 
responsibilities for both hospital and primary care clinicians. 
In recent years there has been a growing trend for some specialised hospital initiated 
treatments to be managed within primary care, attributed to patient convenience, better risk 
management, a reduction in secondary care workload (e.g. out-patient appointments) and 
the transfer out of prescribing expenditure. In England during 2010 / 11 over 1.6 million 
prescription items were issued by GPs for specialist drugs at a cost of £250 million, 3.13% of 
the total £7.98 billion national primary care drugs bill. Of this £65 million (26.3%) was spent 





In addition these four drugs accounted for 31.7% of all specialist drugs prescribed, making 
these the most frequently issued by GPs in primary care. 
 
Firstly we will be discussing some background information about your experience in the use 
of specialist drugs and we will consider the following questions and scenarios;  
 Describe some of the challenges you have experienced with regard to prescribing, 
monitoring and therapeutic management of these drugs? 
 What are your experiences of the transfer of care between secondary care and 
primary care? Please comment on the advantages, disadvantages and specific 
interface issues related to these drugs? 
 What are your experiences of using of shared care protocols? Please comment on 
your experience on the writing, design of shared care protocols  
 What are your experiences of using of shared care protocols to enable GPs to 
manage patients on specialist drugs? 
 Based on your experience which individuals are normally involved in the 
development of a shared care protocol?  
 Would this involve GPs or other primary care based clinicians? 
 What are the barriers and enablers to developing shared care protocols for the 
prescribing and monitoring of specialist drugs by GPs? 
 
Potential Area for CDSS Development 
The last 30 years has seen the emergence of CDSS to aid diagnosis, dose calculations and 
more recently to support computerised or electronic prescribing via alerts to warnings on 
drug interactions, allergies and contraindications. CDSS can function as either “active” 
whereby it interacts within a host clinical system or “passive” whereby the end user decides 
when and where to use it. As a potential area for development this study will be looking to 
explore if CDSS could have a role in helping GPs prescribe and manage specialist drugs in 
primary care. Based on your experience of the NHS and the use of specialist drugs we will 
discuss this area considering a number of aspects to include the following questions and 
scenarios:   
 What are your views on the feasibility of CDSS supporting the prescribing specialist 
drugs compared to current arrangements including using shared care protocols?  
 If a CDSS were to be developed for use in primary care by GPs what key features 
and functionality standards do you feel would be important in relation to the 





 What reservations or concerns (if any) do you have regarding the development of a 
CDSS to support the prescribing of specialist drugs by GPs? 
 
Conclusion 
Thank you for your time and I am very grateful that you have given me an insight into your 
experience of specialist drugs and your views on the potential use of CDSS to support 
prescribing in general practice. I would like to remind you that if you wish to withdraw from 













































  Exploratory study using key informants to investigate the use computerised 
decision support software (CDSS) within UK general practice. 
 
NHS MANAGEMENT VERSION 
 
Introduction 
Thank you for agreeing to participate in this study which aims to explore the views, 
perceptions and experiences of individuals in the use of CDSS. I will be grateful if you could 
confirm that you have seen and read the information sheet and that you have read and 
signed the consent form. During the interview I will be taking written notes but will also be 
using an audio tape recorder to help me write up a transcript. The recording will be 
destroyed after the completion of my doctorate. Please explain things to me as if I am one of 
your colleagues. I may ask you for clarification and examples of the topics discussed. Feel 
free to stop me if you have any questions or need anything explained.   
 
Background 
The last 30 years has seen the emergence of CDSS to aid diagnosis, dose calculations and 
more recently to support computerised or electronic prescribing via alerts to warnings on 
drug interactions, allergies and contraindications. CDSS can function as either “active” 
whereby it interacts within a host clinical system or “passive” whereby the end user decides 
when and where it is used. Firstly we will be discussing your experience in the NHS of 
information technology and systems to aid electronic or computerised prescribing.   
 What is your current (and / or previous) experience of information technology in the 
NHS? 
 Explain the key components that clinical system suppliers provide in relation to 
prescribing support and current contractual arrangements with the NHS including 
specific requirements for CDSS 
 What are the contractual requirements for commercial organisations with regards 








CDSS: Enablers and Barriers  
CDSS is widely available within primary care settings in the UK as computers are now 
common place in GP practices. The actual use and perceptions of those using CDSS may 
be influenced by a number of factors. Based on your knowledge and experience in this area 
we will be discussing this further. We will explore the following aspects:  
 What are your experiences with regards to actual usage and acceptance of CDSS 
from either end users or purchasers (NHS)? 
 How are either end users or purchasers involved in the on-going management and / 
or development of CDSS? 
 What barriers are there to the implementation of CDSS within primary care? 
 How can these barriers be avoided or removed? 
 
Potential Area for CDSS Development 
In England during 2010 / 11 over 1.6 million prescription items were issued by GPs for 
specialist drugs at a cost of £250 million, 3.13% of the total £7.98 billion national primary 
care drugs bill. Of this £65 million (26.3%) was spent on the immunosuppressant drugs 
ciclosporin, mycophenolate, sirolimus and tacrolimus. In addition these four drugs accounted 
for 31.7% of all specialist drugs prescribed, making these the most frequently issued by 
GPs in primary care. As a potential area for development this study will be looking to 
explore if CDSS could have a role in helping GPs prescribe and manage specialist drugs in 
primary care. Based on your experience of information technology in the NHS and taking 
account of current NHS policy we will discuss this area considering a number of aspects.  
These are: 
 What type of information or details would be required by the NHS in order to support 
the development and or implementation of a CDSS to support the prescribing of 
specialist drugs? 
 In your opinion would such a CDSS benefit from being in an “active” form or a 
“passive” form, and why? 
 What would be the cost (if any) of supporting of the implementation of such a CDSS 
within primary care and GP practices? 
 What barriers could there be in either the development or implementation of such a 
CDSS within general practice and could such barriers be overcome? 






 Should or would the NHS fund the development and / or implementation of such a 
CDSS for use by GPs? 
 
Conclusion 
Thank you for your time and I am very grateful for giving me insight into your experience of 
information technology and the NHS and your views on the potential use of CDSS to support 
prescribing in general practice. I would like to remind you that if you wish to withdraw from 




































Exploratory study to gather the views of key informants in relation to the use 
computerised decision support software (CDSS) in UK general practice.  
 
CDSS STAKEHOLDER VERSION  
 
Introduction 
Thank you for agreeing to participate in this study which aims to explore the views, 
perceptions and experiences of individuals in the use of CDSS. I will be grateful if you could 
confirm that you have seen and read the information sheet and that you have read and 
signed the consent form. During the interview I will be taking written notes but will also be 
using a tape recorder to help me write up a transcript. The recording will be destroyed after 
the completion of my doctorate. Please explain things to me as if I am one of your 
colleagues. I may ask you for clarification and examples of the topics discussed. Feel free to 
stop me if you have any questions or need anything explained.   
 
Background 
Firstly I would like some background information about yourself and your work to include:   
 What is your current (and / or previous) experience of CDSS e.g. R&D, Sales? 
 Describe the current uptake of CDSS within the UK, in particular primary care and 
general practice 
 How does CDSS integrate with general practice computer systems? 
 Describe the specific characteristics and design features of the CDSS that you are 
responsible for and if so could they improved in any way?     
 How is the CDSS you are responsible for funded, and are you aware of other funding 
models in the UK? 
 What future developments in CDSS within primary care are you aware of to include 








CDSS: Enablers and Barriers  
CDSS is widely available within primary care settings in the UK as computers are now 
common place in GP practices. The actual use and perceptions of those using CDDS may 
be influenced by a number of factors. Based on your knowledge and experience in this area 
we will be discussing this further, consider the following questions:  
 What are your experiences of with regards to actual usage and acceptance of CDSS 
from either end users or purchasers (NHS)? 
 How are either end users or purchasers involved in the on-going management of or 
development of CDSS? 
 What are the barriers to implementation of CDSS within primary care that you are 
aware of and how can these be avoided or removed? 
 
Potential Area for CDSS Development 
In England during 2010 / 11 over 1.6 million prescription items were issued by GPs for 
specialist drugs at a cost of £250 million, 3.13% of the total £7.98 billion national primary 
care drugs bill. Of this £65 million (26.3%) was spent on the immunosuppressant drugs 
ciclosporin, mycophenolate, sirolimus and tacrolimus. In addition these four drugs accounted 
for 31.7% of all specialist drugs prescribed, making these the most frequently issued by 
GPs in primary care. As a potential area for development this study will be looking to 
explore if CDSS could have a role in helping GPs prescribe and manage specialist drugs in 
primary care. Based on your experience of CDSS, general practice, primary care and taking 
account of current NHS policy we will discuss this area considering a number of aspects. 
These are:    
 What sort of information or detail would be required in order to develop a CDSS to 
support the prescribing of specialist drugs? 
 In your opinion would the CDSS benefit from being in an “active” form or a “passive” 
form, and why? 
 What would be the cost of developing such a CDSS, and how long would it take? 
 What barriers could there be in either the development or implementation of such a 
CDSS within general practice? 










Thank you for your time and I am very grateful that you have given me an insight into your 
views and perceptions of CDSS. I would like to remind you that if you wish to withdraw from 
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An exploratory study using key informants to investigate the use of computerised 
decision support software (CDSS) within UK general practice.   
 
We are writing to invite you to take part in a research study that aims to explore the views, 
perceptions and experiences of individuals involved in the use of CDSS and its potential role 
in supporting GPs in the use and management of specialist drugs. The key informants 
involved in this study represent the following four stakeholder groups; NHS secondary care 
clinicians, NHS management, GPs, representatives from the CDSS industry and expert 
advisors. The study will involve participants being interviewed by a member of the Research 
Team for approximately 1 hour. This study has been approved by King’s College London 
Biomedical Sciences, Dentistry, Medicine and Natural & Mathematical Sciences Research 
Ethics Subcommittee (Reference BDM/11/12-82).   
 
Background 
The last 30 years has seen the emergence of Computerised Decision Support Systems 
(CDSS) to aid diagnosis, dose calculations and more recently to support computerised or 
electronic prescribing via alerts to warnings on drug interactions, allergies and 
contraindications. CDSS can function as either “active” whereby it interacts within a host 
clinical system or “passive” whereby the end user decides when and where to use it. CDSS 
is widely available within primary care settings in the UK as computers are now common 
place in GP practices. Developmental experience of CDSS in UK general practice has 
supported both disease management and therapeutic drug monitoring. In recent years 
CDSS have been introduced that provide prescribing support with national and locally 








In recent years there has been a growing trend for some specialised hospital initiated 
treatments to be managed within primary care, attributed to patient convenience, better risk 
management, a reduction in secondary care workload (e.g. out-patient appointments) and 
the transfer out of prescribing expenditure. In England during 2010 / 11 over 1.6 million 
prescription items were issued by GPs for specialist drugs at a cost of £250 million, 3.13% of 
the total £7.98 billion national primary care drugs bill. Of this £65 million (26.3%) was spent 
on the immunosuppressant drugs ciclosporin, mycophenolate, sirolimus and tacrolimus. In 
addition these four drugs accounted for 31.7% of all specialist drugs prescribed, making 
these the most frequently issued by GPs in primary care.  
 
The results of the this phase of the study will be used to build and extend the current 
knowledge base of the research area and to develop a draft operational framework for a 
potential CDSS to support GPs in the prescribing specialist drugs to include specific clinical 
standards and end-user features. If you are interested in taking part in this study, please 
read the attached participant information sheet, and if you wish to participate in this study 
please complete the attached consent form and return it to the research team in the stamp 
addressed envelope provided by…. (7 days from the letter date). If you would like any further 
information about the study before you make the decision about participating, please contact 
either Narinder Chana (primary contact) by either e-mail (narinder.chana@kcl.ac.uk) or 
telephone (020 331 39310), or Dr Cate Whittlesea via (cate.whittlesea@kcl.ac.uk) or 020 
7848 4796.  
 


























PARTICIPANT INFORMATION LEAFLET. 
 
Exploratory study using key informants to investigate the use of computerised 
decision support software (CDSS) within UK general practice. 
 
 
We would like to invite you to participate in this postgraduate research project.  You should 
only participate if you want to; choosing not to take part will not disadvantage you in any 
way. Before you decide whether you want to take part, it is important for you to understand 
why the research is being done and what your participation will involve.  Please take time to 
read the following information carefully and discuss it with others if you wish.  Ask us if there 
is anything that is not clear or if you would like more information. 
 
What is the purpose of the study? 
 
The study intends to build on the current knowledge base of computerised decision support 
systems (CDSS) in the UK by engaging with key stakeholders and GPs as end user 
clinicians. This will allow a better understanding of current characteristics of CDSS available 
and to determine views and perceptions of their use, performance and scope for further 
development. From this it is intended to develop an operational framework for a novel 
CDSS, to include functionality and clinical standards to address the needs of GPs in the 
prescribing and management of specific specialist drugs. This study has been approved by 
King’s College London Biomedical Sciences, Dentistry, Medicine and Natural & 
Mathematical Sciences Research Ethics Subcommittee (Reference BDM/11/12-82).   
 
Why have I been chosen to participate? 
 
A literature review of CDSS and prescribing has formed the basis of this study. This 
preliminary stage will inform us of key aspects in relation to the research question from those 
individuals that are actively involved within the field. These individuals represent NHS 
management, secondary care clinicians, GPs and the CDSS industry.   
 
Do I have to take part? 
 
No. It is up to you to decide whether or not to take part. If you decide to take part you will be 
given this information sheet to keep and asked to sign a form giving informed consent. If 





reason.  If you do change your mind and decide to withdraw just contact the Research 
Team to let them know. Please note data can only be withdrawn up to 48 hours after the 
interview.   
 
  What would happen to me if I take part? 
 
You will be invited to participate in a confidential interview with a member of the research 
team (Narinder Chana). The interviews will take approximately an hour at a convenient date 
and time. This will be held at a suitable venue that you decide is best for you. With your 
consent, the interviews will be audio-recorded. All data collected by the research team as 
part of the study is strictly confidential.  
 
What are the possible benefits of taking part? 
 
Your input will help and inform future developments in the field of medical informatics which 
will contribute to improving the way patients are treated and managed within primary care. In 
recent years an increasingly greater number and range of specialist drugs and treatments 
are being used outside of hospital prescribed for and managed by GPs. It is important that 
this is done safely and effectively and using CDSS may enhance the prescribing and 
monitoring of these medicines.     
  
What happens when the research study stops? 
 
The Research Team is keen to learn of areas where prescribing quality can be improved and 
will welcome any comments or suggestions in relation to CDSS and the use of specialist 
drugs. These comments should be directed to Narinder Chana.  
 
What if something goes wrong? 
 
It is not anticipated that taking part in this exploratory study will cause any pain, discomfort, 
inconvenience or changes to lifestyle. 
    
Would my taking part in this study be kept confidential? 
 
All information collected about you during the course of the research study is kept strictly 
confidential. The interviews are confidential and the data collected will be anonymised by 
the researcher. It will NOT be possible to link information used in the research report back to 











Individuals will not be identified in any report or publication. The findings will be shared 
across the Medicines Management Teams within the Outer North West London Cluster of 
Primary Care Trusts and the London Primary Care Practice Research Network. The study 
will be described in the Doctorate in Health Care thesis of Narinder Chana. It is anticipated 
the results of this study will be published and or presented at a national / international level 
so all information gained is shared widely. If you would like a copy of any resultant 
publication, you will be sent one. 
 
Who is organising and funding the research? 
 
The research is being organised by Narinder Chana, and Dr Cate Whittlesea (Institute of 
Pharmaceutical Sciences, King’s College London) in collaboration with Professor Brendan 
Delaney (Department of Primary Care and General Practice, King’s College London). The 
research team are providing their time and expertise free of charge. Narinder Chana is a 
Pharmaceutical Adviser at NHS Ealing Primary Care Trust (PCT).  
 
Contacts for further information. 
 
Should you have any further questions, or would like to enquire further please contact 
Narinder Chana or Cate Whittlesea by either e-mail or phone number between 9am-5pm 
Monday to Friday. 
 
Narinder Chana: Narinder.chana@kcl.ac.uk 020 331 39310 
Cate Whittlesea: cate.whittlesea@kcl.ac.uk  020 7848 4796 
 
If you are happy to participate in this study, please complete the attached consent form and 
return it to the research team in the enclosed stamp addressed envelope. If this study has 
harmed you in any way you can contact King’s College London using the details below for 
further advice and information. 
 
Contact:  
Dr Cate Whittlesea Institute of Pharmaceutical Sciences, Room 5.79, 5th Floor, Franklin 
Wilkins Building, Kings College London, Stamford St, London SE1 
  







REC Study Number: BDM/11/12-82 
 
CONSENT FORM 
Exploratory study using key informants to investigate the use of computerised 
decision support software (CDSS) within UK general practice. 
 
 
Research team: Narinder Chana, Dr Cate Whittlesea, Professor Brendan Delaney (King’s 
College London). You are provided with two copies of this consent form; one is to be 
returned to the research team in the stamped addressed envelope provided, and the other 
for you to keep. 
 
 PLEASE INITIAL OR 
TICK IN BOX 
1. I have read and understand the participant information 
leaflet (vesion1) for the above study and have had the 
opportunity to ask questions. 
 
 
2. I understand that if I decide at any time during the research 
that I no longer wish to participate in this project, I can 
notify the researchers involved and withdraw from it 
immediately without giving reason. Furthermore, I 
understand that I will be able to withdraw my data up to 48 
hours after the interview 
 
3. I agree that what I say during the interviews can be used, 
anonymously in the presentation of the research. 
 
 




5. I consent to the processing of my personal information for 
the purposes explained to me.  I understand that such 
information will be handled in accordance with the terms of 
the Data Protection Act 1998’ 
 
 
6. I AGREE, and give INFORMED CONSENT  / DO NOT 




      
Please DO / DO NOT (delete as appropriate) send me a report on the results of this 
study. 
 
Address for those requesting a report 
………………………………………………………………………………………………… 
                                                                           
Name of participant         Signature      
Date 
 














REC Reference: BDM11/12-82 
Dr Cate Whittlesea 
Institute of Pharmaceutical Sciences 
Room 5.79, 5th Floor 
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An exploratory study to gather the views of key informants in relation to the use 
computerised decision support software (CDSS) within UK general practice.   
 
Thank you for agreeing to take part in this study. We are writing to confirm that we have 
received your consent form and that Narinder Chana will be contacting you shortly to 
arrange a suitable date time and venue for your interview. This interview will be confidential 
and the data collected will be anonymised and it will not be possible to link information used 
in the research report to you. The interview will be audio-recorded and the recording will be 
used in order to prepare a transcript. The tape recordings will be destroyed at the end of the 
study. A number of key aspects in relation to the research study will form the basis of these 
interviews and will raise specific discussion areas to include: 
 
 Current usage levels of CDSS within UK general practice 
 Views and perceptions of end-users (GPs) of the quality and effectiveness of CDSS 
 Integration of CDSS with general practice computer systems. 
 Current and possible future funding models for CDSS in the UK 
 Future developments in CDSS in the UK within primary care to include specific 
drugs, therapeutic areas and clinical speciality.  
 Government health policy and the financial position of the NHS related to CDSS 
implementation 
 Current arrangements in the prescribing and on-going management of specialist 
drugs including the relationship between hospital specialists and GPs. 






Please do not hesitate to contact us if you have any further queries or require further 
information about the study. I look forward to speaking to you shortly to arrange your 
interview.  
 














































Exploratory study using key informants to investigate the use computerised 
decision support software (CDSS) within UK general practice. Hierarchical 






 Obtain some background details about the GP to include, gender, specialty, years 
since qualification. Ask the GP to briefly describe his / her level of experience of 
using computers in general practice.  
 Observe the way the consultation room is organised, where does the patient sit, 
where does the GP sit, how does the use of the computer impact on the consultation, 
can the patient see the computer screen?  
 
Building the Task Diagram 
 Can you describe the main stages of a typical patient consultation and how you use 
the computer? 
 Can you show me what you look at on the computer and what functions are used? 
 How are these functions used and what steps do you have to take to complete these 
functions? 
 If during this consultation you require to issue medication what steps do you have to 
take, how does the computer take you through this process? 
 What sort of functions and features either support or hinder this process e.g. CDSS? 




Please describe what you would do in the following scenario? 
 You have received a letter from a hospital to prescribe a “specialist drug” that you are 
not familiar with for one of your patients. The hospital letter refers to a “shared care 
protocol” that you need to follow but it is not enclosed. Describe what you would do 
and how you would use your computer including any specific functions to help you 






 You have decided to prescribe the “specialist drug”, what steps do you now take in 
terms of using the computer and any specific features and functions. Would there be 
any additional tasks that you need to do which would involve the use of the computer 
and any specific features or functions in the longer term for using this specialist drug 







































PARTICIPANT INFORMATION LEAFLET. 
 
Exploratory study using key informants to investigate the use of computerised 
decision support software (CDSS) within UK general practice. 
 
 
We would like to invite you to participate in this postgraduate research project.  You 
should only participate if you want to; choosing not to take part will not disadvantage you 
in any way. Before you decide whether you want to take part, it is important for you to 
understand why the research is being done and what your participation will involve. 
Please take time to read the following information carefully and discuss it with others if 
you wish.  Ask us if there is anything that is not clear or if you would like more 
information. 
 
What is the purpose of the study? 
 
The study intends to build on the current knowledge base of computerised decision support 
systems (CDSS) in the UK by engaging with key stakeholders and GPs as end user 
clinicians. This will allow a better understanding of current characteristics of CDSS available 
and to determine views and perceptions of their use, performance and scope for further 
development. From this it is intended to develop an operational framework for a novel 
CDSS, to include functionality and clinical standards to address the needs of GPs in the 
prescribing and management of specific specialist drugs. This study has been approved by 
King’s College London Biomedical Sciences, Dentistry, Medicine and Natural & 
Mathematical Sciences Research Ethics Subcommittee (Reference BDM/11/12-82).   
 
Why have I been chosen to participate? 
 
A literature review of CDSS and prescribing has formed the basis of this study. In addition an 
initial phase of this study has been completed which involved interviews with key individuals 
that represent NHS management, secondary care clinicians, GPs and the CDSS industry. 
This final phase is an observational study that will analyse and detail how GPs use 








Do I have to take part? 
 
No. It is up to you to decide whether or not to take part. If you decide to take part you will be 
given this information sheet to keep and asked to sign a form giving informed consent. If 
you decide to take part you are still free to withdraw from the study without giving a 
reason. If you do change your mind and decide to withdraw just contact the Research Team 
to let them know. Please note data can only be withdrawn up to 48 hours after the study.   
 
  What would happen to me if I take part? 
 
You will be invited to participate in a confidential observational study with a member of the 
research team (Narinder Chana). This study will take approximately an hour at a convenient 
date and time and will need to take place within your GP practice consultation room. The 
study will involve the researcher asking you to demonstrate how the computer and computer 
software is used both during and after patient consultations. In addition the researcher will 
ask you about usage in a number of clinical scenarios. All data collected by the research 
team as part of the study is strictly confidential.  
 
What are the possible benefits of taking part? 
Your input will help and inform future developments in the field of medical informatics which 
will contribute to improving the way patients are treated and managed within primary care. In 
recent years an increasingly greater number and range of specialist drugs and treatments 
are being used outside of hospital prescribed for and managed by GPs. It is important that 
this is done safely and effectively and using CDSS may enhance the prescribing and 
monitoring of these medicines.     
 
 What happens when the research study stops? 
 
The Research Team is keen to learn of areas where prescribing quality can be improved and 
will welcome any comments or suggestions in relation to CDSS and the use of specialist 
drugs. These comments should be directed to Narinder Chana.  
 
What if something goes wrong? 
 
It is not anticipated that taking part in this exploratory study will cause any pain, discomfort, 
inconvenience or changes to lifestyle 
 
 





What would happen to the results of the research study? 
 
Would my taking part in this study be kept confidential? 
 
All information collected from you during the course of this research study is will be 
anonymised and kept strictly confidential. It will NOT be possible to link information used in 
the research report back to you. Reports and data collected will be stored securely at King’s 




Individuals will not be identified in any report or publication. The findings will be shared 
across the Medicines Management Teams within the North West London Clinical 
Commissioning Groups (CCGs) and the London Primary Care Practice Research Network. 
The study will be described in the Doctorate in Health Care thesis of Narinder Chana. It is 
anticipated the results of this study will be published and or presented at a national / 
international level so all information gained is shared widely. If you would like a copy of any 
resultant publication, you will be sent one. 
 
Who is organising and funding the research? 
 
The research is being organised by Narinder Chana, and Dr Cate Whittlesea (Institute of 
Pharmaceutical Sciences, King’s College London) in collaboration with Professor Brendan 
Delaney (Department of Primary Care and General Practice, King’s College London). The 
research team are providing their time and expertise free of charge. Narinder Chana is a 
Pharmaceutical Adviser at NHS Ealing Clinical Commissioning Group (CCG). .  
 
Contacts for further information. 
 
Should you have any further questions, or would like to enquire further please contact 
Narinder Chana or Cate Whittlesea by either e-mail or phone number between 9am-5pm 
Monday to Friday. 
 
Narinder Chana: Narinder.chana@kcl.ac.uk 020 331 39310 
Cate Whittlesea: cate.whittlesea@kcl.ac.uk  020 7848 4796 
 
If you are happy to participate in this study, please complete the attached consent form and 
return it to the research team in the enclosed stamp addressed envelope. If this study has 
harmed you in any way you can contact King’s College London using the details below for 








Dr Cate Whittlesea Institute of Pharmaceutical Sciences, Room 5.79, 5th Floor, Franklin 
Wilkins Building, Kings College London, Stamford St, London SE1 
  









































Exploratory study using key informants to investigate the use of computerised 
decision support software (CDSS) within UK general practice. 
 
 
Research team: Narinder Chana, Dr Cate Whittlesea, Professor Brendan Delaney (King’s 
College London). You are provided with two copies of this consent form; one is to be 
returned to the research team in the stamped addressed envelope provided, and the other 
for you to keep. 
 
 PLEASE INITIAL 
OR TICK IN BOX 
1. I have read and understand the participant information leaflet 
(Version 2) for the above study and have had the opportunity 
to ask questions. 
 
 
2. I understand that if I decide at any time during the research 
that I no longer wish to participate in this project, I can notify 
the researchers involved and withdraw from it immediately 
without giving reason. Furthermore, I understand that I will be 
able to withdraw my data up to 48 hours after the study.  
 
 
3. I consent to the processing of my personal information for the 
purposes explained to me.  I understand that such 
information will be handled in accordance with the terms of 
the Data Protection Act 1998’ 
 
 
4. I AGREE, and give INFORMED CONSENT  / DO NOT 




         
Please DO / DO NOT (delete as appropriate) send me a report on the results of this 
study. 
 
Address for those requesting a research 
report……………………………………………………………………… 
                                                                          
 
Name of participant         Signature    
 Date 
 
………………………………….  ……………………………………   
Name of researcher    Signature    
 Date 
 
 
 
 
 
 
